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Abstract 
Developing new treatment options, particularly for chronic skin diseases that are 
often poorly controlled by available therapeutics, is a priority in dermatological 
research.
1,2
 Peptides possess enormous potential for the treatment of varied diseases 
and in improving skin aesthetics. The increasing number of new molecules of 
biotechnological origin such as monoclonal antibodies, hormones and vaccines make 
peptide and protein delivery an important area of research.
3
 The current PhD project 
explores the enhanced transdermal delivery of peptides and other small model 
molecules through the use of three techniques. 
Firstly, permeation enhancement of a dipeptide and the anti-inflammatory drug, 
diclofenac with the use of novel cell penetrating peptides (CPPs)–diketopiperazines 
(DKP) is explored. CPPs are peptides with a maximum of 30 amino acids, which are 
able to enter cells in a seemingly energy-independent manner.
4
 To be effective drug 
delivery tools, CPPs need to be very specific in targeting their desired location. Two 
strategies involving CPPs have been described to date; the first one requires chemical 
linkage between the drug and the carrier for cellular drug internalization, and the 
second is based on the formation of stable complexes with drugs, depending on their 
chemical nature.  
Physical admixture of DKP with the dipeptide Ala-Trp and with diclofenac increased 
the epidermal permeation of Ala-Trp by 9 fold and diclofenac by 2 fold. Conjugation 
of DKP with diclofenac enhanced the transdermal flux by 9 fold. DKP was found to 
be a more effective permeation enhancer than the well-established CPP, HIV-1-
Trans-Activator of Transcription (TAT), which when conjugated to diclofenac 
increased its permeation by only 1.9-fold. Further, the amount of DKP-diclofenac 
conjugate present in the skin was at least 6-fold greater than TAT-diclofenac 
conjugate and at least 14 times greater than diclofenac alone.  
Enzyme assay results demonstrated COX inhibition by the DKP-diclofenac 
conjugate, showing the anti-inflammatory activity was retained. This demonstrated 
the potential of the diketopiperazines as CPPs for the enhancement of skin 
permeation.   
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The second study in this project explored the enhanced delivery of three peptides by 
microneedle pre-treatment of the skin. Microneedles (MN) have been shown to 
substantially enhance skin penetration and may offer a painless and effective delivery 
method.
5
 Confocal laser scanning microscopy (CLSM) was used to visualise and 
quantify the penetration of the peptides studied in this project in a rapid and efficient 
manner. The peptides selected for these studies were 3, 4 and 5 amino acids in length 
(melanostatin, rigin and palmitoyl pentapeptide). These peptides were primarily 
selected as cosmeceutical agents to better understand their diffusion and distribution 
within the different layers of the human skin, rather than their role in systemic 
delivery.  
All peptides showed enhanced penetration with microneedle pre-treatment, although 
the enhancement varied considerably between the peptides. Melanostatin (Pro-Lue-
Gly) showed a 10-fold enhancement in penetration area in the viable epidermis at 1 h 
and a 22-fold increase in area in the dermis with microneedle pre-treatment at 24 h. 
Melanostatin has been used in specific hyperpigmentary conditions and as a skin-
lightening agent in cosmetic products.  
Rigin (Gly-Gln-Pro-Arg), the tetrapeptide commonly used in cosmetic industry as 
palmitoyl tetrapeptide-7 showed a 1.8-fold increase in penetration area at 1 h and no 
difference at 24 h with microneedle pre-treatment. Similarly, palmitoyl pentapeptide 
(Pal-KTTKS) showed no difference in penetration area in the viable epidermis with 
the use of microneedles, but over 24 h the passive permeation of Pal-KTTKS was 
increased 2.6-fold when compared to microneedle pre-treatment. Both rigin and Pal-
KTTKS are used in skin firming and anti-aging products, though studies describing 
their transdermal and topical penetration or intradermal accumulation have not been 
reported to date. 
Successful application of microneedles depends on various factors and it is very 
important to choose the right type of microneedle for efficient delivery of medical 
and cosmeceutical products. The imaging technique used to evaluate the outcomes of 
these experiments allows for non-invasive monitoring of the skin with microscopic 
resolution second only to histological analysis.   
A recent skin penetration enhancement technique- magnetophoresis was investigated 
for the transdermal penetration of small model molecules, a fluorescent natural 
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molecule and a fluorescent tripeptide. Magnetophoresis is the enhancement of drug 
permeation across biological barriers by application of a magnetic field, and is 
thought to act predominantly by diamagnetic forces.
6,7
 Different diffusion and skin 
permeation models were used to assess the role of magnetophoresis as a potential 
transdermal delivery enhancement tool. Further, a possible synergistic interaction 
with application of microneedles was also investigated. In a non-membrane model 
study, utilizing agar gel syringes to examine the diffusion of dye molecules in the 
influence of diamagnetic repulsion, the diffusion of brilliant blue dye was enhanced 
by 33%. A study with prepared human epidermis showed a 2.4-fold increase in 
diclofenac permeation in vitro across human epidermis with magnetic film array 
(ETP 012) when compared to passive treatment. 
A volunteer study was done in order to assess the penetration of a naturally 
fluorescent compound curcumin. The results showed a 200% increase in the net 
fluorescence intensity generated by curcumin when compared to passive (dummy 
non-magnetic strips of similar material). When investigated for their use in 
combination with microneedles, the magnetic film array (ETP 012) showed a 5-fold 
increase in skin diffusion of melanostatin in full thickness human skin ex vivo when 
compared to microneedles alone. The ETP 012 magnets also showed a 7-fold 
increase in the area of penetration when compared to dummy strips without the 
microneedles. Though, the total area was much smaller when compared to the area of 
penetration with the use of microneedles. 
This work demonstrates the importance of minimally invasive (MN) and non-
invasive (CPPs and ETP) transdermal delivery techniques in optimising transdermal 
delivery of peptides and small molecules.  
1 
 
Chapter 1  
Introduction 
 
 
“Research on the penetration of drugs through the skin merits renewed attention as a 
result of concerns such as transdermal therapies, safety of cosmetic products and 
skin decontamination.”8 
 
 
 
2 
 
Peptides are considered the new generation of biologically active pharmaceuticals 
because they are key regulators in cellular and intercellular physiological responses. 
These macromolecules possess enormous potential for the treatment of disease. The 
increasing number of new molecules of biotechnological origin such as monoclonal 
antibodies, hormones and vaccines make peptide and protein delivery an important 
area of research.
3
  Research has also led to peptides being important tools for 
understanding protein structure and function.  A large number of new and potentially 
potent peptide and protein drugs have been developed in the past few decades, with 
several finding success in prior areas of unmet need by providing therapeutics based 
on enzyme inhibition and activation.
9
  
Developing new treatment options, particularly for chronic skin diseases that are 
often poorly controlled by available therapeutics, is a priority in dermatological 
research.
1,2
 Most proteins and peptides range in molecular weight from 100 to greater 
than 1000,000 Da. Due to their large molecular size and primary structure proteins 
and peptides are vulnerable to proteolytic attack, and are subject to extensive “first 
pass” metabolism and thus are unsuitable for oral administration. They have short 
plasma half-lives and require frequent injection to maintain therapeutic levels. 
Over the years, much research has been directed towards alternate administration 
routes, other than parenteral injections, for effective peptide and protein drug 
delivery, resulting in fewer side effects as well as better patient compliance.
1,10,11
 
Transdermal delivery is a potential delivery route. However, due to the hydrophilic 
nature and presence of charge at physiological pH, skin permeation of peptides is 
poor and despite generally having high potency, they are ineffective if administered 
transdermally because they do not permeate into the skin. In addition to the inherent 
properties of the peptides, the biggest barrier for the transdermal transport resides in 
the outermost layer of the skin, the stratum corneum (SC).
3,12
 Despite these 
challenges the transdermal route is worthy of investigation due to the potential 
advantages to be realised if the challenges can be overcome. 
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1.1 Structure of human skin 
The skin is the largest and the most readily accessible organ of the human body with 
at least five different cell types contributing to its structure, and other cell types from 
circulatory and immune systems being transient residents.
1
 Its primary function is 
protection, including physical, chemical, immune, pathogen, UV radiation and free 
radical. For the purpose of transdermal drug delivery, human skin can be categorised 
into four main layers: the innermost hypodermis or subcutaneous fat layer, the 
overlying dermis, the viable epidermis and the outermost stratum corneum. (Figure 
1.1)
13,14
  
 
Figure 1.1 Typical structure of mammalian skin
14
 
The hypodermis or subcutaneous fat layer lies between the dermis and the underlying 
body constituents. This layer of adipose tissue provides a store for high energy 
molecules and insulates the body to provide protection against mechanical shock.
13
  
The dermis is 3 – 5 mm thick and is composed of a network of connective tissue, 
predominantly collagen fibrils, which provide support and flexibility.
15
 Blood and 
lymphatic vessels, nerve endings, pilosebaceous units (hair follicles and sebaceous 
glands), and sweat glands (eccrine and apocrine) are found in the dermal tissue. In 
terms of transdermal drug delivery, this layer is often viewed as essentially gelled 
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water, and thus provides a minimal barrier to the delivery of most polar drugs.
13
 For 
transport across the skin the dermal blood supply maintains a concentration gradient 
between the applied formulation and the vasculature across the skin. It is this 
concentration gradient that provides the driving force for drug permeation.
13
 
The epidermis is a complex, multilayered membrane which varies in thickness from 
around 0.06 mm on the eyelids to around 0.8 mm on the palms and soles of the feet. 
The epidermis is differentiated into 5 layers: stratum corneum, stratum granulosum, 
stratum spinosum, stratum lucidum and stratum basale.
13
  
1.1.1 Stratum corneum 
The barrier function of the epidermis resides primarily in the stratum corneum (SC), 
which consists of anucleate cells called corneocytes and varies in thickness from 
approximately 10 -15 µm in the dry state to 40 µm when hydrated.
16
 The corneocytes 
are arranged in a “brick and mortar” like structure where the keratin rich corneocyte-
bricks are embedded in an intercellular matrix-mortar, which is essentially composed 
of long chain ceramides, free fatty acids, cholesterol, cholesterol sulfate and 
sterol/wax esters.
17,18
 The ceramides are covalently bound to the surface of the 
corneocytes.
19
  These bound lipids have alkyl chain lengths of 30 – 34 carbons and 
contain no cholesterol.
20
 The lipid chains are arranged into regions of crystalline, 
lamellar gel and lamellar liquid crystal phases thereby creating various domains 
within the lipid bilayer.
21
 The crystalline nature and the presence of a 13 nm lamellar 
phase are considered to be crucial for the barrier function of the skin. (Figure 1.2 a 
and 1.2 b)  Penetrating molecules have to traverse a highly convoluted tortuous lipid 
pathway for diffusion. Consequently, penetrant molecules must migrate over larger 
distances than the membrane thickness.
20
 The lipid content in the stratum corneum 
differs between individuals and body site.
22
  The stratum corneum has been 
recognised as the main barrier to transdermal penetration for centuries and there have 
been wide ranging ways to overcome it for therapeutic advantage. From ancient 
medical knowledge it is evident that not all medicaments are active orally, and by 
disrupting the top most skin layer medications could be sent inside the human body.  
The first documented application of epicutaneous drug delivery consisted of a 
vaccine, dating back more than 3000 years.
23
 Indeed, the first immunization against 
smallpox was practiced in India by administrating dry scabs of smallpox lesions onto 
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the scarified skin of healthy individuals using sharp needle-like objects, a procedure 
called ‘variolation’.23 Conversely if the stratum corneum is disrupted or 
dysfunctional it leads to loss of hydration out of the skin and access of certain irritant 
allergens into the body.
24
 Psoriasis and atopic dermatitis are common examples of 
dysfunctional skin conditions. Researchers have used parameters such as 
transepidermal water loss (TEWL), tape stripping and instruments such as photo 
acoustic spectrometry to establish the relationship between disrupted barrier function 
of the stratum corneum and increased permeation.
25
  
 
Figure 1.2 (a) Multiphoton microscope image of stratum corneum in human volunteer skin (b) 
Cross section image of human stratum corneum 
1.1.2 Stratum Granulosum 
The stratum granulosum is a thin granular layer of cells in the epidermis. These cells 
contain keratohyalin granules, protein structures that promote hydration and 
crosslinking of keratin.
2
 Keratinocytes in the stratum granulosum continue to 
differentiate. Figure 1.3 below shows a multiphoton image of stratum granulosum 
captured from human volunteer skin during the project. 
a b 
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Figure 1.3 Multiphoton microscope image of stratum granulosum in human volunteer skin 
1.1.3   Stratum spinosum 
The stratum spinosum, also called the pickle layer, is comprised of two to six cell 
layers.
2
  It lies just above the basal layer and together with the basal layer it is 
referred to as the Malpighian layer. Figure 1.4 illustrates an image of stratum 
spinosum captured during a volunteer study. The keratinocytes in this layer 
differentiate to form keratin, which aggregates to form tonofilaments. The 
condensation of these tonofilaments leads to the formation of desmosomes which 
maintain a distance of almost 20 nm between the cells and are vital to the structural 
integrity of the epidermis.
13
 
 
Figure 1.4 Multiphoton microscope image of stratum spinosum in human volunteer skin 
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1.1.4 Stratum basale 
The keratinocytes present in the basal layer undergo mitotic cell division. The 
resulting daughter cells migrate upwards towards the skin surface. In addition to the 
structural precursor cells that produce the stratum corneum, there are three types of 
specialized cells
13
, namely the melanocytes, the immunogenic Langerhans’ cells and 
the Merkel’s cells associated with nerve endings found on the dermal side of the 
basement membrane.
26
 Unlike the upper layers of the epidermis nuclei are less 
visible in the basale as seen in figure 1.5. 
 
Figure 1.5 Multiphoton microscope image of stratum basale in human volunteer skin 
1.2 Fick’s law and delivery routes of peptides through skin 
There are three principal routes of entry from the skin surface to the sub-epidermal 
tissue and systemic circulation: through the hair follicles with their associated 
sebaceous glands called the shunt or appendageal route, the transcellular route 
through the densely packed keratinocytes, or the intercellular route across the 
continuous stratum corneum between the appendages (Figure 1.6).
27,28
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Figure 1.6 Drug penetration across the stratum corneum
28
 
Favourable candidates for transdermal delivery are small molecules with good water 
and lipid solubility, and typically with a logP of  3. Fick’s first law of diffusion 
states that the rate of transfer of diffusing substances through unit area of a section is 
proportional to the concentration gradient measured normal to the section and can be 
used to analyse permeation data predictively.
29
 
  J = -D dc/dx     (1) 
Where J is the flux of the permeant, D is the diffusion coefficient and dc/dx is the 
concentration gradient. 
 
Figure 1.7 Typical permeation profile for an infinite dose application to human skin 
membranes
29
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Fick’s second law can be derived from the first equation: 
δc/δt = D δ2c/δx2     (2) 
Thus the flux is obtained as the gradient of the linear portion of the permeation 
profile Figure 1.7.
29
   
Skin permeation enhancement strategies may be postulated based on Fick’s first law: 
(i) increase the diffusion of the drug across the membrane; (ii) increase drug 
partitioning into the membrane; and (iii) increase the degree of saturation of the drug 
in the vehicle.
30
 
1.3 Strategies to enhance transdermal delivery of peptides 
Several penetration enhancement techniques have been developed to overcome the 
skin barrier and facilitate the permeation of peptides and proteins through the skin. 
The various enhancement strategies have been broadly classified into formulation 
optimisation/permeant modification approaches, chemical penetration enhancement 
and application of active techniques.  
1.3.1 Formulation optimisation/permeant modification approaches 
1.3.1.1 Pro-drugs 
The major hindrance to transdermal drug penetration is the low partition coefficient 
of the drug molecule.
30
 Prodrugs are designed with lipophilic moieties attached to the 
parent compound to increase the partitioning of parent polar solutes across the 
stratum corneum. Upon reaching the viable epidermis the prodrug is hydrolysed by 
esterases to release the parent drug.
31
 Lipophilic ion pairs can be formed by adding 
oppositely charged molecules to increase penetration across the stratum corneum. 
After partitioning into the stratum corneum lipids the complex dissociates releasing 
the ion pair into aqueous viable epidermis from where it diffuses onwards.
32
 
Larsen et al. esterified a model dipeptide (Gly-Phe) at the C-terminal carboxylic acid 
group to convert it into a lipophilic prodrug. Their work indicates that sufficient oil 
solubility might only be obtained for relatively small peptides by using the prodrug 
approach and therefore a combination with other solubility enhancing organic 
solvents like dimethylacitamide (DMA) would be required to achive sufficient 
permeation.
33
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1.3.1.2 Encapsulation 
Encapsulation is a general term used to describe the entrapment of the drug within 
particulate delivery systems such as microspheres, liposomes, or nanoparticles. 
Liposomes are phospholipid based vesicles which have been extensively investigated 
in transdermal delivery. They have been widely used for local delivery but there is no 
evidence that they penetrate the epidermis intact. A number of other liposome-like 
vesicles with increased structural flexibility have been developed including 
transfersomes, niosomes and ethosomes.
3
  
In a study by Touitou et al., in vivo transdermal absorption of the steroid hormone, 
testosterone was enhanced 2.2-2.4 times through rabbit pinna skin using an 
ethosomal patch (vesicles with ethanol in their structure).
34
 Niosomes are vesicles 
composed of non-ionic surfactants that have been evaluated as carriers for a number 
of cosmetic and drug applications. Gupta et al.
35
 studied the relative potential of 
transfersomes, niosomes and liposomes in non-invasive delivery of tetanus toxoid 
(TT). Transfersomes are composed of phospholipids such as phosphatidylcholine, 
but also contain surfactant which acts as an ‘edge activator’ conferring deformability 
on the vesicle.
3,36
 In vivo study revealed that topically administered tetanus toxoid 
containing transfersomes, after secondary immunization elicited immune response 
(anti-TT-IgG) equivalent to one that was produced following intramuscular alum-
adsorbed TT-based immunization. In comparison to transfersomes, niosomes and 
liposomes elicited weaker immune response.  
They observed that the entrapment efficiency, elasticity and topical effect with these 
encapsulated forms were higher than intramuscular administration of alum-adsorbed 
tetanus toxoid.
35
 In another study, conducted on trans-retinoic acid or tretinoin, the 
potential of niosomes as topical delivery systems capable of improving the cutaneous 
delivery of tretinoin was assessed. Tretinoin cutaneous delivery was strongly affected 
by vesicle composition and thermodynamic activity of the drug, with negatively 
charged niosomal formulations showing higher cutaneous drug retention than both 
liposomes and commercial formulations.
37,3,36
 However in all cases, scale up of these 
delivery systems to provide therapeutic peptide levels in humans is yet to be 
demonstrated. 
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1.3.1.3 Nanoparticles 
Controlled release of drugs from nanoparticles is attracting increasing attention 
because of its potential for targeted delivery in cancer therapy and other ailments.
38
 
Compared to liposomes or micelles, polymeric nanoparticles are much simpler to 
prepare and to scale-up, as a low number of excipients are required.
39
 Nanoparticles 
may be composed of metal oxides such as zinc oxide and titanium dioxide
40
 
(common sunscreens), polymer blends and lipids (solid lipid nanoparticles). There is 
considerable controversy regarding the safety of nanoparticles when used 
transdermally. It is generally agreed that non-biodegradable nanoparticles if taken up 
through the skin can be potentially dangerous
41,42
 and caution needs to be exercised 
concerning topical exposure to formulations that have characteristics enabling some 
skin penetration or nanoparticles consisting of inherently toxic constituents.
43
 Studies 
have shown that most commercially available nanoparticles present in sunscreens do 
not penetrate intact stratum corneum.
40,41
  
Nanoparticles such as therapeutic or cosmetic solid lipid nanoparticles for topical 
application have already reached the market (NanoRepair Q10
®
 by Dr. Rimpler uses  
Coenzyme Q10 an endogenous, vitamin-like substance)
44, 45
 The main concern 
during the loading of nanoparticles with peptides or proteins is the chemical stability 
at conditions such as elevated temperatures, shear force, surfactants, presence of free 
radicals and UV radiation.
46, 47
 
Recently, Ailhas et al.
48
 designed a novel type of functional nanoparticle, 22 nm 
diameter self-assembled from single polypeptide chains. The open ended design of 
the peptide chain can be modified to attach targeting peptides, cell penetration 
peptides, certain drugs or molecular markers.
48
 A study by Lee et al. reported 
successful preparation of nanoparticles encapsulated with a plasmid DNA containing 
a reporter gene (CS/g-PGA/DNA). Currently gold micro/nanoparticles are used as 
DNA carriers for transdermal gene delivery.
49
 The authors suggested that the reporter 
genes tested in this study could replace gold nanoparticles.
50
 Coulman et al.
51
 
investigated the influence of surface charge and pore size on the penetration of a 
colloidal fluorescent polymeric nanoparticle formulation through well-defined micro-
channels generated by the application of a microneedle array to the skin. A 
significant impact of these parameters was observed on the permeation and 
subsequent distribution of the nanoparticle formulation within the skin but further 
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work is required to better understand the interaction of nanoparticle formulations 
with the skin layers following disruption of the barrier with a microneedle array.
51
 
Similarly Lee et al. fabricated microneedle projections which had nanoparticles 
attached to the tip. Nanoparticles when used with microneedle arrays have 
tremendous potential as an alternative method to deliver cosmetic or pharmaceutical 
materials into human skin locally without the need for professional procedures.
52
 
1.3.1.4 Chemical conjugation  
Novel drug-delivery systems for the oral administration of drugs and peptides have 
been developed by combining a peptide or drug with a lipophilic chain, then 
encapsulating within liposomes and polyethylene glycol (PEG) conjugates which can 
act as a carrier.
53
 The chemical modification approach may protect peptides against 
degradation by peptidases and other enzymes and render the peptides and proteins 
more lipophilic, resulting in increased permeability.  
In a study conducted by Setoh et al., the in vitro permeability of chemically modified 
tetragastrin with fatty acids was assessed through rat skin. The flux of these acyl 
derivatives was in the order of acetyl > butyroyl > caproyl.  The stability of tetragastrin 
in skin homogenate was also significantly improved by chemical modification with fatty 
acids. These results suggested that chemical modification of tetragastrin with fatty acids 
increases its lipophilicity, which makes it more permeable across the skin. Moreover, it 
also reduced the degradation in the viable skin, resulting in increase in permeation of 
tetragastrin across the stratum corneum.
54
  
In another study luteinizing hormone rereleasing hormone (LHRH) and thyrotropin 
releasing hormone (TRH) were chemically modified by conjugation to a novel class 
of compounds: lipidic amino acids and their homo-oligomers, the lipidic peptides. 
Conjugation to lipidic peptides increased the half-life of LHRH and TRH, with the 
peptides subsequently being released from Caco-2 cell homogenates. The released 
LHRH or TRH demonstrated a longer half-life than when present alone in the 
incubation mixture, suggesting that the cleaved lipidic amino acid is capable of 
inhibiting enzymes.
55
 Naturally occurring Thymogen dipeptide (L-Glu-L-Trp-OH), 
which possesses immunomodulating and anti-angiogenic properties, exhibited higher 
intestinal permeability across Caco-2 cell layers for all lipid and glycoside conjugates 
when compared to the dipeptide alone.
56
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Lipophilic derivatives of Phe-Gly have also been synthesized by chemical 
modification with butyric acid (C4), caproic acid (C6) and octanoic acid (C8).
57
 The 
in vitro stability, permeability and accumulation of this peptide were investigated in 
rat skin. The native peptide rapidly degraded in the skin homogenates but the acyl-
Phe-Gly derivatives were more stable than the parent peptide. After 1 h 
approximately 15% of the native peptide was present in comparison to almost 100% 
of the acyl derivatives. All three conjugates permeated across the skin with the 
permeation of the C6 acyl derivative being the greatest. No permeation of the parent 
peptide was observed.  
Similar lipidation strategies were undertaken with carnosine (β-Ala-His) and human 
calcitonin. To improve the intestinal absorption of human calcitonin (hCT) (Figure 
1.8), novel lipophilic derivatives of hCT were synthesized by chemical modification 
with short-chain length fatty acids such as acetic acid and caproic acid, and the 
intestinal absorption and stability of these derivatives were examined in rats. 
 
Figure 1.8 Chemical structure of human calcitonin 
The effect of absorption enhancers on the absorption of the synthesized derivatives 
was also investigated. The intestinal absorption of hCT was enhanced by chemical 
modification with fatty acids and it was further promoted by the combination of 
acylation and absorption enhancers.
58
 Carnosine is very water soluble and was 
therefore conjugated with a longer chain palmitoyl acid. The parent molecule had 
very low affinity for the skin and did not permeate beyond the first layer of the 
14 
 
stratum corneum. The lipophilic derivative on the other hand, diffused into the 
stratum corneum and into the epidermal and dermal layers. Having shown that 
modified peptide can penetrate into the skin but not through it, Linter et al.
59
 applied 
the concept to the tripeptide glycyl-L-histidyl-L-lysine. They synthesized palmitoyl 
Gly-L-His-L-Lys and studied the stimulation of collagen synthesis in human 
fibroblast culture. Histological examination of skin samples (human biopsies from 
plastic surgery, abdominal tissue) that had been irradiated with daily doses of UVA 
light for a week showed a strong degradation of dermal collagen. Treatment of skin 
samples after irradiation with retinoic acid or with palmitoyl-Gly-His-Lys during the 
same week showed almost total preservation and/or renewal of tissue collagen.
59
  
Lipid conjugation of peptide sequences holds promise in modifying the properties of 
peptides by increasing their stability and permeability across biological membranes 
thus enhancing their activity and potential for therapeutic and cosmetic significance. 
1.3.1.5 Cell-penetrating peptides 
In 1988, two independent research groups discovered that a trans-activating 
transcription factor, TAT, from the human immunodeficiency virus (HIV) was able 
to freely internalize into cultured cells.
60,61
 
 
Since then more than 100 cell-penetrating 
peptide (CPPs) have been described,
60-63
 but it is the TAT peptide that has been most 
successfully used to deliver therapeutic molecules into cells. In a 2004 review of the 
literature, Dietz et al.
64
 described over 300 different applications of CPPs, with TAT 
being used in 50% of the cases, this trend has continued and more  recent reviews 
describe a similar proportion of TAT usage.
64,65
 CPPs are defined as peptides with a 
maximum of 30 amino acids, which are able to enter cells in a seemingly energy-
independent manner; this can be postulated as they internalize even when cells were 
incubated at 4ºC or when inhibitors of endocytosis were present.
4
 CPPs thus were 
believed to translocate across membranes in a non-endocytotic fashion, although 
several other modes of transport have been described.  
CPPs can be broadly divided into two classes based on their net charge. The first 
class consists of amphipathic (i.e. containing both hydrophobic and hydrophilic 
parts) helical peptides where Lys is the main contributor to the positive charge. 
These CPPs deliver more cargo into the cells than the second class, the Arg rich TAT 
and penetratin, which are non-amphipathic. The peptide-induced membrane leakage 
15 
 
is thought to be proportional to amphipaticity.
4,62
 CPPs derived from proteins are 
often referred to as protein transduction domains. Hansen et al.
66
 described the 
current practice and tools used to predict what features in a peptide can lead to it 
being termed as a CPP. Though trial and error seemed to be the most frequent way of 
CPP discovery, bioinformatics and z-descriptors derived from Sandberg's
67
 expanded 
z-scales can be informative.
66
 
There is considerable debate about what specific peptide sequences contribute to the 
ability to translocate across biological membranes, though a high content of basic 
amino acids, resulting in a net positive charge.
68
 Alain et al.
69
 observed that 
replacement of the arginine amino acid by lysine in the basic region reduces the cell 
penetrating ability, thus suggesting that the arginine residues have specific properties 
beyond an interaction with negative charges at the cell surface.
69
 Whilst endocytosis 
is not required for translocation of some CPPs, for others, such as TAT and 
penetratin, endocytosis is the main mode of transport.
70
 TAT is non-amphipathic 
with a high content of cationic amino acids (arginine) and binds to the lipid 
membrane with a high amount of anionic lipids. Membrane leakage is not observed 
at low micro molar concentrations. Whilst endocytosis is important, other active 
modes of transport have also been suggested for TAT. For example, Tyagi et al.
71
 
suggested that heparan sulfate proteoglycans, which are expressed in most cell types, 
could be responsible for the internalization of the full-length TAT protein.
71
 Wender 
et al.
72
 further showed that the TAT peptide, comprising amino residues 48-60 from 
the full length TAT protein, showed an elevated internalization efficacy over the 
parent protein.
72
 Proposed mechanisms for the direct membrane transduction 
included pore formation, carpet-like perturbations and inverted micelles (Figure 
1.9).
65,73
 These different processes demonstrate that peptide mediated membrane 
translocation is mediated by several different pathways simultaneously and different 
peptides utilize diverse uptake mechanisms depending on their cargo and biophysical 
properties.
74
 The penetration of CPPs into cells is rapid and initially governed by 
first-order kinetics, with half-times from 5 to 20 mins. Smaller cargoes usually do not 
affect the rate of internalization, but as the size of the cargoes is increased, the rate is 
substantially decreased.
63
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Figure 1.9 Illustration of the possible interactions of the peptides with the phospholipid 
membranes, and different mechanisms for translocation of CPPs.
68
 
The kinetics of CPP mediated transport has been extensively investigated. Pooga et 
al.
75
 visualized biotinylated transportan in Bowe’s melanoma cells using confocal 
microscopy and suggested it could be used to transport hydrophilic macromolecules 
into the cell to regulate finely tuned cellular processes.
75
 Zorko et al.
63
 specifically 
identified that the concentration of internalized CPP as a function of time, can be 
more reliable and informative if the concentration equilibrium between external and 
internalized CPP is determinable.
63
 Hällbrink et al.
4
 quantitatively characterized the 
yield and kinetics of cellular cargo delivery of different CPPs.
4
 The difference in 
cargo delivery efficiency between the amphipathic peptides and non-amphipathic 
peptides is due to the ability of the amphipathic peptides to enter and exit cells, in 
contrast to the non-amphipathic peptides which are trapped in the cells as they bind 
to the lipid membrane with a high amount of anionic lipids. In terms of the cellular 
uptake and cargo delivery kinetics, model amphipathic peptide (MAP) has the fastest 
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uptake, followed by transportan, TAT (48–60), and penetratin. Similarly, MAP has 
the highest cargo delivery efficiency, followed by transportan, TAT (48–60), and 
penetratin.
76
 
The ability of these peptides to translocate through cell membranes can be 
accompanied by toxic effects resulting from membrane perturbation at higher peptide 
concentrations. This can be attributed to the resemblance of CPPs to the 
antimicrobial lytic peptides that kill microbial cells by disrupting their cell 
membrane.
63
 CPPs have been subjected to a high degree of scrutiny regarding the 
highly controversial issue of direct permeation of the strongly cationic peptide across 
negatively charged lipid membranes. Barany-Wallje et al.
77
 used confocal laser 
scanning microscopy on rhodamine labelled giant vesicles incubated with 
carboxyfluorescein labelled penetratin to show no evidence of trans bilayer 
movement. The studies conducted on charged black lipid membranes were backed by 
additional results from confocal fluorescence spectroscopy.
77
 A study by Saar et al.
78
 
assessed the toxicity of popular CPPs in leukaemia cells and erythrocytes. The 
amphipatic CPPs-MAP and transportan were shown to cause membrane leakage at 
lower concentrations in the leukaemia cells; conversely the non-amphipathic CPPs 
like TAT (48-60) and penetratin showed low membrane damage.
78,68
 When the 
minimal membrane-translocating TAT domain was discovered by Vives et al.
79
, no 
toxicity was found in very extreme conditions on HeLa cells with a 24 h incubation 
at 100 µM concentration.
79,80
 In addition, it is noteworthy that peptide concentrations 
used in toxicity tests are often far above the concentrations used for delivering 
various drugs into cells.
81
 However, it needs to be mentioned that most of the well-
described CPPs are derived from non-human proteins and could potentially induce an 
immune response when injected into the human body, at least when bearing a large 
size cargo.
82
  
To be effective drug delivery tools, CPPs need to be very specific in targeting their 
desired location. This can be achieved by conjugating a CPP to T cell epitope 
peptides or proteins for direct immunization. These conjugates can then be applied to 
several sites by simultaneous intradermal administration and will enter any cell 
without the need for specific receptor targeting of the dendritic cells for 
immunotherapy. Targeting has also been achieved with receptor-specific antibody 
antigen conjugates, carbohydrate–antigen complexes, or nanoparticles. However, 
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CPP-mediated delivery can overcome complexities associated with the manufacture 
of these agents.
83
 The discovery of cancer-specific peptides, for instance, can be 
facilitated by phage display technology, where a library of bacteriophages exposing a 
different peptide sequence on their capsule are intravenously injected into animals 
bearing the tumour to be targeted. The phages displaying the “correct” sequence bind 
specifically to the tumour and are afterwards collected, amplified and their exposed 
sequence identified as the tumour targeting sequence. These “tumour homing 
sequences” have been applied successfully in vivo, demonstrating an accumulation of 
the vector drug complexes into the tumour.
84,85
 
The dual ability of CPPs to covalently and non-covalently bind to a cargo complex of 
much bigger size than their own and translocate it across the plasma membrane, and 
the ability to act as nuclear localization signal, has demonstrated potential to 
revolutionize the field of cell biotechnology.
86
 The ideal cargo for peptide-mediated 
delivery should have a large impact at low concentrations. Therapeutics such as 
recombinases and small interfering RNA-siRNA are prime candidates for an ideal 
CPP cargo. CPP technology is peptide-based, so it is easily modified with the 
addition of specific functional units. Increased retention in specific tissues can be 
obtained by attaching homing peptide sequences or other targeting motifs to CPPs.
87
 
The indiscriminate transduction of CPPs is a drawback if targeted delivery is 
preferred.
25
 Translocation of a CPP from cytoplasm to the nucleus is mediated by a 
signal or localization sequence. There are a variety of sub-cellular localization 
sequences. Each of these signal sequences has a distinct property that targets a 
cytosolic protein to a specific organelle. The nuclear pore complexes which are 
responsible for the uptake of CPPs along with their attached cargo, are capable of 
dilating to 10–25 nm in diameter to facilitate the active transport of large 
molecules.
86
 Laakkonen et al.
88
 showed that a 9 amino acid peptide LyP-1 selected 
from a phage-displayed peptide library specifically binds to tumour and endothelial 
cells of tumour lymphatics in certain tumours. The peptide preferentially localizes in 
hypoxic areas within the tumours. They also showed that systemically administered 
LyP-1 causes tumour cell apoptosis, reduces the number of tumour lymphatics, and 
inhibits tumour growth in mice bearing breast cancer xenografts.
88
 
CPPs can be used to internalise molecules and selectively interfere with diverse 
cellular mechanisms. Gius et al.
89
 used TAT for intracellular delivery of cyclin-
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dependent kinase inhibiting peptide, to enable the arrest of cell proliferation. Ward et 
al.
90
 developed a cell-permeant peptide inhibitor of mitogen-activated protein kinase-
activated protein kinase 2 (MK2). It was observed that the CPPs alone inhibited 
varying amounts of MK2 activity and the conjugation of CPP to the MK2 inhibition 
sequence enhanced the efficacy of the therapeutic domain showing synergism.
90
 An 
interesting application of the CPPs is the design of cytotoxic T lymphocytes (CTL). 
CLTs and vaccines for the treatment or prevention of infectious and malignant 
conditions were shown to rapidly internalize into cells. Furthermore, the use of the 
conjugates as immunogens resulted in considerably enhanced antigen specific CTL 
responses in mice.
91
  
Proteins and peptide delivery with the use of CPPs has gained a lot of attention. The 
major obstacles for in vivo clinical applications of peptides is their poor permeability 
through plasma membrane and their sensitivity to enzymatic degradation.
92
 Nucleic 
acid delivery in cells is commonly carried out using cationic lipids or viruses; 
however, both have several drawbacks. Cationic lipids are restricted to in vitro 
applications, whereas the latter are sometimes immunogenic in vivo.
93
 Based on the 
principal purpose of the cargo molecule, the peptide and protein cargoes can be 
categorized into two distinct subclasses: reporter peptides/proteins (giving simply a 
positive read-out upon effective delivery) and functional peptides/proteins (allowing 
the detection of any alteration in the cellular processes).
84,94
 Protein and peptide 
cargoes do not behave the same when applied using CPPs. Mark et al.
95
 observed 
that, compared to CPP–protein conjugates, substantially greater concentrations of 
CPP–peptide conjugates (>10 μM) were required for biological activity. The proteins 
are likely to have a greater affinity, resulting from their secondary and tertiary 
structure.
95
  
Myou et al.
96
 demonstrated that blockade of Ras protein by administration of TAT- 
dominant negative-dnRas blocks nonspecific airway hyper-responsiveness to 
methacholine.
96
 Fujimoto et al.
97
 demonstrated the growth inhibitory effects of a p16-
derived peptide (P16
INK4A
).
97
 Snyder et al.
98
 used peritoneal carcinomatosis mouse 
model that more closely resembles metastatic human disease to demonstrate a 
selective activation of the p53 protein in cancer cells, but not normal cells. To 
circumvent the problem of proteolytic degradation, the researchers synthesized a 
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retro-inverso version of the parental p53C′ peptide-RI-TATp53C′ and showed it to be 
therapeutically effective in preclinical models of terminal human malignancy.
98
 
Effective drug delivery to the brain is required in neurodegenerative diseases, such as 
Parkinson and Alzheimer disease and central nervous system (CNS) diseases, such as 
schizophrenia, epilepsy, and bipolar disorder.
99
 Neuropharmaceutics is the largest 
potential growth sector of the pharmaceutical industry. Many promising 
neuropharmaceutical compounds do not become successful therapeutics due to 
blood-brain barrier (BBB) transport problems, >98% of these potential agents do not 
reach the drug development stage.
100
 The BBB consists of a monolayer of polarized 
endothelial cells connected by complex tight junctions that separate the blood 
compartment from the extracellular fluid compartment of the brain parenchyma and 
poses a formidable obstacle to drug therapy to the CNS.
91
 Effective brain delivery 
requires that the CPP and its cargo are not trapped within the epithelial cells but 
escape into the brain parenchyma or the other side of the interstitial barrier.
69
 Kumar 
et al.
101
 conjugated a small peptide derived from the rabies virus glycoprotein (RVG) 
with nine arginine molecules. This conjugate was shown to carry siRNA into the 
CNS and bind the acetylcholine receptor resulting in specific gene silencing.
101
 
Rousselle et al.
102
 showed increased brain delivery of doxorubicin when conjugated 
with penetratin, with higher brain concentrations of CPP-doxorubicin (2.14±0.23 
μL/s/g) compared to free doxorubicin (0.25±0.09 μL/s/g). CPP-doxorubicin was 
found at lower levels in the heart, significantly reducing cardiotoxicity, which is the 
main side effect of doxorubicin.
102
 
In 2007 a research group from Barcelona introduced the concept of using small 
cyclic peptides, diketopiperazines (DKPs) as shuttles for brain delivery. They 
illustrated transport of dopamine and baicalin across an in vitro BBB model using the 
Parallel Artificial Membrane Permeability Assay (PAMPA).
99
 DKPs represent an 
important class of biologically active natural products but the advent of 
combinatorial chemistry has revived interest in DKPs for two reasons: firstly, they 
are simple heterocyclic scaffolds in which diversity can be introduced and 
stereochemically controlled at up to four positions; secondly, they can be prepared 
from readily available α-amino acids using very robust chemistry.103  
DKPs have been isolated and identified from a variety of natural sources including 
marine sponges, lichens and herbs. Bolognesi et al.
104
 reported the identification of a 
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novel bifunctional DKP derivative 1D, which exhibits activity in the low micro 
molar range against prion replication in ScGT1 cells, while showing low 
cytotoxicity. Martins et al.
105
 reviewed the biological activities of DKPs and 
described that most of their biological properties are related to the inhibition of 
plasminogen activator inhibitor and alteration of cardiovascular and blood-clotting 
functions. DKPs have antitumor, antiviral, antifungal, antibacterial, and 
antihyperglycaemic activities.
105
 Malakoutikhah et al.
106
 described the influence of 
the terminal groups of a DKP peptide on its permeability. The peptide with acetyl 
and amide groups as N-terminus and C-terminus respectively showed the best 
permeation.
106
 The Barcelona group have synthesised a library of 15 DKPs with 
distinct side chains using a solid-phase synthetic methodology for systematic 
testing.
99
 Chapter 2 of the thesis describes our collaboration with the Barcelona 
group in the investigation of DKP as a potential carrier for transdermal delivery. 
CPPs have been investigated for transdermal delivery. Rothbard et al.
107
 investigated 
the mechanism of transport of oligoarginine conjugates into the cutaneous barrier and 
demonstrated that the conjugates penetrate intact skin and enter into the cells by 
active transport across lipid cellular membrane. Thus CPPs enter the layers of cells, 
accumulate there, and then enter the adjacent layers presumably by forming a 
concentration gradient.
107
 Hou et al.
108
 proposed the involvement of 
macropinocytosis and actin reorganization in transdermal delivery of CPPs into the 
skin.
108
 Jin et al.
109
 described the synthesis and CPP conjugation of an antioxidant 
peptide superoxide catalase-CAT. Immunohistochemistry and specific enzyme 
activity showed efficient penetration into the epidermis and dermis when the TAT-
CAT and 9Arg-CAT fusion proteins were sprayed on animal skin.  Antioxidant 
enzymes like superoxide dismutase (SOD) and catalase (CAT) are very effective 
against diseases mediated by reactive oxygen species such as skin inflammation, skin 
cancer, cutaneous autoimmune diseases, phototoxicity and skin ageing.
109
 Wender et 
al.
110
 showed that biotin peptide can effectively penetrate across the stratum corneum 
when applied topically as a biotin-transporter-9 conjugate. Intense nuclear 
localization was observed in the epidermal cells showing that it translocated into the 
cells faster than even 9Arg and TAT.
110
 
Lim et al.
111
 showed enhanced penetration of Glycine-Lysine-Histidine tripeptide 
(GKH) derived from parathyroid hormone. TAT conjugated GKH penetrated 36 
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times more efficiently than GKH into excised hairless mice skin. TAT-GKH can be 
used as a cosmetic ingredient in slimming products, with both penetration 
enhancement and lipolytic effect without cytotoxicity.
111
 In a recent study, Hsu et al. 
synthesized a novel CPP-skin penetrating and cell entering peptide (SPACE). 
Conjugation of the peptide to siRNA led to their enhanced absorption into full 
thickness porcine skin and knockdown of corresponding protein targets. The ability 
of the SPACE peptide to deliver Interleukin- 10 (IL-10) siRNA and reduce the 
overall level of the cytokine may offer unique therapeutic opportunities in the 
treatment of atopic dermatitis and other dermatological diseases.
112
 
1.3.2 Chemical penetration enhancers 
Chemical enhancers, such as fatty acids, surfactants, esters and alcohols exert their 
action via a temporary alteration of barrier properties of the stratum corneum. The 
various mechanisms involved in skin perturbation include stratum corneum 
partitioning, fluidization of the crystalline structure, increased solubility by 
enhancing thermodynamic activity in the formulation and dissolution of stratum 
corneum lipids leading to enhanced drug flux.  
Lee et al.
113
 and Tsai et al.
114 demonstrated the disruption of intracellular keratin 
networks and intercellular cohesion of corneocytes by penetration enhancers present 
in a depilatory cream using multi photon microscopy (MPM visualization).
113, 114
 
Pretreatment with depilatory cream, which contains potassium thioglycolate or 
calcium thioglycolate in the base, can detach corneocytes from the stratum corneum 
and can also generate intracellular pores in the remaining corenocytes by disrupting 
the intracellular keratin, providing shunts for drug penetration. However, due to low 
permeability coefficients of macromolecules such as peptides, the enhancement 
effects required to ensure delivery of therapeutically effective concentrations are 
likely to be beyond the capability of chemical enhancers at concentrations tolerated 
by the skin.
115
 Peptides require substantially greater enhancement due to their 
hydrophilicity and molecular weight. Magnusson et al.
116
 reported 3 to 5 fold 
enhancement of M-TRH across human epidermis in vehicles combining 
terpene/ethanol and cineole/ethanol. As stated earlier substantial enhancement can be 
achieved for a small peptide but this approach is of limited value for larger peptides 
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and proteins, and moreover care needs to be taken that enhancer chemicals do not 
denature the peptide.
116
 
The practical use of these enhancers in different formulations requires balancing their 
benefits and risks i.e. penetration enhancement effect and skin irritation. For example 
DMSO increases penetration of various drugs but is a powerful aprotic solvent and 
thus altered the biochemical and structural integrity of skin, as was observed during 
certain studies undertaken in chapter 3 in this thesis. The saturated and unsaturated 
fatty acids under occlusive conditions cause erythema and produce irritation. Thus, 
enhancers should be evaluated for potential irritancy under conditions of long term 
occlusion.
117
 
1.3.3   Active penetration enhancement techniques 
1.3.3.1 Iontophoresis 
Iontophoresis is the application of a small electric potential (≤ 0.5 mA/cm2) to drive 
charged molecules into the skin.
118
  The mode of enhancement of transdermal 
transport is principally by two mechanisms: electrostatic repulsion, whereby a solute 
with the same charge as an electrode placed on the skin surface is repelled into the 
skin
3
 (Figure 1.10) and electroosmosis, where at neutral pH, the skin has a net 
negative charge and is permselective to cations and neutral molecules. This passage 
of cations induces a convective flow of water molecules from the anode which 
further enhances the permeability of cations while inhibiting that of anions.
119
 An 
interesting feature of iontophoresis is that its primary action is on the peptide or drug 
molecule itself so it does not just involve passive diffusion and is not solely 
dependent on concentration gradient. By modulating the applied current, the delivery 
rate of peptides/small molecules can be adapted to individualise therapy thus offering 
the potential of pulsatile drug delivery.
120
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Figure 1.10 Schematic of an iontophoretic device
121
 
Iontophoresis is the most extensively researched of the physical enhancer 
technologies and successful transdermal iontophoresis has been demonstrated for a 
number of peptides such as LHRH, TRH, cyclosporin, nafarelin, arginine 
vasopressin (AVP), octreotide, calcitonin and insulin.
3,122
  
Many of the peptides mentioned above have been subject to mechanistic 
investigations and electroosmosis has been proposed to be the dominant mechanism 
in iontophoretic transport of large cationic peptides. Hirvonen et al.
122
 designed and 
synthesized a series of cationic LHRH oligopeptides, three residues in length. They 
conserved the positively charged Arg residue in the oligopeptide and varied the 
degree of lipophilicity in the other two residues in an attempt to examine if the 
permselectivity of the membrane could be increased by augmenting the net negative 
charge. The results indicated that a combination of cationic and lipophilic residues, 
inhibited electroosmosis and in turn peptide flux. It is hypothesized that the cationic 
oligopeptide could interfere with electroosmotic transport by neutralizing the original 
charge of the skin and affecting its permselective properties.
122
  Also, computational 
studies that generated 3D quantitative structure-permeation relationships predicted 
that iontophoresis was favoured by peptide hydrophilicity and hindered by 
voluminous, localized hydrophobicity.
123
 
Leuprolide, a nonapeptide LHRH agonist was studied using constant current 
iontophoresis to explore methods for improving iontophoretic efficiency and 
determine the feasibility of delivery of therapeutic doses of the drug. It was found 
that in two different electrolyte systems and by varying current densities from 0.5 to 
2.3 µA/cm
2
, the fluxes could be extrapolated to show the delivery of therapeutically 
relevant doses of the drug.
124
 Leuprolide containing D-Leu-Leu-Arg has been 
successfully delivered in vivo in humans to produce a peak leutinizing hormone 
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response similar to subcutaneous injection.
125
 Electrically assisted transdermal 
delivery is rapid and plasma levels decline on termination of the applied current. For 
example, arginine vasopressin was pulsed across hairless rat skin in three discrete 1 
µg/cm
2
 spiked doses by application of three 60 min current pulses of 0.47 
mA/cm
2
.
126
  
In addition to the use of iontophoresis as the sole enhancement technique, 
combinations of iontophoresis with chemical enhancers and formulation 
modifications have also been investigated.
127
 Pillai et al.
128
 investigated the in vivo 
and in vitro skin permeation of insulin in rats with chemical enhancer and/or 
iontophoresis. The study investigated the effect of pre-treatment with commonly 
used vehicles such as ethanol, propylene glycol, water and their binary combinations, 
dimethyl acetamide, 10% dimethyl acetamide in water, ethyl acetate and isopropyl 
myristate on insulin iontophoresis. Whilst increased skin penetration was achieved 
this was frequently associated with increased skin irritation.
128
 The authors 
concluded that ethanol was the most useful solvent to combine with iontophoresis. 
Isopropyl myristate produced comparable enhancement but the high viscosity and 
relative incompatibility with other penetration enhancers are drawbacks. Marked 
decreases in blood glucose levels reflecting the increases in the plasma concentration 
of insulin in rats were also observed after combined electroporation/ iontophoretic 
administration, whilst no insulin penetration was detected by passive or iontophoresis 
alone. The results were attributable to the formation of an irreversible route in the 
stratum corneum, through which insulin could be absorbed.
129
 Bhatia and co-workers 
investigated the effect of limonene/ethanol and iontophoresis on the in vitro 
percutaneous absorption of LHRH and on the ultrastructure of human epidermis by 
transmission electron microscopy (TEM). Limonene/ethanol at 5% concentration 
significantly enhanced the passive permeation of LHRH through human epidermis, 
and iontophoresis further increased the flux through enhancer treated epidermis. The 
combination of iontophoresis and enhancer treatment significantly enhanced LHRH 
delivery by disrupting keratin, and loosening and swelling of stratum corneum cell 
layers in comparison to controls with iontophoresis alone.
130
 Boinpally et al.
131
 
reported that the in vitro transport of cyclosporine from lecithin vesicles under 
anodal iontophoresis was greater than when applied in combination with a 
microemulsion.
131
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As a result of this large body of research, the technology is now matured with many 
clinical applications in late stage clinical trials and some on the market.  Examples 
are the LidoSite lidocaine delivery system for local anaesthesia (Vyteris, Inc., Fair 
Lawn, NJ), Iontopatch dexamethasone delivery system for musculoskeletal 
conditions (Travanti Pharma, Inc., Mendota Heights, MN) and the IONSYS fentanyl 
delivery system for patient controlled analgesia (Alza Corp/JNJ, Mountain View, 
CA) The IontoPatch is an extended time-released electronic transdermal drug 
delivery system. An innovative self-contained battery produces an electric current to 
carry drug molecules non-invasively across the skin and to underlying tissue. Drug 
delivery is shut off automatically when the prescribed dosage has been administered. 
IONSYS (fentanyl HCl) system is a needle-free, patient-controlled transdermal 
analgesic (PCTA), integrated system for on-demand dosing, delivering a nominal 40 
μg fentanyl per on-demand dose from a hydrogel over ten minute dose duration. To 
date, iontophoretic transdermal delivery of large peptides and proteins sufficient to 
achieve therapeutic outcomes in humans has not been demonstrated. However the 
technique may be useful for local delivery of small peptides (less than 10 kDa) in the 
treatment of skin conditions or lesions.
53
 Whilst the potential benefits are apparent, 
there are some limitations. Current densities up to 0.5 mA/cm
2
 do not damage human 
skin, though iontophoresis at 1 mA/cm
2
 has been shown to damage the membrane 
structure. The side effects of long term iontophoresis use are yet to be fully 
evaluated.
132
  
1.3.3.2 Electroporation 
Electroporation involves the application of an exponentially decaying high voltage 
(100–1000 V) for a very short time (micro or milli seconds) to produce transient 
changes in cell membranes or lipid bilayers.
133
 It is hypothesized that electroporation 
destabilizes the lipid matrix of the cell membrane, resulting in the creation of 
transient hydrophilic pores that reduces skin resistance by up to three to four orders 
of magnitude for small and macromolecules.
134,135
 Skin electroporation has been 
shown to be an effective method for enhancing transdermal delivery of peptides such 
as LHRH, heparin and oligonucleotides.
133,136-138
 For example, Prausnitz et al. 
demonstrated in vitro skin permeation of heparin by electroporation at amounts 
equivalent to therapeutic levels (100–500 mg/cm2/h). This was an order of magnitude 
greater than the heparin flux achieved with iontophoresis.
139
 Electroporation has also 
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been used for DNA transfection in cells in culture, and in vivo electroporation in the 
presence of DNA plasmid can induce gene expression in several organs.
140
 Wang et 
al.
141
 assessed topical delivery of cyclosporin A (CSA) for treating psoriasis. 
Iontophoretic administration of a solution of cyclosporin A in 40% ethanol in 
phosphate buffered saline did not result in any significant increase in drug delivery. 
However electroporation applied as multiple pulses (25 pulses, 10 ms each) resulted 
in a 60-fold increase in the delivery of CSA to the skin compared to passive 
application.
141
  Previous studies have shown that anionic lipids enhanced the 
electroporative transport of molecules up to 10 kDa in size. It was also shown that 
the charge and not the type of the phospholipid head group influenced the 
transdermal transport under electroporation. Moreover, phospholipids with saturated 
acyl chains enhanced the transport of larger molecules more as compared to those 
with unsaturated chains. 
 Sen et al.
142
 reported a 20-fold increase in transport of fluorescence-labelled insulin 
in the presence of an anionic phospholipid (1,2-dimyristoyl-3-phosphatidylserine) 
with electroporation compared to electroporation alone, across porcine epidermis. 
They hypothesized that this permeation enhancement is due to the phospholipid 
stabilizing the aqueous pathways in the stratum corneum created by electroporation, 
thereby maintaining the pathways for a more prolonged period.
142
 When 
iontophoresis was included in the experimental protocol it further increased insulin 
flux across the skin. A combination of electroporation and iontophoresis also led to 
increase in the transdermal flux of human parathyroid hormone (hPTH) up to 10 
times greater than electroporation alone.
143
 Therapeutic administration of 
macromolecules by skin electroporation could be clinically useful. The efficacy of 
transport depends on the drug physicochemical properties, the formulation and the 
electrical parameters. 
 The potency of the drug and safety concerns will be the critical issues to address.
144
 
The safety and efficacy of in vivo electroporation was assessed using histological and 
visual scores and bioengineering methods by Vanbever et al.
144
. The study yielded 
useful information on alterations of skin function following the application of high 
voltage pulses and the effects were shown to be dependent on the electrical 
parameters of the pulses. In conclusion they reported that improved electrode 
configuration might further improve tolerance and levels of sensation.
144
 Whether 
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electroporation will be more efficient than other techniques used to enhance 
macromolecules delivery (e.g. liposomes or ultrasound) remains to be investigated. 
1.3.3.3 Magnetophoresis 
Magnetic energy has gained a lot of attention in the recent past, though the use of 
magnetic energy for healing dates back thousands of years. It has been described in 
most of the major ancient medical and philosophical records.
145
 Also, biological, 
therapeutic and inductive effects of electromagnetic fields on biological tissues have 
been widely reported. These include enhanced healing of venous ulcers and bone 
fractures and effects on a range of cellular functions.
146,147
 More recent advances in 
medicine have utilised magnetic energy ingeniously in drug targeting and healing 
itself.  
Santini et al.
148
 discussed the interesting idea of employing intelligent systems, based 
on a microchip technology activated by a magnetic impulse to deliver sodium 
fluorescein into a phosphate buffer saline well, and suggested that this system could 
be easily modified to release drugs in controlled-pulsatile mode.
148
 Nishijima et al.
149
 
investigated a magnetically targeted-drug delivery system (MT-DDS), which 
involves binding a drug molecule to small biocompatible magnetic particles. When 
injected into the blood stream these drug-magnet nanoparticles can be pulled out of 
the suspension and moved to the target region using a high gradient magnetic 
field.
149
 The study reported successful accumulation of ferromagnetic nanoparticles 
in an in vitro study. Ferromagnetic nanoparticles were separated in pig blood under a 
blood flow of 200 mm/sec using bulk superconducting magnets of 2.14 T magnetic 
flux density.
149
  
In a previous work of similar nature, Grief et al.
150
 described theoretical analysis of 
magnetically targeted drug delivery technique. A mathematical model tracking 
individual particles under the influence of Stokes drag and a magnetic force was 
derived. The authors also included interactions and collisions between moving red 
blood cells in the bloodstream in their calculations. The study concluded that, though 
it was possible to distribute the drug-magnet nanoparticles heterogeneously, 
magnetically targeted drug delivery with an externally applied field is only possible 
if targeted close to the surface of the body.
150
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Huang et al.
151
 described a novel flexible drug delivery chip-like device which had a 
drug-carrying core-shell magnetic nanoparticle incorporated in a membrane. The 
chip was reported to be capable of delivering drugs with a fast and precise response 
over a wide variety of release patterns, including sustained release, step-wise release, 
and burst release. The chip was capable of eluting therapeutically effective amount of 
ethosuximide, an anti-epileptic drug by external magnetic stimulus in an animal 
model.
151
 Magnetic drug delivery systems like MagNaGel
®32
, FluidMAG
®
 and 
TargetMAG
®
 have already been commercialized and have been found satisfactory 
for use in patients under current regulations.
38
  
Magnetophoresis is the enhancement of drug permeation across biological barriers 
by application of alternating magnetic field. Limited work has been undertaken to 
investigate the ability of magnetic fields to move diamagnetic substances through 
skin,
6
 though this offers potential advantages, particularly in drug delivery into the 
skin. Magnetophoresis is a much recent development in the field of enhanced drug 
delivery.
2
 The term diamagnetism was coined by Michael Faraday in 1845, when he 
realized that all materials in nature possessed some form of diamagnetic response to 
an applied magnetic field.
152
 Drug molecules in a solution are particularly susceptible 
to diamagnetic repulsion due to the availability of localised electrons. The presence 
of large phospholipids in the skin, that with the aid of diamagnetic repulsion can be 
rearranged in hydrated skin further make for a case to magnetophoresis. Any 
rearrangement of the lipids in the skin will be very temporary and hence make 
magnetophoresis one of the most non-invasive techniques for transdermal drug 
delivery.
153
   
Murthy et al. showed that magnetophoresis enhanced the transdermal drug delivery 
of lidocaine hydrochloride in in vitro and in vivo studies.
6,154
 Sammeta et al.
155
 
reported lidocaine hydrochloride delivery flux of 3.07 ± 0.43 μg/cm2/h from a 
magnetophoretic patch system across epidermis compared to 0.94 ± 0.13 μg/cm2/h 
for passive permeation.
155
 Krishnan et al. utilized an electromagnetic field to enhance 
drug permeation across the skin.
156
 This study used the Dermaportation technology, a 
novel transdermal drug delivery system that uses pulsed electromagnetic fields 
(PEMF) to enhance the movement of diamagnetic substances through the skin. This 
technology utilizes a time varying electromagnetic field designed by OBJ Ltd, a 
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Perth-based biotechnology company. The Dermaportation system runs on a low-
energy time varying electromagnetic pulse packet. 
 
Figure 1.11 Schematic representation of PEMF Dermaportation waveform 
Studies by our group using Dermaportation have demonstrated enhanced penetration 
of small molecules and peptides including 5-aminolevulinic acid, naltrexone, 
diclofenac, lidocaine and a model dipeptide Ala-Trp.
153,156-159
 Dermaportation uses a 
low voltage (3V) and does not require direct physical contact with the skin to 
produce diffusion enhancement (Figure 1.11). This research was extended to 
investigate a fixed magnetic field derived from small flexible un-powered magnetic 
film array, termed ETP and also developed by OBJ Ltd. ETP is a thin flexible 
polymer matrix containing multiple magnetic elements arranged to produce complex 
3-dimensional magnetic gradients. The peak magnetic field strength of these magnets 
is 40 mT. However the arrangement and distribution of alternating poles across the 
surface of the material results in a total magnetic gradient of 2 T/m
2
. These small 
magnets were shown to enhance skin permeation of urea and increased hydration of 
the skin.
7
  
Benson et al.
7
 reported that the potential mechanism for magnetophoresis was 
modulation of the permeability of the stratum corneum.
7
 This has however been 
strongly debated by Murthy et al. who believe that an electromagnetic field of 5 mT 
strength is insufficient to cause a change in the stratum corneum membrane lipid 
integrity. Murthy et al.
154
 suggested that the predominant mechanism for drug 
permeation enhancement is magnetokinesis and enhanced partitioning of drug into 
the stratum corneum. Their hypothesis was based on assessment of skin changes by 
attenuated total reflectance Fourier transform infra-red spectrometry (ATR-FTIR) in 
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which they did not show changes in the skin spectrum. Murthy et al. used magnets of 
much greater strength of 450 mT at the skin surface. Thus the magnetophoretic 
devices used by these groups are not comparable and the mechanism of enhancement 
may be different. 
In this PhD project I have investigated the permeation of curcumin (a small 
molecular weight model drug) using ETP (Chapter 4). The penetration of curcumin 
in volunteer skin was assessed using multiphoton tomography (MPT) and 
fluorescence lifetime imaging microscopy (FLIM).  This along with other 
experiments on magnetophoresis will be discussed in Chapter 4.  
1.3.3.4 Ultrasound 
Low-frequency ultrasound (or sonophoresis) has been shown to increase the 
permeability of human skin by several orders of magnitude to many low molecular 
weight drugs (<500) as well as high molecular weight proteins such as insulin.
160
 
Therapeutic frequencies in the range of 1–3 MHz was first applied to enhance the 
skin penetration of small drugs in the 1980s.  More recently low frequency 
ultrasound (<100 kHz) has been used to provide greater enhancement and has been 
extended to the delivery of macromolecules across intact skin.
161
 It is hypothesized 
that ultrasound application induces growth and oscillations of air pockets present in 
the keratinocytes of the stratum corneum by a phenomenon known as cavitation. This 
leads to perturbation of the lipid bilayers thereby enhancing transdermal transport.
162
 
In vitro studies have shown increases in skin permeability of macromolecules such as 
insulin (6,000 Da), β-interferon (17,000 Da) and erythropoietin (48,000 Da) using 
low frequency 20 kHz sonicators with wave intensities of 12.5-225 mW/cm
2
.
163
 
Mitragotri et al.
162
 showed that low frequency ultrasound was much more effective in 
inducing significant transdermal transport of the above mentioned macromolecules 
due to the proposed inverse relationship between ultrasound frequency and 
cavitational effects.
162,164
 In addition to cavitation as the primary mechanism of 
action, it has also been reported that ultrasound causes stratum corneum lipid 
extraction, which contributes to increased permeability.
165
 Tezel at al.
166
 investigated 
the transdermal transport pathways of hydrophilic solutes including peptides, in the 
range 180–70000 Da, under low-frequency ultrasound. Based on a modified porous 
pathway model, they concluded that skin porosity could be enhanced by up to 4100-
fold by the application of low-frequency ultrasound.
166
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Sonophoresis has also been used in combination with other skin permeation 
enhancement techniques such as chemical enhancers and electroporation. Liu et al.
167
 
recently assessed the permeation of cyclosporin A into and across rat skin when 
applied with low frequency ultrasound in combination with chemical penetration 
enhancers and electroporation. Permeation into the skin was enhanced with the 
ultrasound and chemical enhancer combination, but the transdermal delivery across 
the skin only occurred when applied in combination with electroporation.
167
 
Transdermal heparin delivery has been achieved by combining low frequency 
ultrasound with iontophoresis and electroporation. Sonophoretic enhancement of 56-
fold was reported when used in combination compared to 15-fold by iontophoresis 
and 13-fold by ultrasound alone.
168
  
Sonophoresis offers promising potential for non-invasive drug administration and 
commercial sonophoretic units have been developed.  The SonoPrep system (Figure 
1.12) (Sontra Medical Corp, Franklin, MA) which accelerates skin delivery of 
lidocaine has been introduced for rapid local anaesthesia. This company is also 
developing the system for other small and macromolecule applications including 
vaccine delivery. 
 
Figure 1.12 SonoPrep skin permeation device: rapid local anaesthesia by ultrasound enhanced 
delivery of lidocaine (Sontra Medical Corp, Franklin, MA) 
Another commercially available ultrasound system is the Sonopulse II system which 
uses ultrasound frequencies of 1.0 MHz - 3.0 MHz. It also allows the possibility of 
combined therapy, that is, ultrasound associated with electro stimulation. Sonopulse 
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II Combined Therapy was developed to be used in physical rehabilitation and 
aesthetics in conditions such as inflammatory rheumatic diseases, inflammatory 
diseases of superficial skin area, tissue healing etc. In aesthetics, the equipment is 
indicated for cellulite treatment, localized fat, flaccidity, lymphatic drainage and 
analgesia.  
1.3.3.5 Jet applicators 
Jet injectors or needle-less injectors are claimed to be a pain free method of 
administering drugs to the skin. A number of devices are commercially available to 
propel powders and liquids into the skin at high velocity. These examples include 
Ped-O-Jet®, Iject®, Biojector2000®, Medi-jector® and Intraject® for liquids. The 
Vitajet (Bioject), Biojector (Bioject) and Medi- Jector (Antares Pharma, Ewing, NJ) 
systems and their associated versions deliver jet injections of proteins in liquid 
form.
3,169
 The PowderMed system, initially known as Powderject® injector, uses a 
high velocity jet to carry the drug particles to the skin surface (Figure 1.13). The 
Powderject injector has been reported to successfully deliver testosterone, lidocaine 
hydrochloride and macromolecules such as calcitonin and insulin
169
 The physical 
properties of the device, velocity of the carrier gas, discharge pressure and particle 
size dictate the penetration depth achieved by the injector.
170
   
 
Figure 1.13 PowderMed jet propulsion delivery system 
The acceptance of conventional jet injectors has been mixed due to variable reactions 
in the level of pain experienced at the administration site, with some people 
experiencing the same level of pain compared to hypodermic needles. In addition, 
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post injection symptoms have been reported to develop quickly after administration 
and include mild erythema, hyper-pigmentation, flaking and discoloration at the 
injection site.
171-173
 Other issues faced by needle less injector systems include high 
developmental costs of both the device and dosage form and the difficulty of 
controlling drug delivery to compensate for inter subject differences. These devices 
could be very useful in vaccine delivery to the epidermis where frequent dosing is 
not required and a much higher level of immune stimulation could be achieved than a 
traditional injection
174,175
 
1.3.3.6  Photomechanical waves  
Photomechanical stress waves are generated by impact of high power pulse lasers –
LSW on a target material such as polystyrene that is then directed towards the skin 
surface.
3,176
 The waves are broadband (fast rise time), unipolar, compressive and 
interact with cells and tissue in ways that are different from those of ultrasound. The 
action of ultrasound is primarily mediated by heat and cavitation
177
 whereas 
photomechanical wave effects are caused by mechanical forces.
178
 Studies have 
shown that photomechanical waves can induce or enhance delivery of molecules 
across the plasma membrane of cells in vitro without loss of viability. It is thought 
that these waves form a continuous or hydrophilic pathway across the skin.
179
 Lee 
and co-workers
180
 assessed the topical transport of a peptide like small molecule 5-
aminolevulinic acid (5-ALA) with a single photomechanical wave in humans, to 
investigate the impact of the wave on the stratum corneum barrier and its recovery in 
vivo. The results showed that a single 110 nano second photomechanical wave 
increased the permeation of 5-ALA across the stratum corneum in vivo and the 
barrier function recovered within minutes. Lee et al.
181
 also demonstrated that a 
photomechanical wave can facilitate the transport of macromolecules such as dextran 
and fluorescent latex particles through the stratum corneum into the viable epidermis 
and dermis in a rat model.
181
  Delivery of insulin through the skin of diabetic rats 
resulted in 80 ± 3% reduction in blood glucose, with the level maintained below 200 
mg/dL for 3 h.
182
 A design concept for a transdermal drug delivery patch based on 
the use of photomechanical waves has been proposed by Doukas and Kollias.
183
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1.3.3.7 Microneedles  
Transdermal penetration enhancement techniques discussed so far have all dealt with 
finding ways to alter the stratum corneum temporarily or modify the formulation 
characteristics. An alternative approach involves creating larger transport pathways 
of a few µm in dimension using arrays of sub-millimeter needles. These pathways 
are orders of magnitude higher than the molecular dimensions of most drugs and 
therefore should readily permit the transport of macromolecules, as well as possibly 
supra-molecular complexes and microparticles. The microneedle concept of reducing 
the needle size to only a few hundred microns was proposed in the 1970s
184
 and it 
was demonstrated experimentally only in the early 1990s.
185
  
 
Figure 1.14 Types of microneedles A) and D) Hollow; B) solid and C) coated microneedles
186-188
 
Microneedles have been one of the most sought after and extensively studied 
approaches to transdermal drug delivery. Their sudden rise to prominence can be 
attributed to the microelectronics industry that provided microfabrication tools 
needed to make such small structures. The first studies utilizing microneedles for 
transdermal drug delivery were performed in 1998.
186
 Since then a lot of work has 
been done on microneedle-drug delivery efficacy and safety. It is generally accepted 
that small holes in the skin are likely to be safe and are considered to be no different 
to those made by hypodermic needles or accidental cuts and bruises in day-to-day 
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life.
189
 Microneedles are considered to be reasonably pain free as they do not 
penetrate to the dermis where the sensory nerves are present.
186
 
Microneedles are generally shorter than 1 mm in length and very easily breach the 
stratum corneum barrier. The main challenge microneedle researchers face is from 
the elasticity of the skin.
190
 Hence their length, manner of insertion and the speed at 
which they are applied govern the shape and size of the pore formed.
191
 The amount 
of time the pores stay open has often been an area of constant debate. While in a 
publication by Bal et al.
192
 the authors claim a fast closure of the pores, other 
researchers had different opinions. Bal et al. used confocal laser scanning 
microscopy (CLSM) to visualise the amount of a fluorescent dye present in the 
pores. Visualisation using CLSM is an easy way to obtain information on geometric 
parameters of the pores and to monitor the behaviour of a pore and the dye over time. 
The authors reported a quick closure of the pores as there was a strong decrease of 
the dye present at the skin surface after 10-15 min.
191,192
 Banks et al. utilized 
transepidermal water loss (TEWL) measurements after microneedle treatment and 
microscopic visualization to determine pore lifetime. They also measured skin 
permeability of NTXOL (naltrexone analogue 6-β-naltrexol) over time to determine 
the pore lifetime. In addition, a staining technique was developed to microscopically 
visualize microneedle created pores in treated guinea pig skin. Banks et al. concluded 
that microneedle-assisted transdermal delivery appears viable for at least 48 h after 
microneedle-application.
193
 In a subsequent study they showed that the addition of a 
COX inhibitor like diclofenac can keep the microneedle pores open for up to a 
week.
194
  It is widely accepted and proved by mathematical modelling that transport 
of the drug molecules after microneedle application takes place by simple 
diffusion.
185
   
Microneedles are broadly classified into two classes. 
a) Solid Microneedles 
b) Hollow Microneedles 
Solid microneedles (Figure 1.14) can be applied by “poke and patch” or “coat and 
poke” techniques. The former creates pores with the patch then being applied usually 
after the microneedles have been removed. The “coat and poke” technique involves 
insertion of microneedles, with the drug coating then dissolving off the microneedle 
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surface into the pores. In both cases the microneedles create micron-scale holes in 
the skin through which molecules can more easily be transported. The first 
microneedle arrays reported in the literature were etched into a silicon wafer and 
developed for intracellular delivery in vitro by Hashmi et al.
195
 Shortly after this 
work was published, microneedles were developed for transdermal delivery 
applications to deliver a variety of different compounds in vitro and in vivo. Mark 
Prausnitz’s group in 1998 was the first to use microneedles for transdermal drug 
delivery.
186
 They used an array of solid microneedles in cadaver skin, which 
increased the permeability of calcein 3-fold when the microneedle were left in the 
skin, with the enhancement reported to occur through leakage pathways between the 
needles and skin. When the needles were removed skin permeability increased by 4-
fold.
186
  
In vivo studies by Lin et al.
196
 used microneedles either alone or in combination with 
iontophoresis to deliver large oligodeoxynucleotides across the skin of hairless 
guinea pigs. Microneedle arrays were inserted and an oligonucleotide-loaded gel was 
applied to the skin. This design incorporated an iontophoretic electrode on top, in 
most of the cases. Insertion of the microneedles during iontophoresis increased 
transdermal flux by 100-fold relative to iontophoresis alone. Microneedle pore based 
delivery was higher (16.18 ± 1.84 µg) when compared to passive diffusion through 
intact skin (undetectable). Donnelly et al. used silicon microneedle arrays to enhance 
skin penetration of 5-ALA in vitro and in vivo. Microneedle treatment before the 
application of 5-ALA patch led to a significant increase in transdermal delivery of 
ALA. The authors also showed equivalent therapeutic effect with a significant dose 
reduction to 2.6 % w/w could be achieved compared to the 20% w/w dose currently 
used in clinical practise. Microneedles also allowed for shorter application times 
which could improve patient compliance and clinician convenience.
197
  
Microneedles are often fabricated from materials that are prone to breaking, and 
whilst the literature shows a low incidence of metal needle fracture, brittle 
microneedles are a safety concern. Park et al.
198
 described biodegradable polymers 
for microneedle fabrication and envisaged they could alleviate issues of safety as any 
broken needles left embedded in the skin would safely degrade and disappear. 
Further the disposal of polymer microneedles is also facilitated by the ability to burn, 
dissolve in a solvent, or mechanically destroy needles to prevent intentional or 
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accidental re-use.
198
 Unlike metal needles the design of dissolving microneedles is 
governed by a number of inter-dependent material and fabrication constraints, one of 
which is the need for microneedles to have sufficient strength to be inserted into the 
skin without mechanical failure.
199
  
Raphael et al.
200
 introduced a novel method of fabricating arrays of multilayered 
dissolving nanopatches (dNPs). They achieved improved vaccine efficiency by 
device miniaturization using microneedles that easily penetrated the skin and upon 
delivery dissolved within 5 min. Successful delivery and efficient antibody 
generation was achieved from two vaccines, a model antigen-ovalbumin and Fluvax 
2008, a commercial influenza vaccine.
200
  The same group demonstrated a coating 
approach for similar microneedle patches and studied the delivery of a variety of 
molecules including OVA protein vaccine, DNA, and fluorescent dyes (Figure 
14).
201
 They also demonstrated that skin delivery by densely packed micro-
projections invoked no delay in kinetics, compared to intramuscular injection. The 
results matched the kinetics achieved by intramuscular injection of liquid vaccine 
and the vaccines achieved peak serum antibody response within 2 weeks.
202
  
Lee et al.
203
 proposed a stepwise controlled drawing technique to fabricate sharp 
dissolving microneedles directly from maltose without moulding. This was achieved 
by controlling the drawing time and the viscosity of maltose at precisely the right 
level resulting in sharp conical microneedles of 60 mm tip diameter. After insertion 
into the skin in vivo the microneedles completely dissolved within 20 min. These 
dissolving microneedles were used to successfully administer the hydrophilic 
molecules ascorbic acid-2-glucoside and niacinamide that do not passively permeate 
into the skin.
203
 Kommareddy et al.
204
 recently described a proof of concept for 
delivery of unadjuvanted cell culture vaccine using dissolvable microneedle 
patches.
204
  
The coat and poke technique has gained a lot of attention since it was first described 
in a patent by Cormier et al.(2002).
205
 A typical coating process is expected to 
achieve a coating that is both uniform and reproducible. The coated drug should 
achieve high drug load and the coating should be controllable in thickness and 
coating amount. It should ideally release the drug in the skin within minutes after 
insertion.
206
 Cormier et al. later described microneedle-enhanced delivery of 
desmopressin coated onto the microneedle arrays by partial immersion in aqueous 
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formulations containing either 24 or 40% by weight of desmopressin and 0.2 % 
polysorbate 20.
207
 Scanning electron microscopy was used for evaluation of coating 
depth and thickness. An interesting observation was made regarding a significant 
decrease in drug delivery efficiency upon an increase in drug loading of the 
microneedle arrays. This behaviour could be partly explained as a product of the 
increased viscosity of the mixture due to increased drug concentration.  
More recent work by Chen et al.
206
 utilizes small microneedles (< 200 µm) coated 
with vaccines in 0.5% of methylcellulose and 0.5% of ovalbumin protein.
206
 The 
method described within, details the coating process at great depth. The roles of the 
two main components of the coating mixture were the viscosity enhancer, 
methylcellulose and the surfactant, Quil-A was to serve dual purposes saving the 
addition of further excipients. In their later work Chen et al. further described the dry 
coating method. One of the biggest advantages of this coating technique is, unlike 
dip and coat, the jet stream used to dry the coating solution gives a very even coating 
and helps avoid the clogging of microneedle arrays. This is of increased value for 
microneedle arrays that are densely populated and are very small.
188
 
Since there advent in the late 1990’s various types of microneedles have been 
fabricated and designed.
185,186,207
 Microneedle devices are very hard to standardise. 
This has been further exacerbated by the need of microneedle innovators to make 
unique devices with proprietorship in view. Hence an outcome based research 
methodology that could compare the efficacy of different microneedle devices is 
required. Gomaa et al.
208
 described the effect of variables such as size, shape and 
microneedle array density on transepidermal water loss (TEWL). They compared 
microneedles of three different lengths-400 µm, 600 µm and 1000 µm. It was 
observed that microneedles of all sizes caused an initial sharp drop in barrier function 
followed by a slow incomplete recovery due to the temporary generation of micro-
channels that subsequently contract due to skin elasticity.
208
  Multiple insertions had 
a similar effect, showing a proportionate increase in TEWL with increased number of 
insertions. Increasing microneedle density suppressed the partial barrier recovery 
caused by tissue contraction. In early studies it was a common practice to leave the 
microneedles in-situ. This study showed that leaving microneedles embedded in skin 
reduced the initial post-insertion drop in barrier function but once the microneedles 
were removed the behaviour was consistent with the general trend.
208
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Bal et al.
191
 described the outcomes of different sized microneedles on the 
permeation of fluorescein.
191
 The fluorescence intensity of fluorescein was 
characterised as high (HIF) or low (LIF). The authors compared areas covered by 
both HIF and LIF after the application of three different microneedle devices. 
Commercially available Dermastamp® was compared to microneedle devices 
developed in house.  
Al Qallaf et al. attempted to describe the drug penetration in skin tissues after 
microneedle delivery using mathematical modelling software-SKIN-CAD
®
.
209  They 
described different parameters that must be considered in designing and optimizing 
any microneedle system including the length of the microneedles, duration of 
application, surface area of the array system. A small low molecular weight model 
drug fentanyl was used to calculate various parameters like diffusion coefficient and 
elimination rate constant in both the stratum corneum and viable epidermis. Hollow 
microneedles were simulated which were assumed to keep the drug inflow 
constant.
209
  In a later study similar work was done to simulate the penetration of 
insulin from coated microneedles.
210
 This mathematical approach might help design 
an ideal microneedle system with the correct needle height, density and related 
parameters.
211
 The obvious downside though, is all the calculations made were based 
on mathematical simulation and the predictions have not been experimentally 
validated in a systematic way. In their subsequent work they have added variables 
like the effect of metabolism of drugs taking place in the viable epidermis and 
compared the penetration of verapamil in skin models.
210
  
1.3.4 Stratum corneum ablation 
The simplest and easiest way of overcoming the skin barrier is to remove the stratum 
corneum as this will substantially enhance skin permeation and water loss. A number 
of techniques have been developed that provide a controlled removal or ablation of 
the stratum corneum including the application of radiofrequency energy, lasers, and 
formation of suction blisters.
120
 
1.3.4.1 Radio frequency ablation (RF)  
RF ablation is a well-known medical technology to eliminate malignant tissues by 
placing an electrode directly into the tissue. This energy generates movement of ions 
resulting in frictional heating of the tissue to produce necrosis and cell ablation.
212
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The ViaDerm system is a transdermal delivery technology that consists of a 
microarray of radiofrequency electrodes. (Figure 1.15) This system creates micro-
channels in the epidermis by cell ablation thereby permitting drug diffusion via the 
micro-channels.
213
  The technology has been evaluated for transdermal delivery of 
small hydrophilic drugs, peptides and genes.
214-216
. The ViaDerm system showed 
75% more bioavailability of human growth hormone (hGH) as compared to 
subcutaneous injection and recently the delivery of 100 nm nanoparticles and gene 
therapy vectors was demonstrated.
216
 It has also been reported that RF application 
results in 3-5 fold increase in TEWL immediately after application.
215
 RF micro-
channels only penetrate the outer layers of the skin thus minimizing skin trauma and 
unpleasant sensations.
217
  
 
Figure 1.15 Viaderm radiofrequency thermal ablation (TransPharma Medical Ltd) 
1.3.4.2 Laser ablation  
A high energy laser directed at the skin surface creates pores in the skin to increase 
permeability to subsequently applied drugs.
3
 Application of the technique, using a 
laser emitting at 2790 nm, to enhance drug delivery was first described by Nelson et 
al.
212
 in 1991.  They reported a 2.1 times increase in the permeability coefficient of 
interferon-ɣ (IFN-ɣ) across pig skin. In a more recent study, Lee et al.218 reported 
successful transdermal application of polypeptides and related vaccines using an 
erbium: yttrium–aluminium–garnet (Er:YAG) laser. The peptide flux across skin 
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treated with a laser was 3–140 folds higher than that across intact skin. Molecular 
size, lipophilicity, and peptide sequence influenced permeation. It was also 
demonstrated for the first time that laser treatment with no adjuvant or penetration 
enhancer significantly enhanced the production of antibodies in the serum by 3-
fold.
218
 The technique has been further evaluated with a range of small drugs and 
macromolecules including insulin.
218,219,220
 Pantec Biosolutions have developed 
P.L.E.A.S.E – Painless Laser Epidermal System, for large molecule drug delivery 
(www.pantecbiosolutions.com). Although this drug delivery technique may be 
technically feasible many questions regarding safety remain unanswered and it is 
likely that laser ablation would be restricted to the clinical setting with limited 
application.
221
  
1.3.4.3 Suction blister ablation  
This technique utilizes a vacuum to produce a small blister, the upper surface of 
which is removed to expose a pathway of low resistance for entry of small and 
macromolecules into the dermis.
120
 The commercial product Cellpatch incorporates 
all the components of the process: suction device, epidermatome (to remove the 
blister) and drug reservoir. The device is used to deliver morphine in postoperative 
pain.
222
 Svedman et al.
223
 reported the application of the antidiuretic peptide 1-
deamino-8-D-arginine vasopressin using Cellpatch with close to 100% 
bioavailability in healthy human subjects with recovery of the skin spot to normal 
after 6 weeks.
223
 This technique is a multi-step process and it is unlikely to be 
convenient for routine use by patients or clinicians and hence may not progress 
further for peptide delivery.
120
 
1.3.4.4 Thermal poration  
Thermal methods have been used to locally heat and ablate holes in the stratum 
corneum thereby increasing skin permeability by formation of aqueous pathways 
across the stratum corneum.
185
 The technology has been patented
224
 and is being 
developed by Altea Therapeutics under the terminology of PassPort Patch 
(www.alteatherapeutics.com). This approach has been used to deliver conventional 
drugs
215
 and DNA vaccines
225
 to animals, and to extract interstitial fluid glucose 
from human subjects.
226
 Badkar et al.
227
  used this technology to deliver interferon α-
2b through microporated skin. It was shown that interferon could not be delivered 
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through intact skin or even with iontophoresis, but was only delivered when these 
micropores were created in the skin. In another study, a 10 –100 fold greater cellular 
and humoral immune response was reported following topical application of an 
adenovirus vaccine to thermally microporated mouse skin as compared to intact 
skin.
225
  
Methods that pierce micron-scale holes in skin, such as thermal poration and jet 
injection have the potential to dramatically increase transdermal delivery of small 
drugs and macromolecules, but more work is needed to establish safety/skin damage 
and cost effectiveness.
185
  
1.3.5 Peptides as potential therapeutic and cosmetic agents 
A number of peptides of differing molecular weights and chain lengths have been 
identified for their therapeutic or cosmetic potential in the skin.  
1.3.5.1 Bioactive peptides as cosmeceuticals  
Proteins and peptides play an important role in skin health as structural components 
of the skin as well as activators, regulators or inhibitors of certain biochemical 
processes occurring in the skin.
228
 They are also important in many natural processes 
with relevance to skin care, such as the modulation of cell proliferation, cell 
migration, inflammation, angiogenesis, melanogenesis, and protein synthesis and 
regulation.
229
 With variations in amino acid sequence, number of amino acids and 
derivatives thereof the array of possible peptides is almost limitless.
230
 
Cosmeceuticals are topically applied cosmetic products that deliver beneficial 
biological activity in support of cosmetic claims.
231,229
 Peptides as cosmeceuticals is 
a fast-growing segment of the personal care industry with an increasing trend 
towards the use of these agents in skin care regimens for protection from radiation 
and oxidant damage.
232
 As a result bioactive peptides that are beneficial have been 
increasingly used and many more are in the development pipeline.
229
 There are 
numerous cosmeceutically active products on the market which can be broadly 
classified into the following categories: antioxidants, amino-peptides, growth factors, 
anti-inflammatories, polysaccharides and pigment lightning agents.
231
 Some 
examples of peptides used as cosmeceuticals include copper peptides, amino-
peptides, acetyl hexapeptide-3 and dimethylaminoethanol.
231
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A number of peptides play various roles in skin aging. GHK is a tripeptide that has a 
strong affinity for copper, so it is often called copper peptide or GHK-Cu. Copper 
peptides such as GHK-copper complex are included in products to improve skin 
firmness and texture, fine lines and hyperpigmentation. Both the tripeptide alone and 
the copper-tripeptide complex have been found to have beneficial effects on collagen 
stimulation.
233
 Pal-KTTKS is a collagen peptide fragment, and there is evidence in 
wound healing that it may penetrate into the dermis and stimulate collagen 
production.  Pal-KTTKS, marketed as Matrixyl (Sederna, France), is an amino acid 
chain (KTTKS) linked to a fatty acid (palmitoyl) to enhance its lipophilicity, and is 
an ingredient in a number of cosmeceuticals.
231
 Pal-KTTKS was well tolerated and 
significantly reduced fine lines by both qualitative technical and expert grader image 
analysis in a 12-week, double-blind, placebo-controlled, split-face, randomized 
clinical study of 93 Caucasian women between 35 and 55 years of age.
234
  
Acetyl hexapeptide-3 marketed as Argireline
®
  (Lipotec, S.A.) is another popular 
synthetic peptide that has a botox-like effect.
235
 When tested in an open label trial it 
showed improvement in periorbital rhytides (wrinkles on the face and near eyes) an 
effect that was claimed to be due to its muscle-relaxing effects.
236
 Tripeptide-3 (β-
Ala-Pro-Dab-NHbenzyl2 AcOH), currently marketed as Syn®-Ake (Lipotec S.A.), is 
proposed to act similarly to Walglerin-1. Walglerin-1 (Pentapharm, Switzerland) is a 
neurotoxin found in the venom of the temple viper, which causes reversible 
antagonism of muscular nicotinic acetylcholine receptors (mnAChR) at the 
postsynaptic membrane decreasing muscle contraction and reducing wrinkle 
depth.
233
 Similarly, palmitoyl hexapeptide-6, a peptide designed using an innate 
immunity peptide template (Grant Industries, Elmwood, NJ) stimulates fibroblast 
proliferation and scaffolding, collagen synthesis, and cell migration, and is currently 
marketed for inclusion in anti-wrinkle skin care products.  Dipeptide-2 (Val-Trp) is 
believed to improve lymphatic circulation and is used in eye creams for dark circles 
and puffy eyes. The peptide’s structure resembles that of the lipid content of the 
epidermis and is considered to be a natural moisturizing factor as it helps in the 
skin’s healing process and prevents dermal irritation.237 
A number of patents have been filed on the use of peptides for cosmetic products. 
These include a patent describing topical composition containing the tetrapeptide 
Arg-Ser-Arg-Lys for reducing wrinkles. This tetrapeptide is a fibroblast growth 
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factor derived peptide which decreases cellular activity.
238
 Another patent describes 
the use of sirtuin 6 activating peptides, derived from highly conserved regions of 
human SIRT proteins, in a cosmetic composition to prevent and/or treat the 
cutaneous signs of aging and photo aging.
239
 Carnosine (β-alanyl-L-histidine) and 
related naturally occurring histidine containing dipeptides such as anserine, exhibit 
anti-oxidative properties by quenching free radicals.
240-242
 Carnosine also accelerates 
healing of wounds and ulcers and is reported to act as an anti-ageing peptide.
240, 242
 It 
is speculated that the dipeptide may participate in the repair of protein isoaspartyl 
groups. These new observations only add to the enigma of carnosine's real in vivo 
functions and warrant further experimentation.
243
  
Substantial patent activity has been found in the area of chemically modified 
peptides for healing, hydrating and improving skin appearance. A combination of 
peptides with the general sequence X-Thr-Thr-Lys-Y was reported to have activity 
against the formation or deterioration of wrinkles.
244
  Cosmetic compositions with at 
least one ceramide compound and one peptide attached to a fatty acid chain have 
been formulated. Ceramides and their analogues have been known to protect and 
repair skin or hair fibres from damage caused by various agents and hair treatments 
by providing a barrier effect which minimizes the leakage of proteins.
245
 
1.3.5.2 Bioactive peptides as dermatologicals (in skin diseases) 
Bioactive peptides play an important role in maintenance of dermal integrity. Human 
skin is known to produce some antimicrobial peptides (AMPs) that form an innate 
epithelial chemical shield.
246
 Many AMPs have recently been isolated such as 
lysozyme, RNase
247
, elafin, psoriasin, dermicidin (DCD) 1L, granulysin, 
antileukoprotease and human cationic antimicrobial protein (hCAP18).
247,248
 In 
addition to their antimicrobial function, endogenous peptides are also involved in 
extracellular matrix (ECM) remodelling and stimulation of collagen synthesis. 
Katayama et al.
249
 identified the activities of small peptide fragments within 
procollagen I resulting in the identification of the sub fragment KTTKS capable of 
stimulating the production of both collagen and fibronectin.
249
  Sederma later 
marketed this peptide in its lipidated form as palmitoyl pentapeptide-3 (Matrixyl) for 
cosmetic formulations, as noted above.
229
  
46 
 
Wound healing is a localised process which involves a series of specific and 
coordinated events such as inflammation, wound cell migration and mitosis, 
neovascularisation, and regeneration of the extracellular matrix (ECM).
250,251
 Wound 
healing properties have been attributed to many endogenous and non-endogenous 
peptides such as cathilicidin LL-37
252
, HB-107, and a derivative of cecropin B.
253
 
Polypeptide growth factors such as epidermal growth factor (EGF) and transforming 
growth factor-α (TGF-α) play a pivotal role in normal wound healing in tissues such 
as skin, cornea and the gastrointestinal (GI) tract.
12
 Copper peptides also have a 
positive influence on the growth and regulation of hair follicles, and when used on 
wounds increase collagen disposition, tensile strength and angiogenesis in healing 
tissues.
254
  
Another area where endo and exogenous peptides could find application is in the 
treatment of skin diseases such as atopic dermatitis (AD) and psoriasis. AD is a 
chronic inflammatory skin disease with abnormal (usually reduced) expression or 
processing of AMPs and patients demonstrate increased susceptibility to bacterial 
and viral super infection of the involved skin
255
 Early treatment with microbial 
probiotics may be beneficial by boosting Th1 immune responses in AD. Other 
approaches include cytokine modulation (e.g. TNF-α inhibitors), blocking 
inflammatory cell recruitment by using chemokine receptor antagonist, inhibition of 
T cell activation, and the use of synthetic AMPs. Restoration of innate peptides to 
normal levels via external application could provide significant benefit.
12,229
  
Psoriasis is a skin condition of unknown aetiology that is characterised by epidermal 
hyperplasia, vascular alterations and inflammation.
256
 Genetic factors are thought to 
be one of the important causes for the expression of this disease. In addition, 
cytokines, growth factors and arachidonic acid derived mediators are potential 
candidates with a pathogenic role in cutaneous inflammation.
256,257
  Peptides and 
proteins such as elafin and psoriasin are highly upregulated in psoriatic skin.
256,258
 It 
was shown in clinical trials that the Peptide T analogue, DAPTA cleared psoriasis 
lesions and significantly inhibited the monocyte and lymphocyte chemotactic 
properties of RANTES (a beta chemokine found in increased amount in psoriatic 
lesions). A better understanding of the role of these peptides may provide new 
strategies for the treatment of diseases like psoriasis.
259
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Peptides and proteins also play an important role in melanogenesis. The synthesis 
and distribution of melanin contributes to skin and hair colour; however, increased 
levels of epidermal melanin synthesis can darken the skin and cause cosmetic 
problems. Melanocyte-inhibiting factor (also known as Pro-Leu-Gly-NH2, 
Melanostatin, MSH release-inhibiting hormone or MIF-1) is an endogenous peptide 
fragment derived from cleavage of the hormone oxytocin.
260
  MIF-1 has anti-
depressant
261
, nootropic
262
 and anti-Parkinsonian effects, and has been investigated 
for various medical uses. The peptide crosses the blood-brain barrier easily, though it 
is poorly active when administered orally. In their search for active metabolites 
Ishihara et al.
263
 isolated a microorganism from a soil sample to produce an active 
compound, which they designated melanostatin.  
Melanostatin is a novel pseudo-tripeptide with a molecular formula of C19H25N5O5 
and is structurally related to feldamycin.  Melanostatin inhibited melanin formation 
in Streptomyces bikiniensis NRRLB-1049 and B16 melanoma cells. A patent filed in 
2011, describes a "one-step" process for production of esters and acetylated forms of 
peptides such as tripeptide thyroliberin (TRH) and melanostatin (MIF), and other 
organic molecules. This chemical modification approach improved metabolic 
properties leading to increased efficiency for therapeutic and cosmetic purposes 
including oral, transdermal, sublingual, buccal, and topical administration.
264
 The use 
of α-MSH (melanocyte-stimulating hormone) analogues that function as MC1-R 
agonists has been investigated for potential topical agents to prevent skin photo-
carcinogenesis. In cultured human melanocytes, tetrapeptide α-MSH analogues, Ac-
His-D-Phe-Arg-Trp-NH2, N-pentadecanoyl and 4-phenylbutyryl-His-d-Phe-Arg-Trp-
NH2, were more potent than α-MSH in stimulating the activity of melanogenesis, 
reducing apoptosis and release of hydrogen peroxide, and enhancing repair of DNA 
photoproducts in melanocytes exposed to UV radiation.
265
 Melanostatin-5 (Aqua-
Dextran-Nonapeptide-1), is a new skin lightening biomimetic peptide. This peptide 
acts as a α-MSH antagonist thus preventing and lightening hyperpigmentation.266 
Melanostatin-5 produces noticeable skin lightening by at least 33% when formulated 
into a lightening product, and showed continued improvement over time.  
Rigin, an immunostimulating tetrapeptide (Gly-Gln-Pro-Arg) that connects the CH2 
and CH3 domains of human immunoglobulin G (IgG) molecule, has been shown to 
exhibit significant in vitro phagocytosis stimulating activity toward rat blood 
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leukocytes and Staphylococcus aureus.
267
 Synthesis of rigin was first described in 
1981 by Veretennikova et al.
268
 Later Rocchi et al.
269
 synthesised modified analogues 
of rigin with D-gluconic acid or 2-amino-2-deoxy-D-glucopyranose linked to the 
parent molecule through amide bonds. These compounds however where found to be 
ineffective in vitro. The down regulation of inflammatory mediators such as 
Interlukin-6 (IL-6) by rigin can produce increased skin firmness, smoothness, and 
elasticity.
229,270
 Palmitoyl tripeptide (Pal-KVK) improves micro circulation, 
increasing the oxygen supply to tissues, strengthening and protecting the integrity of 
elastin and collagen in the skin by inhibiting elastase and collagenase activity. Its 
benefits include reduction of puffiness and dark circles around the eyes and a 
softening of fine lines and wrinkles.
271
  
1.4 Significance 
Enhanced skin delivery by the carrier conjugation approach using diketopiperazines 
(DKP) as proposed in this research would offer new opportunities in cosmetic and 
dermatological applications. CPPs have the potential to change the world of 
pharmaceutics as we know it today.
84
  This strategy will be of particular importance 
for molecules with poor skin penetration profile that could offer novel therapeutics. 
DKPs are heterocyclic scaffolds in which diverse cargos of active molecules can be 
introduced and stereochemically controlled at up to four positions and DKPs can be 
prepared from readily available α-amino acids using very robust chemistry.103  
Over the past few years since first described by Henry et al.
186
, a variety of different 
microneedle designs have been fabricated using materials such as silicon, metals and 
polymers.
186,187
 In this project fluorescent model molecules were used to look at a 
time correlation upon microneedle delivery. The peptides used for this were very 
well studied molecules with a multitude of applications.  We believe that by 
delivering functional amounts of these peptides deep within skin we can unlock their 
true therapeutic potential. Consequently, we investigated microneedle facilitated 
delivery of melanostatin, rigin and Pal-KTTKS. 
Magnetophoresis was investigated in in vivo, ex vivo and in vitro studies. Further, 
synergistic effects of microneedles with magnetophoresis were investigated.  The 
proprietary magnets used in this PhD can be very easily developed into transdermal 
patches with the capacity to deliver a wide range of molecules from a suitable 
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reservoir. Further, we hope to throw more light on this very bleakly understood 
subject by undertaking mechanistic studies that can enable us to be better equipped to 
comment on the mechanism of magnetophoresis. 
1.5 Objectives  
The overall objective of this research was to investigate novel technologies for the 
enhanced transdermal delivery of peptides, particularly those with therapeutic or 
cosmetic application in skin. Despite the increasing importance of peptides and 
protein therapeutics and vaccines, the need to deliver them by hypodermic injection 
remains a major limitation.
272
 Peptides are rapidly cleared from the bloodstream, can 
be of large molecular size and tend to undergo aggregation. Moreover peptides are 
vulnerable to proteolytic attack and denaturation.
1
 Delivery of protein drugs through 
the skin is an attractive alternative to needles, but requires overcoming significant 
challenges.  
The major objective of this research was to assess three enhancement strategies 1. 
Cell penetrating peptides; 2. Microneedles; and 3. Magnetophoresis for the delivery 
of small and high molecular weight peptides and model molecules for cosmetic and 
therapeutic uses. The project was divided into following parts: 
o Assessment of transdermal penetration of a novel class of cell penetrating 
peptide-DKPs 
o Assessment of the ability of DKPs to carry small therapeutic cargo, through 
and  into human skin 
o Assessment of the therapeutic activity of conjugated cargo, with the use of 
appropriate enzyme assays 
o Assessment of transdermal penetration of model fluorescent molecules after 
microneedle based delivery 
o  Assessment of transdermal penetration of model molecules under the 
influence of magnetic field generated by proprietary small fixed magnets, 
exploration of possible synergism with the use of microneedles 
o Explanation and comments on possible modes of magnetophoretic delivery in 
skin 
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Chapter 2  
Permeation of Cell Penetrating Peptides and their Influence 
on the Permeation of Diclofenac and a Dipeptide through 
Human Skin 
 
 
“The peptides named Cell Penetrating Peptides vary greatly in size, amino acid 
sequence, and charge, but share the common feature that they have the ability to 
rapidly translocate membranes and enable delivery across it”74 
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2.1 Introduction 
Considerable research effort has been focussed on the development of skin 
penetration enhancement techniques primarily directed at overcoming the stratum 
corneum barrier. However, many of these techniques have been limited by 
insufficient penetration enhancement and/or induced irritancy.  To date none of these 
approaches have been sufficiently useful in the topical/transdermal delivery of 
peptides and proteins, though low molecular weight drugs have been transported 
with some success.
273
 To circumvent the problems of poor permeability, studies have 
been focused on improving the chemistry of these molecules, and several carrier-
mediated delivery systems have recently been developed. A suitable drug carrier 
should 
274
  
 be biodegradable and biocompatible 
 lack intrinsic toxicity and antigenicity 
 show no accumulation in the body 
 bear adequate functional groups for chemical fixation 
 retain the original specificity for the target 
 maintain the original activity of the delivered drug until it reaches the site of 
action 
In this study we are going to embark upon a novel skin penetration enhancement 
technique- diketopiperazines (DKP) as cell penetrating peptides. Several cell 
penetrating peptides including HIV-1-Trans-Activator of Transcription (TAT), 
polyarginine and penetratin, which were initially identified for delivering drugs into 
the cytoplasm of cells, have been tested for penetration across the stratum corneum 
and a few have shown some efficacy in delivering small molecules into 
epidermis.
107,108,112 275
  
Two  strategies have been described to date; the first one requires chemical linkage 
between the drug and the carrier for cellular drug internalization, and the second is 
based on the formation of stable complexes with drugs, depending on their chemical 
nature.
274
 In this research project I have studied both these approaches.  The various 
mechanisms of action, uses and pharmacokinetics of cell penetrating peptides have 
been discussed elaborately in the first chapter. Despite enormous gaps in the 
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understanding of the topic, experiments continue to demonstrate the highly desirable 
features of cell penetrating peptides.
276
 
2.2 Aims of the project 
The aim of this project was to investigate the permeation and retention of cell 
penetrating peptides in human skin and to investigate their ability to enhance the 
delivery of an active molecule into the skin. The project was divided into four parts 
as detailed below: 
1) Determination of the permeation into and through human epidermis of the 
cell penetrating peptides diketopiperazine (DKP) and HIV-1-Trans-Activator 
of Transcription (TAT). 
2) Determine the influence of DKP on the skin penetration of two compounds: 
the non-steroidal anti-inflammatory drug, diclofenac and the dipeptide, Ala-
Trp when applied as a physical admixture.  
3) Conjugation of DKP with diclofenac and determination of the skin 
penetration and accumulation of the conjugate in human skin.  
4) Determination of the skin penetration and accumulation of TAT conjugated 
to diclofenac.  
5) Determination of the COX-2 inhibition activity of diclofenac and DKP-
diclofenac conjugate using a specific enzyme assay kit. 
2.3 Materials and Methods 
2.3.1 Chemicals  
Diketopiperazine (DKP: N-MePhe-N-MePhe; molecular weight = 359.44 g/mol) was 
synthesised at the University of Barcelona (in collaboration with Dr Teixidó and Prof 
Giralt). Alanine-Tryptophan (Ala-Trp), a model dipeptide with a molecular weight of 
275.30 Da and diclofenac a model non-steroidal anti-inflammatory drug (NSAID) 
with a molecular weight of 318.13 Da were purchased from Sigma Aldrich (USA). 
TAT and TAT-diclofenac were synthesised by GLS Pharma (China). Propylene 
glycol (PG) and dimethyl sulphoxide (DMSO) were obtained from BDH Chemical 
pvt Ltd and Ajax FineChem respectively. Acetonitrile, HPLC solvent was supplied 
by JT Baker (USA) and phosphate buffered saline solution (PBS) was prepared 
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according to the United States Pharmacopoeia. COX enzyme assay kit was 
purchased from Cayman Ltd USA.  
2.3.2 Synthesis of DKP and DKP-diclofenac 
The following information describing the synthesis, purification and validation of the 
peptides was supplied by Professor Earnest Giralt and Dr. Meritxell Teixido’s group 
at the University of Barcelona. A first library of 15 DKPs with distinct side chains 
was prepared using a solid-phase methodology (Figure 2.1, Scheme 1). For most 
cases, the only purification required was a de-salting step. The side chains were 
chosen in order to explore the effect of adding or removing a methylene group, 
adding a nitrogen or oxygen atom, and adding a larger aromatic ring or a 
hydrophobic, but not aromatic, side chain. All DKPs in this first library were 
characterized by HPLC, HPLC-MS, and MALDI-TOF MS. All were obtained with 
purity higher than 90%. The DKP selected for further skin delivery studies was 
DKP-2Nal-N-MePhe (Figure 2.2)  
 
Figure 2.1 Synthesis of DKP library (scheme 1) 
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Figure 2.2 Chemical structure of DKP-2Nal-N-MePhe 
The conjugation of DKP with diclofenac was carried out in a similar approach as the 
synthesis of DKP library (Figure 2.3, Scheme 2). The main difference was the use of 
Fmoc protected starting material instead of Boc protected. The synthesis was carried 
out to first construct the intermediate DKP-2Nal-N-MePhe, followed by a coupling 
reaction to add diclofenac. The purification was achieved by filtration and solvent 
evaporation under pressure (N2) to yield DKP-diclofenac (Molecular weight = 
652.60 g/mol) (Figure 2.4)    
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Figure 2.3 Synthesis of DKP-diclofenac (scheme 2) 
 
 
Figure 2.4 Chemical structure of DKP-diclofenac 
2.3.3 Synthesis of TAT and TAT-diclofenac 
Synthesis of TAT (Gly - Arg - Lys - Lys - Arg - Arg - Gln - Arg - Arg - Arg - Pro - 
Pro - Gln - Cys -NH2) and TAT-diclofenac was carried out by a commercial 
laboratory based in China (GLS Biochem). HPLC and MS-MALDI data provided by 
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the suppliers was then revalidated in our laboratory. The diclofenac molecule was 
attached to the TAT peptide through an amide linkage at the N-terminus. 
2.3.4 HPLC instrumentation and conditions 
The samples obtained after in vitro skin permeation studies were analysed by reverse 
phase HPLC Agilent 1200 system which consisted of a binary pump (G1312A), 
autosampler (G1329A), degasser (G1379B) and photo diode array detector 
(G1365B). Separation was achieved on a Phenomenex Jupiter C18, 300 A column (5 
μm, 4.6 mm×150 mm). Integration was undertaken using Chemstation software. The 
elution conditions for each of the compounds are outlined separately.  
2.3.4.1 DKP 
Elution was performed at ambient temperature using a mobile phase gradient with a 
flow rate of 1 mL/min and the wavelength of detection was 220 nm. Buffer B was 
0.036% TFA in acetonitrile and Buffer A was 0.045% TFA in water. The peptide 
was eluted using a linear gradient protocol; Buffer B was held at 10% for 5 min 
followed by a linear gradient from 10 to 100% buffer B over 10 min. All samples 
were analysed by HPLC using injection volumes of 20 μL. 
2.3.4.2 DKP-diclofenac 
Elution was performed at ambient temperature using a mobile phase gradient at a 
flow rate of 1 mL/min and the wavelength of detection was 278 nm. Buffer B was 
0.036% TFA in acetonitrile and Buffer A was 0.045% TFA in water. The peptide 
was eluted using a linear gradient protocol; Buffer B was held at a linear gradient 
from 10 to 100% buffer B over 10 min.  
2.3.4.3 Ala-Trp 
Elution was performed at ambient temperature using a mobile phase gradient at a 
flow rate of 1 mL/min and the wavelength of detection was 215 nm. Buffer A was 
0.1% TFA in water and Buffer B was 0.1% TFA in acetonitrile. The dipeptide was 
eluted using a combination of isocratic and linear gradient protocol; Buffer B was 
held at 10% for 5 min followed by a linear gradient from 10 to 100% buffer B over 
10 min.  
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2.3.4.4 Diclofenac 
Elution was performed at ambient temperature using a mobile phase gradient at a 
flow rate of 1 mL/min and the wavelength of detection was 278 nm. Buffer A was 
0.036% TFA in acetonitrile and Buffer B was 0.045% TFA in water. The peptide 
was eluted using a linear gradient protocol; Buffer B was held at a linear gradient 
from 10 to 100% over 10 min.  
2.3.4.5 TAT 
Elution was performed at ambient temperature using a mobile phase gradient at a 
flow rate of 1 mL/min and the wavelength of detection was 220 nm. Buffer A was 
0.1% TFA and Buffer B was 0.1% TFA in acetonitrile. The peptide was eluted using 
a linear gradient protocol; Buffer B was held at a linear gradient from 10 to 100% 
over 22 min. 
2.3.4.6 TAT-diclofenac 
Elution was performed using a mobile phase gradient at a flow rate of 1 mL/min and 
the wavelength of detection was 220 nm. Buffer A was 0.1% TFA and Buffer B was 
0.1% TFA in acetonitrile. The peptide was eluted using a linear gradient protocol; 
Buffer B was held at a linear gradient from 93 to 0% over 27 min. 
2.3.5 HPLC analysis and validation 
2.3.5.1 Linearity 
A 1 mg/mL stock solution of all peptides, conjugates and models drugs was prepared 
by dissolving 5 mg of the compound in 5 mL of 25:75 propylene glycol (PG): 
phosphate buffered saline (PBS). Linear dilution was performed using PG:PBS and 
calibration curves were obtained using 1.95, 3.9, 7.81, 15.62, 31.25, 62.5 and 125 
μg/mL for DKP; 1.56, 3.125, 6.25, 12.5, 25 and 50 μg/mL for Ala-Trp; 3.9, 7.81, 
15.62, 31.25, 62.5, 125 and 250 μg/mL for DKP-Ala-Trp physical admixture; 3.9, 
7.9, 15.6, 31.25, 62.5 and 125 μg/mL for diclofenac; 3.9, 7.9, 15.6, 31.25, 62.5 and 
125   μg/mL for DKP-diclofenac physical admixture; 3.9, 7.81, 15.62, 31.25, 62.5, 
125 and 250 μg/mL for DKP-diclofenac conjugate; 3.25, 6.5, 13, 26, 52 and 104 
μg/mL for TAT; 7.81, 15.62, 31.25, 62.5, 125 and 250 μg/mL for TAT-diclofenac 
conjugate. Linearity (quoted as R
2
) was evaluated by linear regression analysis, 
which was calculated by the least square regression method.  
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2.3.5.2 Precision 
The precision of the assay was determined by injecting three standard concentrations 
of 1.95, 15.6 and 62.5 μg/mL DKP; 1.56, 6.25 and 50.0 μg/mL Ala-Trp; 3.9, 15.6 
and 62.5 μg/mL DKP-Ala-Trp physical admixture, diclofenac, DKP-diclofenac 
physical admixture and DKP-diclofenac conjugate; 3.25, 13.0 and 52.0 μg/mL TAT; 
7.81, 31.25 and 125 μg/mL TAT-diclofenac conjugate six times on the HPLC. 
2.3.5.3 Intra-day repeatability 
The intra-day repeatability was assessed by injecting 1.95 and 15.62 μg/mL DKP; 
1.56 and 12.5 μg/mL Ala-Trp; 3.9 and 15.6 μg/mL DKP-Ala-Trp physical admixture, 
diclofenac, DKP-diclofenac physical admixture and DKP-diclofenac conjugate; 3.25 
and 13.0 μg/mL TAT; 7.81 and 31.25 μg/mL TAT-diclofenac standards six times at 
different times in a day. 
2.3.5.4 Inter-day repeatability 
The inter-day repeatability was determined by injecting 1.95 and 15.62 μg/mL DKP; 
1.56 and 12.5 μg/mL Ala-Trp; 3.9 and 15.6 μg/mL DKP-Ala-Trp physical admixture, 
diclofenac, DKP-diclofenac physical admixture and DKP-diclofenac conjugate; 3.25 
and 13.0 μg/mL TAT; 7.81 and 31.25 μg/mL TAT-diclofenac conjugate standards 
six times on 3 different days. The intra and inter-day repeatabilities were quoted as 
the coefficient of variance. 
2.3.5.5 Lower limit of detection (LOD) 
The minimum detectable and quantifiable limits (LOD and LOQ) were measured by 
diluting the stock solution of DKP, Ala-Trp, diclofenac, physical admixture of Ala-
Trp and diclofenac with DKP, DKP-diclofenac conjugate, TAT and TAT-diclofenac 
conjugate with 25:75 PG:PBS to give a concentration range from 1.56 to 250 μg/mL 
and then injected on the HPLC. The LOD was calculated as greater than 3 times the 
baseline noise level by the following formula: LOD = 3 × standard deviation of peak 
area of standard / slope. 
2.3.5.6 Lower limit of quantification (LOQ) 
The LOQ was calculated as 10 times the baseline noise level. The LOQ was 
calculated by the following formula: LOQ = 10 × standard deviation of peak area of 
standard / slope. 
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2.3.6 Human skin preparation 
Full thickness human skin samples excised from female patients (26-48 year old 
female abdominal sections were used in the present study) undergoing 
abdominoplasty at Perth hospitals were refrigerated immediately after surgery. 
Sampling was approved by the Human Research Ethics Committee of Curtin 
University (Approval numbers HR132/2001, HR 70/2007 and HR 129/2008) and 
was conducted in compliance with the guidelines of the National Health and Medical 
Research Council of Australia. The following procedure was used to obtain 
epidermal sheets. The subcutaneous fat was removed by dissection, the full thickness 
skin then immersed in water at 60°C for 1 min, allowing the epidermis to be teased 
off the dermis.
277
 The epidermis was placed between two sheets of Parafilm
TM
 and 
then onto an aluminium foil, air dried, then placed in a zip-lock bag and stored at –
20°C until required. Skins from different donors were used to account for 
reproducibility. 
2.3.7 Skin permeation experiments to determine effect of cell penetrating 
peptides  
2.3.7.1  Skin hydration  
Skin hydration can improve the delivery of drugs across the continuous stratum 
corneum. This was investigated by hydrating the epidermal membranes to be used in 
the diffusion study with phosphate buffered saline (PBS) for 0.5 h and overnight. 
Epidermal membranes were placed between the donor and receptor compartments of 
a Franz cell (Figure 2.5) and allowed to equilibrate overnight (up to 10 h) with the 
receptor solution (PBS pH 7.4). Before the start of the experiment, PBS was 
withdrawn and a fresh sample of pre-equilibrated receptor medium at 37°C was 
replaced in the receptor compartment. 
2.3.7.2 In vitro skin diffusion studies 
In vitro permeation studies across human epidermis were performed in Pyrex glass 
Franz-type diffusion cells (enabling permeation across skin sections of cross 
sectional area 1.18 cm
2
; receptor volume approximately 3.5 mL: Figure 2.5). 
Epidermal membranes were placed between the donor and receptor compartments 
and allowed to equilibrate for 0.5 h or overnight with the receptor solution (PBS pH 
7.4) that was stirred continuously with a magnetic stirrer bar. The receptor 
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compartment of the cell was immersed in a water bath at 37±0.5°C. PBS (1 mL) was 
placed in the donor compartment, allowed to equilibrate for 1 h or overnight and the 
conductivity across the epidermis was measured using a digital multimeter to 
determine membrane integrity. Membranes exhibiting an electrical resistance of less 
than 20 kΩ were rejected from the study. The PBS solution was then removed from 
the donor and receptor compartments and the receptor refilled with approximately 3 
mL of fresh pre-warmed 25:75 PG:PBS. The donor solution, which consisted of 300 
μL of either 150 µg, 300 µg or 1500 µg cell penetrating peptide (DKP or TAT), 
physical admixture of cell penetrating peptide and active, or conjugated cell 
penetrating peptides to the active in 25:75 PG:PBS, was added. Two hundred μL 
samples of the receptor phase were withdrawn and replaced with an equal volume of 
fresh pre-warmed (37°C) 25:75 PG:PBS over a 24 h period to maintain sink 
conditions. The active content in the samples was determined using HPLC. 
 
Figure 2.5 Schematic representation of skin diffusion experimental cell 
At least 5 replicates were conducted for each of the cell penetrating peptides, 
physical admixtures and cell penetrating peptide – active conjugates. The cumulative 
amount of cell penetrating peptide or active permeated through the epidermis 
(μg/cm2) versus time (h) was plotted. The cumulative amount was corrected for 
amount removed in each sample. The flux through the human epidermis was 
determined from the slope of the plot of cumulative amount versus time and 
expressed as μg/cm2/h. Permeability coefficients (cm/h) were calculated using the 
following equation: 
Permeability coefficient Kp (cm/h) = Flux (J) / Concentration in the donor (C) 
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2.3.8 Mass balance and recovery 
The uptake of the each cell penetrating peptide (DKP and TAT), Ala-Trp, diclofenac 
and cell penetrating peptide-active conjugates in the epidermis was investigated. 
Propylene glycol and methanol were used as extraction solvents and the protocol for 
propylene glycol and methanol extraction was as follows:  
The recovery of DKP, TAT, Ala-Trp, diclofenac, DKP-diclofenac conjugate and 
TAT-diclofenac conjugate from skin tissue was determined by spiking skin sections 
with the conjugates in propylene glycol. The skin sections were allowed to rest in 
500 μL methanol and vortexed for 2 min. The skin section was then transferred to a 
second Eppendorf tube containing 500 μL methanol and vortexed for another 2 min. 
The skin sample was then placed in 1 mL propylene glycol for 1 h with agitation. 
After centrifuging each extract at 10,000 × g for 10 min, the resultant supernatants 
were diluted appropriately and quantified by HPLC. This extraction method using 
methanol and propylene glycol proved to be very efficient and was therefore used for 
the experimental samples. 
Mass balance/recovery after the skin permeation experiments was determined by 
removing the donor solution from the donor compartment and appropriately diluting 
it to quantify the amount of active present in the donor at the end of the experiment. 
The donor compartment with the skin was rinsed with 300 μL PBS and the wash was 
collected. The receptor compartment was emptied and washed with 500 μL PBS. 
Samples from both washes were injected on HPLC to quantify the active present in 
the washes. 
2.3.9 Cyclooxygenase (COX) inhibition assays 
COX-2 inhibition by DKP-diclofenac conjugate and diclofenac was assessed using a 
COX Fluorescent Inhibitor Screening Assay Kit (700100, Cayman Chemical, USA). 
Cyclooxygenase is a bifunctional enzyme exhibiting both COX and peroxidise 
activities. COX-2 is responsible for the biosynthesis of prostaglandins under acute 
inflammatory conditions.
278,279
 This inducible COX-2 is believed to be the target 
enzyme for the anti-inflammatory activity of non-steroidal anti-inflammatory 
drugs.
279
 Diclofenac was the standard to which the conjugated DKP- diclofenac 
molecule was compared.  The major components of the kit were COX-2 (human 
recombinant) enzyme, heme, arachidonic acid and the fluorimeteric substrate, ADHP 
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(10-acetyl-3,7-dihydroxyphenoxazine) . The assay utilizes the peroxidise component 
of COXs. The COX component converts arachidonic acid to a hydroxyl 
endoperoxide (PGG2), and the peroxidise component reduces the endoperoxide to the 
corresponding alcohol (PGH2), the precursor of prostaglandins, throboxanes and 
prostacyclins.
280,281
 The reaction between PGG2 and ADHP (10-acetyl-3,7-
dihydroxyphenoxazine) produces the highly fluorescent compound resorufin.  
Resorufin fluorescence can be easily analysed with an excitation wavelength of 530-
540 nm and an emission wavelength of 585-595 nm.  
The activity of diclofenac and DKP-diclofenac conjugate was assessed at different 
concentrations from 0.000155-0.31 mM. A two minute incubation period and a 
fluorescence microplate reader equipped with standard fluorescein filters were used 
to detect the COX-2 activity.  
2.3.9.1 Dilution of assay buffer 
Three mL of assay buffer concentrate was diluted with 27 mL HPLC grade water. 
The buffer consisted of 100 mM Tris-HCl, pH 8.0. This final buffer was used in the 
assay and for diluting reagents. 
2.3.9.2 Heme 
Forty μL heme in dimethylsulfoxide (DMSO) was diluted with 960 μL of diluted 
assay buffer. 
2.3.9.3 COX-2 (human recombinant) 
Fifty μL of enzyme was diluted with 550 μL of diluted assay buffer and stored on 
ice. This enzyme solution was used in the assay 
2.3.9.4 Arachidonic acid 
One hundred μL of arachidonic acid in ethanol was transferred to another vial and 
100 μL of potassium hydroxide was added. The mixture was vortexed and diluted 
with 800 μL of HPLC grade water to achieve a final concentration of 2 mM. A 10 μL 
aliquot yielded a final concentration of 100 µM in the wells.  
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2.3.9.5 Preparation of the fluorimeteric substrate, ADHP (10-acetyl-3,7 
dihydroxyphenoxazine) 
Immediately prior to assaying, the contents of the vial were dissolved in 100 μL 
DMSO and then 900 μL of diluted assay buffer was added.  
2.3.9.6 Preparation of standard concentration of the Inhibitors 
A 1 mM solution of inhibitor standards was prepared by dissolving 0.318 mg 
diclofenac and 0.652 mg DKP-diclofenac in the assay buffer. Further dilution was 
carried out with the buffer to give 0.31, 0.031, 0.0031, 0.00031 and 0.000155 mM 
working standard concentrations. 
2.3.9.7 Reaction mixture 
1) For the 100% initial activity wells, 150 μL of assay buffer, 10 μL of heme, 10 μL 
of fluoremetric substrate, 10 μL of COX-2 enzyme and 10 μL of solvent (the same 
solvent used to dissolve the inhibitor)  
2) For the background wells, 160 μL of assay buffer, 10 μL of heme, 10 μL of 
fluorimeteric substrate and 10 μL of solvent (the same solvent used to dissolve the 
inhibitor) were added to the well 
3) For the inhibitor wells, 150 μL of assay buffer, 10 μL of heme, 10 μL of 
fluorimeteric substrate, 10 μL of COX-2 enzyme and 10 μL of inhibitor (diclofenac 
or DKP-diclofenac) were added to the wells. 
4) The reactions were initiated quickly by adding 10 μL of arachidonic acid solution 
to all the wells that were used. 
5) The wells were incubated for 2 minutes at room temperature and were read at the 
appropriate wavelengths in a fluorescence microplate reader equipped with standard 
fluorescein filters. 
6) The fluorescence intensity was measured for all samples. The fluorescence of the 
background wells was subtracted from the fluorescence of the 100% initial activity 
and the inhibitor wells. 
7) The percent inhibition for each sample was determined and a graph was obtained 
by plotting the percent inhibition or percent initial activity as a function of the 
inhibitor concentration. 
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2.3.10 Statistical analysis 
Skin permeation data consisted of cumulative measurements of the drug amount 
taken at various times (1 to 24 h) following active and passive treatments.  A random 
effects regression model was used to compare the treatments at various time points, 
with the timings treated as categorical variables (so that no linear relationship was 
assumed between permeation and time).  This type of regression model is equivalent 
to a repeated measures analysis of variance, in that it properly takes into account 
correlations between measurements made on the same sample at different time 
points.  If the standard deviations of the permeations appeared to differ widely for 
different time periods, a logarithmic transformation was performed on the 
permeation before analysis. 
Pairwise comparisons were calculated from the regression model by requesting 
certain ‘contrasts’ as required.  Contrasts were tailored to make specific comparisons, 
and obtain the p-values for them.  The standard errors on which the contrasts were 
based were estimated from the regression model which was based on all the available 
data.  If the analysis was performed on the log-transformed data, the p-values for the 
pairwise comparisons were based on this analysis, but the mean permeation were 
quoted on the original scale (to simplify interpretation). 
For the analysis of CPP and CPP conjugates retained in the skin, there were no 
repeated measurements, so a straightforward analysis of variance (ANOVA) was 
performed to compare results between treatments. 
All statistical analyses were performed using the SAS version 9.2 statistical software 
(SAS Institute Inc, Cary, NC, USA, 2008).  A p-value <0.05 was taken to indicate a 
statistically significant association.   
2.4  Results and discussion 
2.4.1 Chromatography 
2.4.1.1  DKP 
The current HPLC method was an adaptation of that established previously by our 
collaborators at the University of Barcelona with minor mobile phase changes. The 
method provided good selectivity and specificity and DKP eluted at approximately 
6.7 min. The linearity shown by the HPLC method was 0.9993 and the precision was 
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0.78% for 1.95 µg/mL, 0.54% for 15.6 µg/mL and 0.47% for 62.5 µg/mL DKP.  The 
LOD and LOQ for DKP were 173 ng and 579 ng respectively. The intra-day 
repeatability was 0.86% for 1.95 μg/mL and 0.56% for 15.6 µg/mL (within the 
acceptable criteria for intraday repeatability of RSD < 5%) and the inter-day 
repeatability of 1.36 % for 1.95 µg/mL and 1.03 % for 15.6 µg/mL. Thus the method 
was validated for detection of DKP after permeation through skin. A typical 
chromatogram for DKP is shown in Figure 2.6 below. The chromatogram shown 
below exhibits a small shoulder but it is not attributed to the degradation of DKP. 
The shoulder is also evident in the DKP standard synthesized and established by 
LCMS at University of Barcelona. The peak area of DKP for all standards, working 
solutions and samples was hence integrated as the entire peak including the shoulder. 
 
Figure 2.6 Chromatogram of 100 μg/mL standard of DKP 
2.4.1.2 Ala-Trp 
The method developed for Ala-Trp was a modification of the DKP method. Ala-Trp 
eluted at approximately 8.2 min. The linearity was 0.9999 and the precision was 
0.45% for 1.56 µg/mL, 0.31% for 6.25 µg/mL and 0.24% for 50.0 µg/mL.  The LOD 
and LOQ were 45.06 ng and 150.21 ng respectively. The intra-day repeatability was 
0.61% for 1.56 μg/mL and 0.41% for 12.5 µg/mL and the inter-day repeatability was 
0.60 % for 1.56 µg/mL and 0.47 % for 12.5 µg/mL. Thus the method was validated 
for detection of Ala-Trp after permeation through skin. A typical chromatogram for 
Ala-Trp is shown in Figure 2.7 below. 
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Figure 2.7 Chromatogram of 100 μg/mL standard of Ala-Trp 
2.4.1.3 Diclofenac 
The method developed for diclofenac was a modification of the DKP method. 
Diclofenac eluted at approximately 8.2 min. The linearity was 0.9994 and the 
precision was 0.88% for 3.9 µg/mL, 0.62% for 15.6 µg/mL and 0.34% for 62.5 
µg/mL.  The LOD and LOQ were 98 ng and 326.5 ng respectively. The intra-day 
repeatability was 0.90% for 3.9 μg/mL and 0.62% for 15.6 µg/mL and the inter-day 
repeatability was 0.84 % for 3.9 µg/mL and 0.74 % for 15.6 µg/mL. Thus the method 
was validated for detection of diclofenac after permeation through skin. A typical 
chromatogram for diclofenac is shown in Figure 2.8 below. 
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Figure 2.8 Chromatogram of 15.7 μg/mL standard of diclofenac 
2.4.1.4 DKP and Ala-Trp physical mixture 
The HPLC method developed for Ala-Trp enabled co-analysis of both the dipeptide 
and the DKP in the same run. The retention times for DKP and Ala-Trp were 11.2 
min and 8.2 min respectively. The linearity shown by the HPLC method was 1.0 for 
DKP and 0.9993 for Ala-Trp. The precision was 0.94% and 0.95% for 3.9 µg/mL 
Ala-Trp and DKP respectively, 0.38% and 0.55 for 15.6 µg/mL Ala-Trp and DKP 
respectively and 0.11 and 0.43% for 62.5 µg/mL Ala-Trp and DKP respectively. The 
LOD and LOQ of Ala-Trp were 35.11 ng and 117.05 ng respectively. The LOD and 
LOQ of DKP in the physical admixture were 283 ng and 943 ng respectively. The 
intra-day repeatability was 0.82% for 3.9 μg/mL and 0.33% for 15.6 µg/mL and 
inter-day repeatability was 1.18 % for 3.9 µg/mL and 0.48 % for 15.6 µg/mL Ala-
Trp in the physical admixture. For DKP, the intra-day repeatability was 1.11 % for 
3.9 μg/mL and 0.83% for 15.6 µg/mL and inter-day repeatability was 0.86 % for 3.9 
µg/mL and 0.75 % for 15.6 µg/mL. A typical chromatogram for DKP and Ala-Trp in 
physical admixture is shown in Figure 2.9 below.  
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Figure 2.9 Chromatogram of 125 μg/mL standard of DKP-Ala-Trp (physical admixture) 
2.4.1.5 DKP- diclofenac physical admixture 
The HPLC method developed for DKP enabled the analysis of diclofenac as well as 
the co-analysis of both diclofenac and DKP in the same run. The retention time for 
DKP and diclofenac in the physical admixture were 6.7 min and 8.2 min 
respectively. The linearity was 0.9998 and 0.9997 for diclofenac and DKP 
respectively. The precision was 0.72% and 0.93% for 3.9 µg/mL diclofenac and DKP 
respectively, 0.59% and 0.82% for 15.6 µg/mL diclofenac and DKP respectively and 
0.44% and 0.66% for 62.5 µg/mL diclofenac and DKP respectively. The LOD and 
LOQ of diclofenac and DKP when applied in the physical admixture were 68 ng and 
228 ng, and 235.6 ng and 785.5 ng respectively. The intra-day repeatability was 
0.85% for 3.9 μg/mL and 0.61% for 15.6 µg/mL and inter-day repeatability was 
0.80 % for 3.9 µg/mL and 0.67 % for 15.6 µg/mL diclofenac in the physical 
admixture. For DKP, the method showed intra- day repeatability was 0.94 % for 3.9 
μg/mL and 0.85% for 15.6 µg/mL and inter-day repeatability was 0.96 % for 3.9 
µg/mL and 0.87 % for 15.6 µg/mL DKP in the physical admixture. A typical 
chromatogram for DKP and diclofenac applied in the physical admixture is shown in 
Figure 2.10 below. 
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Figure 2.10 Chromatogram of 125 μg/mL standard of DKP-diclofenac (physical admixture) 
2.4.1.6 TAT and TAT-diclofenac conjugate 
The HPLC method for TAT and TAT-diclofenac conjugate were obtained from GLS 
Biochem. The method was modified to suit the system specifications in our 
laboratory. The retention time for TAT was 17.1 min. The linearity was 0.998 and 
the precision was 0.95%, 0.78% and 0.50% for 3.25 µg/mL, 13 µg/mL and 52 µg/mL 
TAT respectively.  The LOD and LOQ of TAT were 800 ng and 2.66 µg 
respectively. The intra-day repeatability was 0.99% for 3.25 μg/mL and 0.82% for 13 
µg/mL and inter-day repeatability was 1.04 % for 3.25 µg/mL and 0.89 % for 13 
µg/mL TAT. A typical chromatogram for TAT is shown in Figure 2.11 below. 
For TAT-diclofenac the retention time was 10.1 min. The linearity was 0.9997 and 
the precision was 0.81%, 0.73% and 0.69% for 7.81 µg/mL, 31.25 µg/mL and 125 
µg/mL TAT-diclofenac respectively.  The LOD and LOQ of TAT-diclofenac were 
393 ng and 1.31 µg respectively. The intra-day repeatability was 0.90% for 7.81 
μg/mL and 0.71% for 31.25 µg/mL and inter-day repeatability was 0.92 % for 7.81 
µg/mL and 0.72 % for 31.25 µg/mL TAT-diclofenac. A typical chromatogram for 
TAT-diclofenac conjugate is shown in Figure 2.12 below. 
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Figure 2.11  Chromatogram of 104 μg/mL standard of TAT 
 
 
Figure 2.12 Chromatogram of  250 μg/mL standard of TAT-diclofenac conjugate 
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2.4.1.7 DKP-diclofenac conjugate 
For DKP-diclofenac conjugate the retention time was 8.2 min. The linearity was 
0.9997 and the precision was 1.16%, 1.0% and 0.65% for 3.9 µg/mL, 15.6 µg/mL 
and 62.5 µg/mL DKP-diclofenac respectively.  The LOD and LOQ of DKP-
diclofenac were 973.2 ng and 3.24 µg respectively. The intra-day repeatability was 
1.31% for 3.9 μg/mL and 1.1% for 15.6 µg/mL and inter-day repeatability was 1.2 % 
for 3.9 µg/mL and 1.02 % for 15.6 µg/mL DKP-diclofenac conjugate. A typical 
chromatogram for DKP-diclofenac conjugate is shown in Figure 2.13 below. 
 
Figure 2.13 Chromatogram of 50 μg/mL standard of DKP-diclofenac conjugate 
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Table 2.1 HPLC summary data for analysis of cell penetrating peptides, actives, physical admixtures and conjugates 
Peptide 
Correlation 
coefficient 
(r
2
) 
Linear 
range 
(µg/mL) 
Precision Intra-day 
Repeatability 
Inter-day  
Repeatability 
LOD 
(ng) 
LOQ 
(ng) 
DKP 0.9993 1.95 - 125 
0.78% at 1.95 µg/mL 
0.54% at 15.6 µg/mL 
0.47% at 62.5 µg/mL 
0.86% at 1.95 µg/mL 
0.56% at 15.6 µg/mL 
 
1.36% at 1.95 µg/mL 
1.03% at 15.6 µg/mL 
 
173.0 579.0 
Ala-Trp 0.9999 1.56- 50 
0.45% at 1.56 µg/mL 
0.32% at 6.25 µg/mL 
0.24% at 50 µg/mL 
0.61% at 1.56 µg/mL 
0.41% at 12.5 µg/mL 
0.60% at 1.56 µg/mL 
0.47% at 12.5 µg/mL 
 
45.1 150.2 
Diclofenac 0.9994 3.9 - 125 
0.88% at 3.9 µg/mL 
0.62% at 15.6 µg/mL 
0.34% at 62.5 µg/mL 
0.90% at 3.9 µg/mL 
0.62% at 15.6 µg/mL 
0.84% at 3.9 µg/mL 
0.74% at 15.6 µg/mL 
98.0 326.5 
DKP 
mixed with 
Ala-Trp 
1.000 
 
 
0.9993 
3.9 – 250 
 
 
3.9 - 250 
0.95% at 3.9 µg/mL 
0.55% at 15.6 µg/mL 
0.43% at 62.5 µg/mL 
0.94% at 3.9 µg/mL 
0.38% at 15.6 µg/mL 
0.11% at 62.5 µg/mL 
1.11% at 3.9 µg/mL 
0.83% at 15.6 µg/mL 
 
0.82% at 3.9 µg/mL 
0.33% at 15.6 µg/mL 
 
0.86% at 3.9 µg/mL 
0.75% at 15.6 µg/mL 
 
1.18% at 3.9 µg/mL 
0.48% at 15.6 µg/mL 
 
283.0 
 
 
35.1 
943.0 
 
 
117.0 
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DKP 
mixed with 
diclofenac 
0.9997 
 
 
 
0.9998 
3.9 – 125 
 
 
 
3.9 - 125 
0.93% at 3.9 µg/mL 
0.82% at 15.6 µg/mL 
0.66% at 62.5 µg/mL 
0.72% at 3.9 µg/mL 
0.59% at 15.6 µg/mL 
0.44% at 62.5  µg/mL 
0.94% at 3.9 µg/mL 
0.85% at 15.6 µg/mL 
 
0.85% at 3.9 µg/mL 
0.61% at 15.6 µg/mL 
 
0.96% at 3.9 µg/mL 
0.87% at 15.6 µg/mL 
 
0.80% at 3.9 µg/mL 
0.67% at 15.6 µg/mL 
 
228.0 
 
 
68.0 
235.6 
 
 
785.5 
 
 
 
DKP-diclofenac 
conjugate 
0.9997 3.9 - 250 
1.16% at 3.9 µg/mL 
1.0% at 15.6 µg/mL 
0.65% at 62.5 µg/mL 
 
1.31% at 3.9 µg/mL 
1.1% at 15.6 µg/mL 
 
1.2% at 3.9 µg/mL 
1.02% at 15.6 µg/mL 
 
973.2  3240.0 
TAT 0.9988 3.25 - 104 
0.95% at 3.25 µg/mL 
0.78% at 13.0 µg/mL 
0.50% at 52 µg/mL 
 
0.99% at 3.25 µg/mL 
0.82% at 13.0 µg/mL 
 
1.04 % at 3.25 µg/mL 
0.89 % at 13.0 µg/mL 
 
800.0 2660.0 
TAT-diclofenac 
conjugate 
0.9997 7.81 - 250 
0.81% at 7.81 µg/mL 
0.73% at 31.25 µg/mL 
0.69% at 125 µg/mL 
 
0.90% at 7.81 µg/mL 
0.71% at 31.25 
µg/mL 
 
0.92% at 7.81 µg/mL 
0.72% at 31.25 µg/mL 
 
393.0 1310.0  
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2.4.2  Human epidermal penetration and accumulation: preliminary 
experiments 
Preliminary investigations were carried out with DKP, diclofenac, Ala-Trp and DKP- 
diclofenac conjugates. It should be noted that experiments were conducted based on 
the availability of the peptides and conjugates. As the synthetic procedures are time 
consuming and expensive some compounds were available in limited quantities, 
therefore some experiments could not be repeated where the available compound was 
required for other assessment procedures. Preliminary experiments were undertaken 
to determine the optimal experimental protocol with respect to final donor 
concentration, donor vehicle, receptor vehicle and appropriate period of epidermal 
membrane hydration.  
2.4.2.1 Choice of donor vehicle 
In order to choose a suitable vehicle for the permeation experiments, a preliminary 
study was undertaken with DKP, Ala-Trp and diclofenac to determine the solubility 
in 100% propylene glycol (PG), 75:25 v/v PG:PBS and 25:75 v/v PG:PBS. The 
results indicated that Ala-Trp had good solubility in both 100% PG and 75:25 v/v 
PG: PBS mixture. The high molecular weight peptide and peptide conjugates TAT 
and TAT-diclofenac had optimal solubility in absolute PG with further dilution with 
PBS. The peptide conjugate DKP-diclofenac had similar solubility characteristics as 
its parent compound DKP. Considering the solubility study, 25:75 v/v PG: PBS 
mixture was chosen as a vehicle as it was compatible with all the compounds.  
2.4.2.2 Determination of donor concentration 
Donor concentration plays an important role in transdermal experimentation. For 
infinite dose-type studies the diclofenac concentration needs to be high enough to 
maintain sink conditions throughout the duration of the study. However it has been 
suggested that very high concentrations of lipophilic molecules can lead to 
aggregation and clogging of the passive transdermal channels.
282,283
 Figure 2.14 is a 
representative graph of the cumulative amount of DKP-diclofenac (µg/cm
2
) 
permeated in 24 h for a donor amount of 1.5 mg and 150 µg. It shows that the 
permeation is greater for the lower dose application. In addition to reduced 
permeation (2.36 µg/cm
2
) with the 1.5 mg total dose, considerable variability and a 
longer lag time of 1.5 h was also observed. Consequently, 150 µg donor amount as 
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present in 300µL of 500 µg/mL was adopted for subsequent experiments. A high 
concentration could also lead to accumulation of the active in the superficial layers of 
the skin with minimal permeation across the barrier.
283
    
 
Figure 2.14 Permeation profile of cumulative amount vs. time of DKP-diclofenac conjugate 
(300µL donor volume i.e. 1.5 mg and 150 µg) across human epidermis. Results are expressed as 
mean (±SEM), n=5  
2.4.2.3 Pre-hydration of epidermal membrane 
Hydration of the Franz cell mounted skin prior to experimentation is common 
practice and has been shown to reduce variability in the experimental skin condition. 
Researchers have hydrated skin for times ranging from a few minutes
284
, to a few 
hours
285,286
, to longer durations like 8-10 h (overnight)
287
 and observed a marked 
reduction in variability and loss of cells due to leakage from the membrane by 
overnight hydration. In this study skin was hydrated for 8-10 h (overnight) in Franz 
cells. 
2.4.2.4 Stability of DKP/study duration of permeability experiments 
Preliminary studies were conducted to establish the optimal experimental protocol 
with respect to duration of permeability experiment and establishing the stability of 
the compound when in contact with the human skin. Experiments with regular 
receptor sampling were carried out for 24 h, 48 h and 72 h durations. No degradation 
of the DKP peptide was detected on the HPLC chromatogram for receptor samples 
up to 72 h in contact with the skin. However it was observed that at 72 h the skin was 
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damaged and would not be suitable for the skin recovery studies that were one of the 
primary aims of our experiments. Hence for the reliable recovery of drug from the 
skin and to minimise variability of the experiments the duration of experiments was 
limited to 24 h. However, this experiment was of particular value in establishing the 
stability of DKP over 72 h. Figure 2.15 below shows a progressive increase in the 
receptor concentration of DKP from 24 h-72 h.  
 
 
Figure 2.15 A) Cumulative amounts of DKP permeated after 24 h, 48 h and 72 h studies. B) An 
HPLC chromatogram of the receptor sample after 72 h study.  
The structure of DKP is quite different to the cell penetrating peptides tested to date. 
DKP is a cyclic peptide thus providing unique properties. One of the issues in 
applying peptides to the skin is the ability of skin enzymes to metabolize the 
peptide.
288
 The other issue worth considering is the stability of the cell penetrating 
peptides in contact to skin. Several authors have demonstrated good stability of 
peptides in biological tissues, including skin.
275,288
 The cyclic structure of DKP 
confers better stability as was demonstrated when we exposed the DKP to human 
A 
B 
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epidermis at 37ºC for 72 h with only a 4% loss of DKP. Indeed diketopiperazine 
formation or cyclization of peptides is a common phenomenon and often found to be 
a result of unstable peptides forming diketopiperazines of stable conformations. 
Goolcharran et al.
289
 determined the rates of deamination, oxidation, and 
diketopiperazine reactions in model peptide systems and compared them to those of 
recombinant human vascular endothelial growth factor (rhVEGF). The authors 
reported that the rate of the diketopiperazine reaction was slower in the protein 
(rhVEGF), which is more stable compared to the model peptides. Carpenter et al.
290
 
reported similar reactions leading to stable diketopiperazine formation in a 
tripeptide.
290
  Kubo et al.
291
 have similarly discussed the stable conformations of 
diketopiperazines.
291
       
2.4.2.5 Final experimental protocol 
Based on the preliminary data a final protocol for the skin permeation studies was 
formulated: 
 Three hundred μL of a 500 μg/mL concentration of the donor for all 
compounds (i.e. application amount of each compound was 150 μg) 
 25:75 v/v PG:PBS for the donor vehicle and receptor medium 
 Overnight (8-10 h) hydration of the epidermal membrane with the receptor 
medium. 
 Total experiment duration of 24 h. 
2.4.3 Permeation of cell penetrating peptides, admixtures of cell penetrating 
peptide and active, and conjugated cell penetrating peptide-actives 
across human epidermis in vitro 
In this study the co-administration and conjugation of cell penetrating peptides with 
model and therapeutic molecules was investigated as an enhancement strategy to 
increase the permeation of these molecules across the human skin. 
Table 2. 2 Overview of the research plan 
Compound Single ingredient 
control 
Physical 
admixture 
Conjugate 
DKP and 
diclofenac 
   
DKP and Ala-Trp    
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TAT and 
diclofenac 
   
 
2.4.3.1  Influence of DKP on skin permeation of diclofenac and Ala-Trp 
2.4.3.1.1 DKP 
DKP (150 μg in 300 μL 25:75 PG:PBS) was applied to human epidermis for 24 h as 
per the protocol determined from preliminary experimentation. Figure 2.16 shows 
the cumulative amount of DKP permeated through the epidermis (μg/cm2) versus 
time (h) following administration of 300 μL of 150 µg DKP in 25:75 PG:PBS. The 
steady-state flux (μg/cm2/h), lag time and permeability coefficient (cm/h) are noted 
in Table 2.3. Over the 24 h experimental period, the cumulative amount permeated 
was 10.46 μg/cm2. The transdermal flux over the 24 h period was 0.43 µg/cm2/h and 
the permeability coefficient was 8.7×10
-4
 cm/h. (Table 2.3) 
 
Figure 2.16 Passive permeation of DKP over 24 h, Amount in donor - 150 µg, Results are 
expressed as mean (±SEM: n=7). 
Cell penetrating peptides, including TAT,  have recently been shown to cross the 
stratum corneum barrier.
92
 In this study we have demonstrated the skin penetration of 
DKP from this novel diketopiperazine class of cell penetrating peptides. DKP was 
previously shown to cross the blood-brain barrier by our collaborators.
99,292
   
Rothbard
107
 et al. reported the application of the cell penetrating peptide Peptide R7 
(Polyarginine-7) for the delivery of peptides into the skin. They showed that the cell 
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penetrating peptide permeated into the epidermis and that the depth and intensity of 
skin penetration depended on the length and concentration of the active cargo peptide 
applied. Lopes
275
 et al. conjugated the cell penetrating peptides TAT (MW: 2020) 
and a recent, molecular modification of TAT (YARAAARQARA) named as YARA 
(MW: 1668) with the peptide P20 (Heat shock protein 20 -WLRRASAPLPGLK, 
MW: 2005 Da).  They reported rapid penetration of YARA and TAT alone in the 
porcine ear skin in vitro. They also demonstrated that combination with the chemical 
penetration enhancers, monoolein and oleic acid did not further enhance skin 
permeation of these cell penetrating peptides. However when the cell penetrating 
peptides were conjugated to the peptide P20, skin penetration was slow and very 
limited despite the high permeation of the cell penetrating peptides alone. Most of 
the cell penetrating peptides used in cellular and transdermal delivery to date are 
arginine rich
95,108,293
 and questions have been raised regarding their membrane 
shuttling properties.
63
  
DKP has been shown as a stable compound in the presence of human skin. The 
stability of DKP has been discussed in detail in the previous section (2.4.2.4). In 
contrast, TAT is prone to trans-activation and has often been methylated on the 
arginine amino acid. Moreover, protein transduction using TAT fusion protein 
systems may require denaturation of the protein before delivery to increase the 
accessibility of the TAT-cell penetrating peptide domain. This requirement 
introduces an additional delay between the time of delivery and intracellular 
activation of the protein.
294
 The mode of transport of DKP across the skin is not very 
clear at this stage. Unlike TAT where the predominant mode of transport is at least 
partially endocytotic, DKP most likely penetrates through a rather energy 
independent pathway (diffusion). Endocytosis is inherently a saturation driven 
pathway and can easily be overwhelmed by high peptide concentrations.
295
  
Diketopiperazines have been detected in a variety of natural sources and are 
generally considered safe. In a recent review, Huang et al. looked at activity and 
toxicity of DKPs.
296
 Most of the reported activity of DKPs is very selective and 
hence they appear to be reasonably safe. Other molecules with a diketopiperazine 
ring at the core have been studied for toxicity by Watts et al. and were shown to be 
safe.
297
 Specific toxicity studies are necessary to evaluate the carrier dikepiperazine 
used in this study.  
80 
 
2.4.3.1.2 Ala-Trp 
Permeation profile of Ala-Trp in the current study was established at a low 
concentration of 500 µg/mL (150 µg) (Figure 2.17). The permeation after 24 h was 
0.13 µg/cm
2
 with transdermal flux of 0.01 µg/cm
2
/h and permeability coefficient 
(KP) of 2.0 ×10
-5
 cm/h (Table 2.3). 
 
 
Figure 2.17 Passive permeation of Ala-Trp over 24 h, Amount in donor - 150 µg.  Results are 
expressed as mean (±SEM: n=4). 
There have been limited reports on skin penetration enhancement of dipeptides. The 
molecular weight of Ala-Trp (MW = 275 g/mol) would ideally fit the 500 Dalton 
rule,
298
 however its transdermal penetration suggests that other factors are not 
optimal. This may be due to the highly hydrophilic nature of the drug. Altenbach et 
al.
299
 observed no iontophoretic and passive transport of a dipeptide (Tyr-Phe) across 
human skin in vitro without the addition of an enzyme inhibitor.
299
 In previous work 
conducted in our laboratory a novel magnetophoretic technique Dermaportation was 
used to enhance the transdermal permeation of Ala-Trp. Dermaportation significantly 
enhanced the delivery of Ala-Trp through human epidermis in vitro over an 8 h 
period (permeability coefficient: 7.7 × 10
-4
 cm/h) when compared to passive 
diffusion.  The dipeptide was shown to be unstable on exposure to human epidermis 
with an increasing amount of degradation product evident in the receptor phase over 
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the 8 h period.
153
 However, this was not observed with studies conducted during the 
current experiments. It can be hypothesised that the vehicle PG: PBS used in this 
project had a stabilising effect.  
In a study, Lin et al.
300
 measured the passive diffusion of Ala-Trp in porcine skin and 
reported a permeability coefficient of 1.39 × 10
-2
 cm/h. The results of this phase of 
the study implied that Ala-Trp would be an ideal molecule to test for penetration 
enhancement using an active strategy.  
2.4.3.1.3 DKP-Ala-Trp (physical admixture) 
Figure 2.18 shows the permeation across human epidermis of DKP and Ala-Trp 
applied as a physical admixture at 150 µg of each component. The cumulative 
amount of DKP and Ala-Trp permeated over 24 h was 10.83 and 1.19 µg/cm
2
 
respectively (Table 2.3). Over the 24 h experimental period, the transdermal flux of 
DKP in the physical admixture was 0.45 µg/cm
2
/h and the permeability coefficient 
was 9.0 × 10
-4 
cm/h. The transdermal flux and permeability coefficient was found to 
be comparable to that for passive DKP permeation across human epidermis.  The 
steady state flux on the other hand for Ala-Trp was 0.049 µg/cm
2
/h and the 
permeability coefficient was 9.9 × 10
-5 
cm/h. An approximately 10-fold increase in 
the cumulative amount was observed when the dipeptide was co-administered with 
the cell penetrating peptide, DKP. It was interesting to note that the transport of DKP 
was unaffected. 
 
Figure 2.18 Passive permeation of DKP-Ala-Trp (physical admixture) over 24 h, Amount in 
donor - 150 µg, Results are expressed as mean (±SEM: n=7). 
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Cell penetrating peptides are known to cross membranes with a great degree of ease 
and when conjugated they are also known to be able to carry a reasonable payload. A 
study was designed to determine if they can create channels big enough to enhance 
transdermal transport of small hydrophilic molecules when co-administered. If so, 
can these channels stay open long enough to show a detectable skin permeation 
enhancement. An interesting viewpoint on this can be deduced from the recent work 
published in 2012 by Sakuma et al.
301
 The authors reported that since cell penetrating 
peptides are highly cationic, they adsorb strongly on the membrane surface via 
hydrogen bond-induced formation of guanidino moieties in arginine with anionic 
phosphates, sulfates, and carboxylates of cellular components. Membrane-associated 
proteoglycans including heparan sulfate play crucial roles in the macropinocytosis of 
cell penetrating peptides. The process is initiated by cell activation and plasma 
membrane ruffling and leads to a consequential engulfment of large volumes of 
extracellular fluid into macropinosomes. It was hypothesised that poorly membrane-
permeable molecules physically mixed with cell-penetrating peptide are incidentally 
internalized into cells when the cells fail to uptake the peptidyl branches in the cell 
penetrating peptide complex.
301
 
Sakuma et al.
301
 studied this mechanism by monitoring the permeation of anionic 
carboxyfluorescein (CF) alone and as conjugate in Caco-2 monolayer cell lines. 
Enhanced CF penetration of more than 5-fold was observed for the cell penetrating 
peptide -polymer complex (0.0123 ± 0.0026 nmol/mg to 0.213 ± 0.045 nmol/mg). 
Macropinocytosis was confirmed as the mechanism of uptake because the specific 
inhibitor [5-(N-ethyl-N-isopropyl)-amiloride; EIPA] significantly inhibited cell 
penetrating peptide permeation. Clearly the skin provides a more complex membrane 
than Caco-2 monolayers. We demonstrated a similar trend with Ala-Trp in the 
presence of cell penetrating peptide. When co-administered with DKP we observed a 
10-fold enhancement of Ala-Trp penetration. Hence, we believe that DKP may form 
temporary channels by lipid bilayer rearrangements which can facilitate transport of 
other co-administered small molecules. 
2.4.3.1.4 Diclofenac 
To continue from the work described above a small therapeutic molecule, diclofenac 
was selected as a model, because of its low passive permeability through the skin. In 
83 
 
this study the cumulative amount permeated over 24 h was 4.06 µg/cm
2
. (Figure 
2.19). The estimated transdermal flux was calculated over 24 h as 0.173 µg/cm
2
/h 
(Table 2.3).  
 
Figure 2.19 Passive permeation of diclofenac over 24 h, Amount in donor - 150 µg, Results are 
expressed as mean (±SEM: n=5). 
Ionized diclofenac sodium faces tough resistance passing through the stratum 
corneum and has been used with various chemical enhancers in topical formulations 
to aid in its penetration.
302
  Diclofenac sodium has been very well reviewed and 
found to be effective transdermally in randomized controlled trials.
303,304
 Though 
diclofenac sodium has good water solubility (9 mg/mL)
305
 the reported transdermal 
permeation has been generally low. In in vitro experiments Dehghanyar et al. studied 
the transdermal penetration of diclofenac after multiple as well as after single 
application at different doses and locations of human volunteer skin and reported it to 
be highly variable.
306
 It has been recently suggested that dermal oxidative stress from 
UV radiation may impede absorption of topical diclofenac, although, a clinical trial 
in patients with sunburn did not show any significant increase or decrease in 
absorption measures.
307,308
 It could also be inferred that the low concentrations of 
diclofenac in in vitro skin studies can be due to the presence of free radicals in 
excised skin. Abdulmajed et al.
309
 showed that esterase activity in excised skin stored 
at –20 ° C is substantially lower than in freshly excised skin, which is likely to be 
due to deactivation of protein structure as result of freezing.
309
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2.4.3.1.5 DKP-diclofenac (physical admixture) 
After successfully demonstrating an enhancement in transdermal permeation of Ala-
Trp by co-administering the dipeptide with DKP, we studied the co-administration of 
DKP with diclofenac. The cumulative amount of DKP permeated was almost 
doubled and a 2-fold enhancement in the transdermal flux and permeability 
coefficient of diclofenac was observed.  Figure 2.20 shows the permeation across 
human epidermis of DKP and diclofenac applied as a physical admixture at 150 µg 
of each component. The cumulative amount of DKP and diclofenac permeated over 
24 h was 17.39 and 7.61 µg/cm
2
 respectively. The estimated transdermal flux over 
the 24 h period for DKP and diclofenac in the mixture was 0.72 µg/cm
2
/h and 0.31 
µg/cm
2
/h respectively. (Table 2.3) The calculated permeability coefficient was 1.4 × 
10
-3
 cm/h for DKP and 6.3 × 10
-4
 cm/h for diclofenac. (Table 2.3) 
 
Figure 2.20 Passive permeation of DKP-diclofenac (physical admixture) over 24 h, Amount in 
donor - 150 µg, Results are expressed as mean (±SEM: n=5). 
A similar co-administration study was conducted by Cohen-Avrahami et al.
310
 
Diclofenac was dissolved with and without cell penetrating peptides in reversed 
hexagonal (HII) mesophases. Cell penetrating peptides included Penetratin, a 16 
amino acid (RALARALARALRALAR) named RALA and a 9 amino acid cell 
penetrating peptide with sequence (RRRRRRRRR) named nona-arginine or NONA. 
All peptides examined were found to increase diclofenac permeation through skin. 
Permeation was diffusion-controlled, and the cell penetrating peptides were not 
involved in the diclofenac diffusion steps, out of the mesophase. The skin permeation 
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enhancement of these cell penetrating peptides is therefore based on their interaction 
with the skin.
310
 To substantiate this hypothesis
311
 ATR-FTIR was used to observe 
the lipid structure of the porcine ear skin. While the HII mesophase itself had a minor 
effect on the lipid chain conformation, penetratin encapsulated within this carrier, 
triggered a transformation of lipid structure which is hexagonal in porcine skin to a 
more liquid transition.
311
 Unlike the enhancement seen with Ala-Trp in the previous 
section and with diclofenac using other cell penetrating peptides, we did not observe 
as substantial an enhancement in the permeation of diclofenac when co-administered 
with DKP.   
Results of this study are comparable to recent work by Lohcharoenkal et al.,
312
 in 
which the authors observed greater permeation with a co-administration approach 
than with a conjugate (4.25-fold and 1.79-fold respectively) when administrating 
TAT for the permeation enhancement of a model green peptide.
312
 When compared 
to the passive permeation of diclofenac in similar conditions the results were very 
encouraging. 
2.4.3.1.6 DKP-diclofenac conjugate  
Conjugation of DKP with diclofenac was successful and the conjugate was 
quantified by HPLC and MS. Apart from its therapeutic relevance, diclofenac was 
chosen due to the ease of biological activity assessment of the conjugate. 
In this study we have demonstrated carrier mediated delivery of diclofenac when 
conjugated to DKP. Figure 2.21 shows the skin permeation of DKP-diclofenac 
conjugate at 150 µg across human epidermis. The cumulative amount of DKP–
diclofenac conjugate permeated over 24 h was 7.82 µg/cm
2
 (Table 2.3). The results 
indicated that upon addition of an active payload on the scaffold the permeation was 
comparable to that of DKP and diclofenac admixture. However, we believe that the 
size of this molecule must have played a role in its lower permeation when compared 
to DKP. 
86 
 
 
Figure 2.21 Passive permeation of DKP-diclofenac conjugate over 24 h, Amount in donor - 150 
µg, Results are expressed as mean (±SEM: n=4). 
The conjugate retained the COX-2 activity of diclofenac (assay results discussed in 
subsequent sections) and showed a marked reduction in lag time when compared to 
passive diclofenac. In the case of DKP-diclofenac conjugate, the cumulative amount 
of permeation to the receptor was 1.54 µg/cm
2 
at 2 h and continued to increase 
linearly to 5.34 µg/cm
2
 at 8 h (compared to passive permeation of 0.91 µg/cm
2
 at 8 
h). The transdermal flux for the conjugate was 1.21 µg/cm
2
/h and the permeability 
coefficient was 2.4 × 10
-3
(Table 2.3). Conjugation of diclofenac to DKP resulted in 
7-fold enhancement in transdermal flux when compared to passive diclofenac 
permeation across human skin. The comparison between cumulative amounts of 
passive diclofenac and DKP-diclofenac conjugate was found to be significant (p < 
0.05) from 4 h onwards. Given the low concentration used for this study and the 
small surface area studied, further simulation on a greater area would have a 
reasonable therapeutic potential. 
COX enzyme inhibition by NSAIDs and other COX inhibitors can be assessed with a 
readily available assay kit. Orally administered NSAIDs can cause complications, 
including ulcers, GI bleeding and some renal function abnormalities.
313
 Therefore, 
improved topical delivery of the NSAIDs would offer an appropriate solution 
because it would provide the patient with relief without the side effects. Percutaneous 
penetration can be greatly advantageous because it would preserve its high 
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therapeutic potency and yet avoid hepatic first-pass metabolism and considerable 
gastrointestinal disturbances.  
Table 2.3 Summary of DKP and active drugs permeation  
Compound Cumulative 
amount 
(µg/cm
2
) 
Steady state 
flux (µg/cm
2
/h) 
Lag time (h) Permeability 
coefficient (cm/h) 
DKP 10.46 0.43 0.5 8.7×10
-4
 
Ala-Trp 0.13 0.01 2 2.0×10
-5
 
Diclofenac 4.06 0.173 1 3.46 ×10
-4
 
DKP-Ala-Trp 
admixture 
DKP: 10.83 
Ala-Trp: 1.19 
DKP: 0.45 
Ala-Trp: 0.049 
DKP: 0.5  
Ala-Trp: 1  
DKP: 9.0 ×10
-4
 
Ala-Trp:  
9.9 ×10
-5
 
 
DKP-
diclofenac 
admixture 
DKP: 17.39 
Diclofenac: 7.61 
DKP: 0.72 
Diclofenac: 
0.31 
DKP: 0.5 
Diclofenac: 
0.5 
DKP: 1.4×10
-3
 
Diclofenac: 6.3×10
-4
 
DKP-
diclofenac 
conjugate 
7.82 1.41 1 2.4×10
-3
 
2.4.3.2 Skin permeation of TAT and TAT-diclofenac conjugate  
The experiments described in the sections above demonstrated that DKP could be 
used as a penetration enhancement technique both as a cell penetrating peptide to 
carry conjugated molecules to targets within the skin and as a penetration facilitator 
for low permeability drug molecules when applied concurrently without conjugation.  
At this stage a direct comparison of DKP and its conjugate DKP-diclofenac with 
other cell penetrating peptides was desired. TAT was selected because it has been a 
predominant vector used in the delivery of large molecules (e.g. proteins) making it 
one of the best known cell penetrating peptides. In the study, the passive permeation 
of TAT across human epidermis was 3.43 µg/cm
2
 over 24 h (Figure 2.22). The 
cumulative amount of DKP at the same concentration was 3-fold higher (p < 0.05). 
The transdermal flux and permeability coefficient of DKP was 4-fold higher than 
that of TAT (DKP flux 0.43 µg/cm
2
/h: TAT flux  0.10 µg/cm
2
/h, DKP Kp 8.7×10
-4
 
cm/h: TAT Kp 2.0×10
-4
 cm/h: p < 0.05 Table 2.3 and 2.4).  
88 
 
 
Figure 2.22 Passive permeation of TAT over 24 h, Amount in donor - 150 µg, Results are 
expressed as mean (±SEM: n=6). 
The conjugate of diclofenac with TAT (TAT-diclofenac) was custom synthesized, to 
compare with DKP-diclofenac conjugate. Adding diclofenac possibly altered the skin 
permeability which can be seen as a 2-fold increase in penetration when compared to 
the passive (7.92 µg/cm
2
 p < 0.05 at 24 h Figure 2.23). This was comparable to the 
permeation of DKP-diclofenac (7.82 µg/cm
2
) with the same amount in the donor of 
150 µg. The flux and permeability coefficient of DKP-diclofenac however, were 3.6-
fold higher. (TAT-diclofenac- flux 0.33 µg/cm
2
/h; Kp – 6.6×10
-4
 cm/h, p < 0.05)  
 
Figure 2.23 Passive permeation of TAT-diclofenac conjugate over 24 h, Amount in donor - 150 
µg, Results are expressed as mean (±SEM: n=6). 
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Table 2.4 Summary of TAT and active compounds permeation  
Compound Cumulative 
amount (µg/cm
2
) 
Steady state flux 
(µg/cm
2
/h) 
Lag time 
(h) 
Permeability 
coefficient 
(cm/h) 
TAT 3.43 0.10 0.5 2.0 × 10
-4
 
TAT-
diclofenac 
7.92 0.33 0.5 6.6 × 10
-4
 
Lopes and colleagues examined permeation of TAT and other cell penetrating 
peptides and concluded that TAT penetrated abundantly in the skin and permeated 
modestly across this tissue.
275
 The reported transdermal delivery of TAT-FITC 
(fluorescein isothiocyanate) per cm
2 
porcine ear skin in vitro was 0.027 ± 0.009 nmol 
over an 8 h experiment. In the in vitro human epidermis model we found higher 
permeation of 2.0 nmol TAT at 8 h.  This could be attributed to the relatively smaller 
size of TAT as compared to TAT conjugated to fluorescein isothiocyanate, FITC. 
The transdermal delivery of DKP was calculated as 29.13 nmol/cm
2 
 in 24 h and the 
transdermal delivery of DKP-diclofenac was 11.99 nmol/cm
2
 in 24 h. The molecular 
weight of TAT is substantially higher when compared to DKP; likewise it was found 
from these studies that its permeation was significantly lower than DKP.  To our 
knowledge this is the first time the carrier abilities of diketopiperazines have been 
tested and compared in human skin. The molecular weight and hydrophilicity of 
DKP make it a prime candidate for transdermal delivery.
298
 Diketopiperazines as 
discussed previously can be very easily modified to synthesize numerous analogues 
which can be tailored to carry a wide range of drugs.
103
 DKP can form an excellent 
scaffold for future transdermal delivery in addition to the reports of successful brain 
delivery of highly therapeutic molecules targeting a host of disease 
conditions.
99,106,292
    
2.4.4 Recovery from and retention of cell penetrating peptide and cell 
penetrating peptide conjugates in the skin 
Having demonstrated higher skin permeation of DKP as compared to TAT, the 
ability of DKP to increase the penetration when conjugated to diclofenac was 
evaluated. Diclofenac was conjugated with DKP and TAT and the topical and 
90 
 
transdermal delivery was assessed as a function of time.  The cell penetrating 
peptides studied were able to carry the conjugated diclofenac through the skin to a 
similar extent though a substantial increase in the amount of DKP-diclofenac 
conjugate accumulated in the epidermis was observed as compared to the TAT-
diclofenac conjugate. Figure 2.24 indicates the amount of DKP retained in the skin as 
a function of donor concentration. The amount of DKP recovered from the skin 
increased as the donor amount increased from 150 µg to 300 µg. A significant 
difference in the amount of the CPP recovered from the skin was seen when the 
amount of the donor was increased from 300 µg to 1500 µg (p < 0.05). Figure 2.25 
compares the amount of DKP, diclofenac, Ala-Trp, TAT, DKP-diclofenac and TAT-
diclofenac conjugates present in the skin after the skin permeation studies. The 
recovery of DKP, Ala-Trp, diclofenac, DKP-diclofenac conjugate, TAT and TAT-
diclofenac conjugate was validated using the extraction procedure with propylene 
glycol and methanol. After two successive extractions with methanol followed by 
propylene glycol the recovery was 95%, 90%, 91%, 98% , 95%, 97% and 92% for 
DKP, Ala-Trp, diclofenac, DKP-diclofenac conjugate, TAT-diclofenac conjugate 
and TAT respectively of the theoretical concentration. The minor losses incurred in 
the recovery of cell penetrating peptide and cell penetrating peptide conjugates may 
be attributed to activity of skin enzymes, skin handling and other processes involved 
in the experiment. 
 
Figure 2.24 Amount of DKP  in the skin after the permeation experiments (Donor amount of 
150 µg, 300 µg and 1500 µg).  Results are expressed as mean (±SEM: n=4) 
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Figure 2.25 Amount of DKP, diclofenac, DKP-diclofenac conjugate, TAT-diclofenac conjugate, 
Ala-Trp and TAT in the skin after permeation studies (Donor amount of 150 µg). Results are 
expressed as mean (±SEM: n=4) 
A previously reported study showed that accumulation of TAT in the skin is more 
than its penetration across the skin.
275
 The DKP-diclofenac and TAT-diclofenac 
conjugate was able to permeate in the skin to a significantly higher extent as 
compared to diclofenac alone (p < 0.05).  The amount of DKP-diclofenac in the skin 
was 7 times that of TAT-diclofenac conjugate (p < 0.05). We observed that a high 
amount of the TAT-diclofenac conjugate was recovered from the donor and hence 
not permeated to the lower layers of the skin. It was also found, that similar amounts 
of TAT and DKP were extracted from the epidermis. This comparison gives us 
preliminary data of the possible skin retention of DKP, a novel cell penetrating 
peptide as compared to TAT, a well-established cell penetrating peptide.   
It has long been established that some NSAIDs have an antitumorigenic effect which 
may be attributable to NSAID-mediated inhibition of the cyclooxygenase pathway 
and specifically to reduced prostaglandin E2 synthesis.
314,315
 This increase in the 
partitioning of DKP-diclofenac conjugate into human skin and its retention and 
localization in the epidermis when compared with diclofenac alone indicates the 
formation of a depot or reservoir of drug in the epidermis. Such localization would 
be extremely beneficial for the topical use of diclofenac or other NSAIDs for the 
topical treatment of actinic keratoses.
316
  The DKP scaffold could also be used to 
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conjugate many drugs including corticosteroids, antifungal and antibacterial agents. 
This would be advantageous for the treatment of skin conditions such as psoriasis, 
atopic dermatitis and for targeting drugs for the treatment of skin cancers where the 
adverse side-effects of the drugs when delivered systemically can cause considerable 
problems. 
2.4.5 Inhibition of Cyclooxygenase (COX) by diclofenac and DKP-diclofenac 
conjugate 
The primary objective of this study was to assess the biological activity of the DKP-
diclofenac conjugate in comparison to diclofenac. The COX-2 inhibitory activity of 
the DKP-diclofenac conjugate and diclofenac by itself was assessed at a 
concentration range of 0.000155-0.31 mM. The ability of the COX enzymes to digest 
the fluoremetric substrate ADHP (10-acetyl-3,7-dihydroxyphenoxazine) decreased as 
the concentration of each of the inhibitors in the reaction mixture increased (Figure 
2.26). The inhibition caused by DKP-diclofenac was comparable to diclofenac: there 
was approximately 80% and 66% reduction in COX-2 activity with diclofenac and 
DKP-diclofenac at 0.31mM. DKP itself had no COX-2 inhibition. 
 
Figure 2.26 Percent inhibition of COX-2 by diclofenac and DKP-diclofenac conjugate (n=1) 
In this project we have primarily assessed the capacity of DKP, unconjugated and 
conjugated diketopiperazines to permeate into and through the human skin. The other 
major aim was to analyse whether the COX-2 inhibition activity of diclofenac is 
retained in the DKP-diclofenac conjugate.  It was concluded from this COX-2 
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inhibition study that the biological activity of diclofenac was not significantly 
affected by conjugation with DKP.  
2.5 Conclusions 
Skin permeation of DKP was high and consistent over different human skin donor 
samples. Passive permeation of Ala-Trp and diclofenac was lower than DKP. So was 
the passive permeation of TAT when compared to DKP at 24 h. Physical admixture 
of DKP with Ala-Trp increased the flux of Ala-Trp (9.15-fold). Permeation of 
diclofenac was enhanced 1.9-fold due to the presence of DKP in the physical 
admixture. Further the conjugation of DKP with diclofenac enhanced the transdermal 
flux 9-fold and in comparison to only 1.9-fold increased permeation of diclofenac 
with TAT.  Amount of DKP-diclofenac present in the skin was at least 6-fold greater 
than TAT-diclofenac and at least 14-fold greater than diclofenac by itself. 
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Chapter 3  
Microneedle Based Skin Penetration Studies on Fluorescent 
Peptides 
 
 
 
 
 
 
“Images play a unique role in scientific communications by delivering vast 
information that impacts the very reflection of the observer”. 
317
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3.1 Introduction 
Peptides and proteins are key regulators in cellular and inter-cellular physiological 
processes and are potentially useful for the treatment of many diseases. Transdermal 
delivery has potential for the convenient and effective administration of protein and 
peptide drugs if the stratum corneum barrier can be overcome.
2
 Microneedles (MN) 
have been shown to substantially enhance skin penetration and may offer a painless 
and effective delivery method.
5
 In vivo confocal laser scanning microscopy is used in 
dermatology as an investigative tool in skin research as well as in clinical routine.
318-
322
 This imaging technique allows for non-invasive monitoring of the skin with 
microscopic resolution second only to histological analysis. Reflectance confocal 
microscopy (RCM) employs the reflected light after laser illumination of the tissue to 
obtain morphological information. This is based on the fact that light is reflected 
differentially according to the specific refractive indices (e.g. melanin, keratin, lipid, 
water, or collagen) within the skin, producing the required contrast. Similar to 
computerized tomography, reflectance is detected only from the focal plane via a 
pinhole. In this confocal manner, images of thin optical sections of horizontal tissue 
are gained in vivo, revealing cellular and even sub-cellular detail, thereby lending 
this technique the term reflectance confocal microscopy (RCM).
321,323
 
3.2 Aims 
The aim of the current study was to evaluate diffusion of fluorescent peptides after 
MN based delivery using fluorescence imaging and to determine distribution of the 
peptides within the skin strata. In particular the effect of peptide chain length (3, 4, 5 
amino acid chain length) on passive and MN facilitated skin penetration was 
investigated. The studies were divided in two parts. 
a) Ex vivo studies with sodium fluorescein to deduce a time co-relation on the 
penetration of sodium fluorescein.  
b) In vitro studies on a series of fluorescein conjugated peptides to investigate 
the effect of size, peptide chain length and molecular weight on their 
permeation. 
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3.3 Materials and methods 
3.3.1 Peptides and other chemicals  
The fluorescent peptides were custom synthesised from Genscript USA Inc.  Sodium 
fluorescein, laboratory solvents, propylene glycol (PG) and dimethyl sulfoxide 
(DMSO) were obtained from Sigma-Aldrich (Sydney, NSW Australia). Phosphate 
buffered saline was prepared according to United States Pharmacopeia and purified 
deionised Milli-Q water from Millipore (North Ryde, NSW Australia).  
3.3.2 Instrumentation and techniques   
3.3.2.1 Reflectance confocal microscopy and florescence imaging 
 
Figure 3.1 VivaScope 2500 
Confocal laser scanning microscopy was used to measure fluorescence in this study. 
The VivaScope 2500 Multilaser (Figure 3.1) used in this study provided the 
advantages of reflectance depiction and reliable analysis of tissue within a short time 
unlike conventional methods such as histology. The skin tissue did not require 
complex preparation and preservation procedures. The VivaScope 2500 Multilaser 
uses three lasers with wavelengths of 658 nm (red), 488 nm (blue) and infrared laser 
(830 nm or 785 nm).  The device is fitted with a motorised stage (Figure 3.2) for the 
sample, which moves to generate a tiled image over a large area. The stage can move 
+/– 8.0 mm in direction of x and y totalling a complete area of 16 mm square. The 
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confocal microscope can image up to 9 frames per second with 1000 x 1000 pixels in 
an individual image. 
 
Figure 3.2 Motorised sample placement stage - VivaScope 2500. 
The laser power enables imaging up to 200 μm. The VivaScope was designed as a 
quick and easy technique to assist physicians with the precise detection of margins 
between tumours and healthy tissue. For this study we have used the L1 or the blue 
laser to image sodium fluorescein. The confocal microscope was used with 488 nm 
excitation and 550 ± 88 nm emission bands to record images.  Reflectance images 
can easily help differentiate between the different layers of the skin hence reflectance 
mode was used to a gain better understanding of the morphology of the skin. 
3.3.2.2 Microneedles and Microneedle applicator 
The microneedles used in this study were cut from a 50 μm thick 304 stainless steel 
sheet with the help of a LaserPro S290 laser milling machine. The microneedle 
arrays shown in Figure 3.3 were cut onto a single plate with 700 μm length × 250 μm 
width. Each plate consisted of 3 microneedles separated by a 5 mm distance. These 
plates were then assembled in banks of 2 with a 3 mm spacing in between. The 
microneedles were cut in batches with a strict quality control cut-off of 5% standard 
deviation. The tip of the microneedles was created at 55º forming a 250 μm long 
cutting surface. This method of laser cutting of microneedles was validated for 
consistency. A typical batch when observed for quality assurance had an average 
height of 703.1 ± 16.1 μm (SD = 2.25) and an average width of 257.8 ± 9.4 μm (SD 
= 3.64).  
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Figure 3.3 MN plate with three 700 μm length × 250 μm width MN.  
The applicator developed for this study was designed to create an impact on the skin 
surface at a delivery speed of 1.5 m/s. Figure 3.4 shows a typical setup of the skin 
before the microneedles are applied.  
 
Figure 3.4 Skin setup for MN application.  
The skin was moderately stretched by putting a rolled paper towel under it (figure 
3.4) to allow for the proper insertion of the microneedles followed by placing the 
applicator on the desired location on the skin. After firmly pushing the applicator 
against the skin, the trigger was released to make six holes corresponding to the six 
microneedles. In figure 3.4 the microneedle spacers (small grey and orange blocks) 
have been left on the skin for explanation. 
3.3.2.3 Transepidermal water loss (TEWL) 
TEWL has long been used as an indicator of skin barrier integrity. Recent studies 
have validated the use of both open and closed chambers in the measurement of 
TEWL.
324
  TEWL measurements in this study were performed using an AquaFlux 
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AF200 closed chamber evaporimeter (Biox Systems Ltd., London, UK). AquaFlux 
V6.2 software was used to analyse the data (Figure 3.5). TEWL readings were 
recorded in triplicate prior to the study and immediately after the study before 
imaging. Additionally on the skin groups which were applied microneedles, TEWL 
was measured immediately after the MN application.  
 
Figure 3.5 AquaFlux AF200 TEWL meter. 
3.3.3 Skin preparation for permeation studies  
All experiments in this study were conducted on excised human skin in compliance 
with the guidelines of the National Health and Medical Research Council of 
Australia. Human skin was collected with prior approval from University of 
Queensland Human Ethics Committee. (2007/197) The subcutaneous fat was 
removed by dissection and the full thickness skin then stored at –20°C until required. 
Skin from different donors was used to demonstrate reproducibility of the study. 
Before commencing the study the skin was thawed to room temperature and 
carefully dabbed with clean tissue paper to remove excess moisture. The skin was 
then cut using a circular cutter to exact specifications to fit Franz cells with very little 
skin hanging over the receptor compartment.  
3.3.4 Study design 
3.3.4.1 Studies on sodium fluorescein  
In an attempt to model the movement of the fluorescent dye after microneedle 
application, delivery studies were designed to determine the time taken for the dye to 
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move a set measure of distance away from the needle hole. Due to the proximity of 
the microneedle hole it was decided to study only time points prior to the 
overlapping of fluorescence planes. Figure 3.6 below demonstrates a typical 
fluorescence image taken 5 min after sodium fluorescein application.     
 
Figure 3.6 Sodium fluorescein imaged 5 min after treatment application. 
Freshly excised skin was obtained mostly on the day of the experiment or within 24 h 
of the experiment at the latest. In vitro permeation studies of sodium fluorescein 
across full thickness human skin were performed in Franz-type diffusion cells. The 
skin was mounted in the Franz cell with the stratum corneum uppermost. The 
receptor compartment of the cell was filled with saline, stirred with a micro stirrer 
and maintained at 35°C in a temperature controlled water bath. TEWL measurements 
were made before and after the experiment to confirm barrier integrity. All skin 
samples with TEWL reading above 35-40 g/m
2
h were discarded. The experiments 
were carried out by applying the drug on either MN treated or control skin pieces. 
Sodium fluorescein at a concentration of 500 µg/mL was first massaged into the skin 
after the application of microneedles. Then a reservoir of 300 μL of sodium 
fluorescein solution was left in the donor compartment to provide an infinite dose. 
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The donor compartment was occluded with Parafilm
TM
 and aluminium foil to avoid 
light and loss of hydration. The duration of the study was varied from 5 min up to 2 
h. After completion of the intervention time, the excess drug was dabbed off the skin 
carefully, followed by imaging using confocal microscopy. Images were generated 
after 5, 10, 20, 40 and 120 min of drug application.  
3.3.4.2 Studies on fluorescent peptides 
Despite the increasing importance of protein therapeutics and vaccines, the need to 
deliver them by hypodermic injection remains a major limitation, due to the pain 
associated with it and the need for supervised application. Delivery of protein drugs 
through the skin is an attractive alternative to needles, but has proved elusive thus 
far, barring a few examples.
272
 Because the primary barrier to transport through the 
skin is located in the upper 10-15 µm of skin and nerves are found only in deeper 
tissue, we used microfabrication techniques to make arrays of microneedles long 
enough to cross the permeability barrier with ease (700 µm) but not so long that they 
are painful.
325
 The peptides used in this study were selected as cosmetic and 
therapeutic peptides with increasing chain length and increasing molecular weight. 
The design of the study was to observe penetration enhancement of the peptides as a 
function of their molecular weight or size. The experimental protocol used was 
similar to the sodium fluorescein studies. Fluorescein conjugated peptides 
melanostatin (MEL) (MW 803.92 Da), rigin (MW 959.04 Da) and palmitoyl 
pentapeptide (Pal-KTTKS) (MW 1191.06 Da) were first dissolved in appropriate 
solvents as per manufacturer’s instructions. The study included eight groups each 
conducted in triplicate. Negative controls were solvent only and solvents post 
microneedle application to account for any auto fluorescence that may be 
encountered. Sodium fluorescein, in the amounts equivalent to that present in the 
peptide, was used as a positive control in both passive interventions where 
microneedles were not applied, and in active interventions where microneedles were 
applied. The last two interventions included the peptides with and without 
microneedles applied at a 500 µg/mL concentration. The treatment time during the 
study was 1 h for all interventions. For the peptides a separate 24 h time point from 
the same skin donor was also conducted.  The replicate experiments on each peptide 
were conducted using skin from multiple donors.  
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3.3.4.3 Standard curves for sodium fluorescein and fluorescent peptides 
The visual analysis of images to provide quantitative measurements such as protein 
concentration and the identification of specific fluorescent signals is a complicated 
task. It is dependent on both the methods used to acquire and analyse the data as well 
as the accuracy and precision of instrument functions.
317
 The drawback of working 
with a mode of experimentation that measures luminous/fluorescent intensity is that 
it is not fully quantifiable in all instances. It is rather straight-forward to compare the 
different active and passive interventions and measure their fluorescent intensities, 
but correlation to their exact amounts is a desired outcome. Serial dilutions of the 
solutions of sodium fluorescein and the peptides were quantified. To make standard 
curves, images were taken at different power levels. The sample solutions were 
placed in a rubber ring that was stuck on a glass slide with the help of high vacuum 
grease. The ring was covered with a cover slip and sealed with cellophane tape on 
the sides. Figure 3.7 illustrates prepared samples for standard curve imaging. 
 
 
Figure 3.7 Samples prepared for standard curve. 
3.3.5 Imaging and analysis of images 
After completion of the treatment time the skin samples were cut to a smaller size. 
Before the samples were imaged with LSCM, a dermoscopic image was first taken to 
identify the exact location of the microneedle holes. The sample was then mounted 
with microscopy oil and covered with a cover slip. The VivaScope 2500 Multilaser 
was used for this study as it covers an area big enough to image the microneedle 
holes completely in one tiled image. The images were generated as cubes of tiled 
103 
 
images of 8×8 individual images over 20 layers. The cube was generated over 100 
µm with images at a step of 5 µm. Similarly cubes were also generated from the 
same area (depth and location) in reflectance mode. The reflectance image in 
conjunction with the z-axis profile of the intensity depth was used to determine the 
top layer of the skin sample. The top 20 microns were designated as the stratum 
corneum (SC), the following 30 microns were designated as the viable epidermis 
(VE) and the images from below this (50 microns + deeper) were designated as the 
dermis (DER).
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Analysis of the intensity images was carried out on Image J software designed by the 
NIH (USA). Three different settings were used for the analysis of images from the 
sodium fluorescein time profile penetration experiments.  
Analysis technique 1: Firstly a line plot of intensities and integrated densities (ID) on 
each of the layers was generated starting from the centre of each microneedle hole. 
Line plots were generated in all four directions on all six microneedle holes. Figure 
3.8 a) illustrates a typical image with line plot drawn, b) illustrates a plot of the 
intensities observed.      
 
Figure 3.8 a) Image with line plot, b) Plot of the intensities measured 
Analysis technique 2: The second method of analysis used modification of threshold 
intensity to select out the area of intensity around the microneedle hole. For all 
analysis a mean threshold of 54 (in arbitrary units) was used as minimum permitted 
intensity corresponding to the FITC or NaFsc fluorescence. The threshold was 
selected by visual analysis and repeated testing. Once the area of high intensity 
corresponding to sodium fluorescein was isolated, the size, area and integrated 
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density values were calculated using the Analyse particles tool on Image J. Figure 
3.9 a) illustrates a high intensity area separated from the cube image by adjusting the 
threshold intensity, b) illustrates an outline of the area of intensity which can then be 
measured in either pixels or µm.  
 
Figure 3.9 a) High intensity area, b) Outline of the area of high intensity. 
Analysis technique 3: The third method of analysis used the radial profile plugin 
from Image J. A circular area around the microneedle hole with a predefined radius 
was selected, the threshold adjusted as previously described (Figure 3.10 a) and the 
Radial Profile angle tool from plugins was used to generate a plot (Figure 3.10 b) of 
integrated intensity vs. radius.   
 
Figure 3.10  a) Circular area around the microneedle hole, b) Integrated intensity vs. radius 
plot. 
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The line plots generated from analysis technique 1 and radial profiles generated from 
technique 3 were compartmentalised into four different compartments of equal area 
(1766250 Pixels). Intensities and integrated density (ID) in these compartments were 
plotted against time to represent the movement of the dye from one 
compartment/zone to the other. 
3.3.6 Statistical analysis 
The skin permeation data consisted of normalised penetration area and integrated 
density measurements of active, passive, negative control and positive control taken 
at various times (1, 4 and 24 h) imaged in the skin layers, viable epidermis and 
dermis.  A random effects regression model was used to compare the treatments at 
various time points, with the timings treated as categorical variables (so that no linear 
relationship was assumed between permeation and time).  This type of regression 
model is equivalent to a repeated measures analysis of variance, in that it properly 
takes into account correlations between measurements made on the same sample at 
different time points.  If the standard deviations of the permeation appeared to differ 
widely for different time periods, a logarithmic transformation was performed on the 
permeation before analysis. 
Pairwise comparisons were calculated from the regression model by requesting 
certain ‘contrasts’ as required.  Contrasts were tailored to make specific comparisons, 
and obtain the p-values for them.  The standard errors on which the contrasts were 
based were estimated from the regression model which was based on all the available 
data.  If the analysis was performed on the log-transformed data, the p-values for the 
pairwise comparisons were based on this analysis, but the mean permeations were 
quoted on the original scale (to simplify interpretation). 
All statistical analyses were performed using the SAS version 9.2 statistical software 
(SAS Institute Inc, Cary, NC, USA, 2008).  A p-value <0.05 was taken to indicate a 
statistically significant association. 
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3.4 Results and Discussion 
3.4.1 Preliminary studies  
3.4.1.1 Preliminary studies on sodium fluorescein  
Time profiling studies on NaFsc were conducted to gain information about the 
kinetics of drug diffusion post microneedle (MN) application. We hypothesised that 
MN based delivery will follow different kinetics in different layers of the skin (SC, 
VE and DER) that can be statistically verified. To optimise the experimental protocol 
for the time based study we conducted numerous pilot studies and examined different 
variables.  
3.4.1.1.1 Effect of concentration of Sodium fluorescein (NaFsc) on its lateral diffusion 
Solutions of NaFsc were prepared in water with concentrations of 500 µg/mL and 1 
mg/mL. The 1 mg/mL solution gave an intensity signal which was very strong and in 
some cases was giving results which were to the maximum threshold intensity (254). 
A very high intensity image makes it difficult to quantify and isolate the area around 
the MN. On reduction of the concentration to 500 µg/mL the pictures were of 
reasonable contrast and detail with minimal photo bleaching. The area of penetration 
around the MN was measurable and fluorescence was observed up to 200 µm deep. 
Passive administration of NaFsc at 500 µg/mL permeated to the shallow layers of the 
skin and was concentrated in the skin furrows. Figure 3.11 (a) shows a 500 µg/mL 
NaFsc image from the passive treatment in viable epidermis, (b) shows a 500 µg/mL 
NaFsc image from the active MN treated skin in viable epidermis. 
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Figure  3. 11 a) NaFsc diffusion (passive) in viable epidermis, b) NaFsc diffusion (active-MN) in 
viable epidermis. 
3.4.1.1.2 Effect of time  
To observe a time correlation of penetration after MN application we conducted pilot 
studies on times ranging from 5 min to 8 h. Due to the highly hydrophilic nature of 
NaFsc its penetration after the stratum corneum is breached is extremely fast.
191
 It 
was observed that the movement of the fluorescent peptides was much slower when 
compared to NaFsc. Therefore at the longer time points studied, NaFsc showed rapid 
movement of the bright fluorescent area away from the MN hole and towards the 
periphery of the skin sample. In all time points over 1 h the highest intensity 
fluorescent area was not observed around the microneedle holes. The fluorescence 
was of much lighter intensity but the area of fluorescence was vastly increased, 
encircling all the holes and distinction of fluorescence from the fluorescent drug 
present around individual MN holes was not feasible. Figure 3.12 shows a 4 h image 
of NaFsc after MN application.  
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Figure 3.12 NaFsc at 4 h after MN application. 
3.4.1.1.3 RCM settings- Auto power control 
The VivaScope 2500 provides a tunable range to adjust laser power and gain.
321-323
  
However automatic image control allows the VivaScope to automatically optimize 
the laser power so that the image is displayed with the proper illumination. 
Reflectance confocal microscopy has been extensively used in the field of 
dermatology and there are more than 150 publications where RCM has been used.
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However, confocal microscopy is not optimal for quantitative measurements when 
using a single power setting. It has been shown that epidermal scattering and 
absorption limit the penetration depth of light, both in the acceptable laser excitation 
powers as well as the emitted fluorescence.
328
 In the automatically adjusted laser 
power used for this study, the reflectance mode laser power ranged between 0.4 and 
1.2 milliwatts (mW) and in fluorescence mode, the laser power ranged between 4 and 
6.9 mW. 
3.4.1.1.4 Effect of microneedle size/ design and impact velocity of the applicator  
For this project we have used multiple MN designs and some have been shown in 
Figure 3.13 (a) 1 mm row of 3 MN, (b) 700 µm row of 5 MN, (c) 1 mm polymer row 
of 3 MN, (d) 700 µm row of 3 MN. The MN designs were governed by various 
factors such as ease of piercing into the skin, strength of the MN, reproducibility of 
puncture and area of fluorescence after MN application.
209,325,329,330
 The 1 mm MN 
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were discontinued after the pilot stages, as they were deemed to be slightly longer 
than the generally required length to sufficiently pierce the skin. Moreover the 
polymer (epoxy) microneedles fabricated in the lab using Polydimethylsiloxane 
(PDMS) moulds were found to be brittle and posed a risk of breaking on application. 
In a study conducted on human volunteers by Gill et al.
325
 30% of subjects reported 
both the 480 μm and the 700 μm long microneedles as completely painless, whereas 
0% and 10% reported the 960 μm and 1450 μm long microneedles painless, 
respectively.
325
 The 700 µm row of 5 MN was equally effective in strength and 
reproducibility to the 700 µm row of 3 MN which were ultimately selected for the 
studies. However, due to the proximity of needles to each other the zone of 
florescence penetration plane was not accurately measureable. Hence the MN plate 
with a row of 5 MN was replaced by the 3 MN plate and the distance between the 
needles set as 2.1 mm. The tip of the microneedles was angled at 55º. Two plates of 
these microneedles were arranged in the applicator with the help of spacers totalling 
6 MN per array. The study by Gill et al. also showed that MN arrays containing 5 to 
50 microneedles were completely painless as reported by a significant number of test 
subjects; however there was no significant correlation found with pain and the 
microneedle tip angle.
325
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Figure 3.13 a) Stainless steel MN plate with a row of 5 MN, b) Stainless steel MN plate with a 
row of 3 1mm MN, c) Cured epoxy adhesive MN plate with a row of 3 MN, d) ) Stainless steel 
MN plate with a row of 3 MN  
The strength and speed at which the MNs are applied not only governs the optimal 
piercing of the skin but also the shape and size of the pores/conduits formed.
191, 208,329
 
Verbaan et al.
331
 showed that a higher piercing velocity resulted in a higher transport 
rate of dyes after MN application. The authors have been granted a patent on an 
electronically operated MN applicator which can insert MN at a piercing velocity of 
1 to 3 m/s.
331
 For this study we used a spring loaded mechanical applicator which 
inserted the MNs with 1.5 m/s piercing velocity. 
3.4.1.2 Preliminary studies on fluorescent peptides 
3.4.1.2.1 Effect of concentration 
The peptides used in this study were applied at a concentration of 500 µg/mL as the 
preliminary studies with NaFsc were used as a yardstick to decide various 
transposable parameters. However, for these studies NaFsc was used as a positive 
control and it was decided by careful consideration that NaFsc should not be used at 
a 500 µg/mL concentration. Firstly, NaFsc has considerably better transport 
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properties then the peptides in the study. Moreover, the amount of fluorescein 
present in the peptides is a molar ratio, and hence substantially lower. Therefore, 
NaFsc equivalents were calculated for all 3 peptides: the amount of NaFsc used was 
310 µg/mL, 261 µg/mL and 163 µg/mL for melanostatin, rigin and palmitoyl 
pentapeptide (Pal-KTTKS) respectively.   
3.4.1.2.2 Effect of time 
Pilot studies were conducted with treatment times of 1 h, 2 h, 3 h, 4 h, 8 h and 24 h in 
an attempt to effect maximum penetration of the peptides with minimum damage to 
the skin. After numerous attempts to optimise the study duration, the studies on the 
peptides were conducted for 1 h. This was mainly due the markedly high lateral 
penetration of NaFsc (positive control) after MN based delivery. Figure 3.12 shows a 
4h NaFsc treatment. However, for the peptides a 24 h sample point was carried out in 
expectation of a greater degree of penetration both passively (without MN) and 
actively (with MN). Peptides are highly prone to lipid binding and their partitioning 
from the transdermal lipids can be time consuming.
272,332
 The peptides used in this 
study are primarily cosmetic peptides and a longer duration of intervention before 
they can show the desired effects is generally more tolerable then for therapeutic 
molecules.
12,333,334
 
3.4.1.2.3 Effect of vehicle for peptide dissolution  
The peptides were dissolved according to the solubility studies completed by the 
synthetic laboratory (Genscript USA). Melanostatin was soluble in water at pH 10; 
ammonia solution was used to adjust the pH. Rigin was soluble in water at pH 7. 
However, with Pal-KTTKS, the ideal solvent after solubility test was found to be 
DMSO. DMSO has been used as a very potent chemical penetration enhancer and at 
higher concentrations can lead to cornification of the skin.
335
 Moreover, the outcome 
of our studies was entirely dependent on the ability to image the various layers of the 
skin with good contrast and quality. This was not possible as the morphology of the 
skin was severely altered. Figure 3.14 shows images from the viable epidermis taken 
during a pilot study with (a) Water as solvent and (b) DMSO as solvent. The 
disintegration of cellular structure and disappearance of furrows is clearly visible 
from the images where DMSO was used as a solvent. 
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Figure 3.14 Images from the viable epidermis taken during a pilot study a) Water as solvent b) 
DMSO as solvent  
For Pal-KTTKS and later on for all the controls 25:75 PG: Water was used as the 
solvent. Though propylene glycol is a mild penetration enhancer,
153,336
 it does not 
affect the imaging quality. The penetration enhancement effect of PG however was 
not observed during our studies. 
3.4.2 Imaging protocol for MN based delivery studies 
The skin samples were cut into a desirable size to expose only the MN applied area. 
The immersion gel was placed between the objective lens and the glass slide, 
whereas the excised skin was covered with a coverslip using microscopy immersion 
oil. The reflectance mode was used to locate the top of the skin, the objective was 
moved up by 5-10 microns and this was set as the Zero depth. This was followed by 
a switch to fluorescence mode where the ‘Z’ position was moved to 40-50 μm from 
Zero depth. A complete ‘Viva block’ was captured which basically is one layer of the 
cube at a given depth. This was done to make sure all six needle holes and their 
fluorescence planes were imaged in the block. Imaging was performed to capture 
cubes of composite maps. The composite maps were a series of full field (750 × 750 
μm) images in a single, horizontal plane that are automatically captured and 
"stitched" together to form a composite image that ranged from 4 × 4 mm to 8 × 8 
mm square. This mosaic of images essentially "cuts" an optical section into the 
specimen close to its surface. Sequential stacks of images were captured as long as 
image quality and resolution were maintained, to a maximum depth of 200 μm. 
Individual full field images and stacks of area containing the MN holes were 
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captured as needed. The complete imaging process took 20–40 minutes, although 
initial images were obtained in less than five minutes. 
The ‘Z’ stack images of the individual MN hole were used only for illustration 
purpose and better understanding of the morphology. No analysis was carried out 
using these pictures. Figure 3.15 (a) shows a ‘Z’ stack image of MN hole in 
reflectance mode and (b) ‘Z’ stack image in fluorescence mode. The VivaScope 2500 
is capable of imaging with good clarity up to 300 μm, for this study cubes and stacks 
were produced with a 200 μm depth.    
 
Figure3.15 a) ‘Z’ stack image of MN hole in reflectance mode and b) ‘Z’ stack image in 
fluorescence mode 
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Transverse sections of skin are often used in dermoscopic evaluation.
337
 In this study 
we have used cryosectioning in the pilot stages to locate MN holes and look at lateral 
penetration from the MN holes. However, cube images of the VivaScope are a very 
reliable and quick way to gain the same information in one place. Though sectioning 
can provide more detailed information, it is a time consuming and arduous task. The 
confocal optical section thickness compares very well to the typically 5 μm thin 
sections that are prepared for conventional histopathology using skin freezing 
followed by fixing. With Reflectance confocal microscopy, skin can be imaged either 
in vivo or ex vivo without any processing.
338
  
3.4.3 MN based delivery studies on Sodium Fluorescein (NaFsc) 
Fluorescent molecules are the easiest way of studying not only the histology of skin 
and morphology of live and excised tissue; they are also a very useful tool in 
exploring effectiveness and feasibility of novel skin penetration technologies. 
Fluorescent molecules like sodium fluorescein (NaFsc) have been used to study 
transdermal penetration enhancement for a very long time.
339,340
 In this study we 
aimed to evaluate the effectiveness of the MN fabricated and designed in-house. It 
was also envisaged to develop a working transdermal delivery model from the MN 
based delivery of NaFsc. This model would be able to better characterise the 
diffusion of molecules from the MN hole in sink conditions. Various parameters like 
transdermal flux and permeability coefficients would ideally drive towards better 
optimization of MN design and provide useful information on the expected flow 
properties of a host of other therapeutic molecules. A time based 
compartmentalisation of NaFsc in the various layers of the skin such as stratum 
corneum (SC), viable epidermis (VE) and the dermis (DER), along with the 
movement of the dye from the centre of the MN hole to the periphery of the 
fluorescent aura can be studied in sink conditions. Hence in this study, the lateral and 
depth penetration of NaFsc was studied over a series of short to medium durations. 
The data analysis was carried out using methods 2 and 3 described in section 3.3.5 
Figures below show the penetration of NaFsc in stratum corneum (SC), viable 
epidermis and dermis in the three replicates produced in different skin donors: Figure 
3.16 donor 1, Figure 3.17 donor 2 and Figure 3.18 donor 3. The replicates show a 
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degree of variability within the skin donor group that varied from 27 to 54 year old 
females.     
 
Figure 3.16 Penetration of NaFsc in stratum corneum, viable epidermis and dermis from 5-120 
min after microneedle mediated skin delivery (Donor 1) 
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Figure 3.17 Penetration of NaFsc in stratum corneum, viable epidermis and dermis from 5-120 
min after microneedle mediated skin delivery (Donor 2)  
 
Figure 3.18 Penetration of NaFsc in stratum corneum, viable epidermis and dermis from 5-120 
min after microneedle mediated skin delivery (Donor 3) 
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Using the second method of analysis and selecting out the area of intensity around 
the microneedle hole by modifying of the threshold intensity, the total area of 
penetration was calculated. These calculations were based on the average 
fluorescence intensity between 54 and 255. The merit of doing this was the ability to 
select out only an area of even fluorescence surrounding the MN holes. Establishing 
the threshold to eliminate noise or background was carried out by subtracting the 
threshold from the image.
341
 Bal et al.
191
 categorised pixel intensity into three 
different classes: the class with the highest pixel intensity between 230 and 255 AU 
was referred to as high intensity fluorescence (HIF); the class with pixel intensity 
between 230 and 14 AU was referred to as low intensity fluorescence (LIF) and the 
class with pixel intensity values below 14 AU was regarded as background. The 
Figure 3.19 below shows an image from the 40 min time in our study (a) the area 
selected in at intensity range of 54-255 AU. Conversely in (b) selected at intensity 
threshold range of 14-255 AU the entire image was selected as the zone of 
penetration.  
 
Figure 3.19 Image from the 40 min time point a) selected intensity threshold range of 54-255 AU 
b) selected intensity threshold range of 14-255 AU. 
The concentration of NaFsc used in our study was a quarter of the concentration used 
by Bal et al. (Bal et al. 2 mg/mL vs. our study 500 µg/mL). At 500 µg/mL the area of 
penetration from the MN used in this study was 3.47 mm radially from the centre of 
MN. This area gradually increased to 5.2 mm by 120 min of NaFsc application. The 
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results in Figure 3.20 show an increase in area of penetration as the time period was 
increased and the area of penetration in the VE and DER increased gradually. 
 
Figure 3.20 Average area of NaFsc penetration in skin strata (n=3, results expressed as mean ± 
SD) 
Figure 3.21 below shows a 3D view of the area of penetration around one of the MN 
holes after 5 min time point. Images are shown in a series from the DER to the top of 
the SC across 60 µm. The axis ‘x’ and ‘y’ are planner and ‘z’ is the axial depth 
adding the third dimension. 
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Figure 3.21 3D view of the area of penetration-5 min 
In the next method integrated density (ID) values were calculated in a series of 
compartments/zones (Z) starting from Z1, the closest to the MN hole. Integrated 
density is the sum of the values of the pixels in the image or selection. This is 
equivalent to the product of area and mean grey value (MGV). Circular sections of 
the complete penetration zone were divided into 4 compartments of identical area 
(1766250 pixels). Concentric circles of radius 750 pixels, 1060.65 pixels, 1299.03 
pixels and 1500 pixels were drawn. Figure 3.22 illustrates the zoning of the 
fluorescent planes. 
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Figure 3.22 Fluorescence plane divided in 4 Zones 
The analysis showed a decrease in the average integrated density in the zone closest 
to the MN hole and a gradual increase in the ID in the zones away from the MN 
holes. Figure 3.23 shows the average ID in all layers of the skin a) Stratum corneum 
(SC) b) Viable epidermis (VE) c) Dermis (DER) and d) Total ID of the fluorescence 
in different lateral zones. The ID in zone 1 at 5 min was 50% more than that of the 
ID in zone 1 at 120 min (Z1 5 min 12266756 – Z1 120 min 8385689). The data from 
the previous area analysis show an increase in the penetration area, hence the 
decrease in ID. The results in the VE were more obvious where there was a 3 fold 
decrease in the ID from 5 to 120 min (Z1 5 min VE 15621369 – Z1 120 min VE 
5343177)  
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Figure 3.23 Average integrated density in all layers of the skin a) Stratum corneum (SC) b) 
Viable epidermis (VE) c) Dermis (DER) and d) Total ID (n= 4, results are expressed as mean ± 
SD)  
Radial profile angle tool from Image J downloadable Plug-ins was used in the final 
analysis (as described section 3.3.5) to generate intensity profiles from the centre of 
the needle hole to a radius of 1500 pixels or 1129 µm. Intensity numbers were 
generated on the entire 60 µm depth from the top of stratum corneum to the top part 
of dermis. To improve the consistency in the analysis 20 µm each was denoted as 
SC, VE and DER. The intensities in these 20 µm (4 images) were averaged. The 
average intensities were then separated to accommodate four penetration zones 
(compartments) C1, C2, C3 and C4 starting from the centre of the microneedle hole. 
The penetration zones are expressed as ‘ZONES’ in the previous section and as 
‘COMPARTMENTS’ here. It was hypothesised that in sink conditions as time 
increases the drug (model dye NaFsc) will move away from the microneedle hole 
towards the periphery or the C4. Figure 3.24 shows the average intensity in the three 
layers of the skin across the four compartments. As expected, there was a 1.5 times 
increase in the intensity in C4 from 5 min to 120 min in the stratum corneum. The 
movement away from the needle hole was also consistent in the other layers of the 
skin as well with 1.4 and 1.7 times increase in the viable epidermis and dermis 
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respectively. The average intensity representing the total amount of drug in each 
compartment can be seen in the figure to move from the centre of the MN hole to the 
peripheral compartments. Towards the 120 min mark the average intensities were 
almost similar in all the four compartments.  
 
 
Figure 3.24 Average intensity in the three layers of the skin across the four compartments (n=3, 
results are expressed as mean ± SEM) 
3.4.4  Standard curves and fluorescence quantification of NaFsc and 
fluorescent peptides  
Measurements in fluorescence microscopy may be discussed in the context of three 
major criteria: (1) intensity which is usually expressed as a function of spectral 
frequency, (2) spatial analysis which is three dimensional where x, y are planer and z 
is the depth, and (3) temporal.
317
 The studies in the previous section describe the 
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entire three measurement criterion. In this section we tried to draw a parallel between 
these measurements and the actual concentration of the fluorescent entity. For this 
we measured the fluorescence intensity in a known volume (50 μL) of a series of 
standard samples. The intensity values were plotted against concentration at 5 
different power levels. The standard curves were generated in triplicate and a plot of 
the average values is illustrated in Figure 3.25 below.  The purpose of a standard 
curve apart from the ability to work out concentrations of NaFsc and peptides was to 
standardise the imaging process. As previously described, all the images taken during 
this study were done with automated power and gain control feature in VivaScope 
2500. To normalise the difference in power at which each cube of image was 
captured, a standard curve would be ideal. However, the intensity values 
corresponding to the standard solutions of NaFsc were not entirely reflective of the 
intensity values from a deeper axial area. 
 
Figure 3.25 Standard curves of NaFsc at different power levels 
Boi et al. described a method that can be used to evaluate the DNA content or the 
concentration of any protein, marked by an appropriate fluorescent dye, in single 
cells or in a tissue.
342
 The method involved simple measuring of the total intensity in 
all the imaged layers/ optical sections and summing the intensities. The total intensity 
over the thick optical section would then correspond to the total amount of 
fluorochrome/fluorophore in the sample.
343
 The researchers used mathematical 
124 
 
calculations to deduce the correct size of the optical section that should be imaged 
for accurate measurement capacity. The system described in Boi et al.’s research was 
not reproducible within our laboratory; however the technical intricacies regarding 
avoiding sources of error such as photo bleaching were very valuable. Most recent 
studies using fluorescent molecules have either quoted intensity values as an 
outcome
191
 or used tape stripping and fluorimeteric analysis
275, 344-346
 to quantify the 
amount of drug permeated. Fluorescence quantification by virtue of a standard curve 
will be pursued in the future as the group gains access to more knowhow and 
infrastructure. For the completion of this research however, intensity values 
combined with analysis of area of penetration and integrated density (ID) will be 
used as outcome measures.               
3.4.5 MN based delivery studies on fluorescent peptides 
Transdermal delivery studies using fluorescently tagged peptides have been 
described frequently.
112,133,272,275,347-349
  Microneedles have been used for safe and 
effective administration of a range of large and poorly permeable 
molecules.
5,51,190,193,194,201,204,207,350,351
 In this study we have aimed to investigate the 
permeability of peptides of increasing chain length and molecular weight, using 
fluorescence microscopy after MN based delivery. Microneedles used in this study 
showed marked enhancement in penetration of the peptides across the full thickness 
excised human skin when compared to no MN used.  
3.4.5.1 Melanostatin   
In this section and the subsequent sections on rigin and pal-KTTKS the names of the 
native peptides has been used but the description provided is that of the fluorescently 
conjugated peptides. This has been done to keep the discussion relevant to the 
peptides as primary targets of this investigation.  
Melanostatin is a tripeptide (Pro-Leu-Gly) with theoretical molecular weight 803.92 
Da post conjugation with FITC on the N-terminal. The log P of melanostatin was -
0.485. Hence, it was expected that post breaching of the stratum corneum with MN, 
this peptide would permeate very well. As was expected the small size, combined 
with hydrophilicity, helped melanostatin permeate to a great degree in all the layers 
of the skin. To understand the study better, images from the different sampling arms 
are shown below. Figure 3.26 shows the experimental images in the order imaged in 
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the study. It is clear from visual analysis that negative controls (solvent and solvent 
with MN) showed no fluorescence and positive controls (NaFsc and NaFsc with 
MN) showed the most fluorescence. Active (MEL MN) and passive interventions 
(MEL) at 1 h and 24 h showed fluorescence in between the range. 
 
Figure 3.26 Mosaic images of the 8 study groups 
Figure 3.27 below shows the penetration of melanostatin at 1 and 24 h. 
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Figure 3.27 Melanostatin penetration at 1 and 24 h (n=3, results expressed as ± SEM) 
At 1 h melanostatin showed a 10-fold enhancement in penetration area in the viable 
epidermis with the use of MN (Area 311848 pixels) when compared to without MN 
(Area 32641 pixels). This was found to be statistically significant (p < 0.05) At the 
same time point the integrated density was enhanced 2.6-fold. (ID without MN-549, 
ID with MN-1410) With the increment of time to 24 h, enhancements of 50% and 
80% were seen in the area and ID respectively (p < 0.05). The results improved with 
increasing depth. MN showed a 132-fold increase in the total area of penetration in 
the dermis (without MN: 1308; with MN: 173361). This was highly significant in the 
regression model analysis (p < 0.0001). At 24 h the comparison was similar, a 22-
fold increase in area was seen in the dermis (without MN:19386; with MN: 443623). 
This was accompanied with a 19-fold increase in ID (without MN: 289; with MN: 
5582). Despite its bigger size and lower hydrophilicity compared to NaFsc, 
melanostatin showed appreciable penetration in similar conditions and concentration. 
NaFsc was clearly penetrating to a greater degree at the 1 h time point, but over 24 h 
melanostatin reached the same amount of penetration/diffusion (NaFsc 1 h with MN: 
5204; MEL 24 h with MN: 5582). This comparison was not statistically significant. 
Without the barrier perturbation of the MN, NaFsc permeated 3-fold higher than 
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MEL (NaFsc 1 h without MN: 853; MEL 24 h without MN: 289).  Figure 3.28 shows 
the 1 h and 24 h penetration of melanostatin passively and actively after MN based 
delivery in three different skin donors.  
 
Figure 3.28 1 h and 24 h penetration of melanostatin after MN based delivery in three different 
skin donors 
Melanostatin is a melanin synthesis inhibitor, which was identified and its structure 
was elucidated by Ishihara et al.
263
 Numerous researchers have worked on the 
structure and activity of melanostatin
352,353,354
 but work relating to its biological 
activity has not been published in great detail. Transdermal delivery of melanostatin 
for non-cosmeceutical use has not been reported. Melanostatin and its analogues 
have also been studied for their antidepressive activity
355-357
 and researchers have 
also modified the -Leu-Gly- sequence to include a beta-lactam ring and found it to be 
very active biologically.
358
 Several studies have shown that melanostatin potentiates 
the behavioural effects of L-Dopa and facilitates morphine dependence.
359
 It is, 
therefore, under development for Parkinson’s disease therapy.360 Another example of 
melanostatin use was shown in a patent on the interactions of the neurologic-
endocrine-immune complex in malignant melanomas. Treatment with melanostatin 
was based on the hypothesis that neuroendocrine suppression of MSH would 
enhance the effectiveness of immune modulation.
361
 The reported usage of 
melanostatin in research has been predominantly parenteral including subcutaneous. 
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Though Ripka et al. have stated in the patent that it can be formulated in transdermal 
dosage forms, it has not been reported as yet.
361
 In this project I have demonstrated 
the capability to delivery melanostatin to all the layers of epidermis and also to the 
dermis. This outcome can be of great relevance to the current knowledge base. Along 
with the CNS effects, one particularly important role of melanostatin is in specific 
hyperpigmentary problems such as post inflammatory hyperpigmentation (PIH), 
solar lentigos, and melasma.
362,363
 Other examples where melanostatin could play a 
definite role include freckles and red patches due to hyperactive melanocytes that 
start in infancy, particularly in fair skin and areas of the Chloasma, also known as 
pregnancy mask. For complicated and uncomplicated skin disease states involving 
the hyperactivity of melanocytes, MN based delivery as shown here can be of 
clinical value upon further development. Atrium owns the rights to a melanostatin 
sequence based nona-peptide Melanostatine 5 which is marketed for skin lightening 
in cosmetic products.
266
 The use of invasive techniques such as Derma Roller, 
cosmetic facial surgery and semi invasive techniques such as microneedles is not 
very uncommon is cosmetic dermatology. Hence, MN based delivery of melanostatin 
could be suitable for cosmetic purposes. 
3.4.5.2 Rigin   
Rigin is a tetrapeptide (Gly-Gln-Pro-Arg) with molecular weight 959.04 Da post 
conjugation with FITC on the N-terminus. The log P of the native peptide Rigin was 
-2.887. Rigin had good water solubility and hence was also expected to permeate 
well. However the results were contrary to this prediction and may be associated 
with the higher molecular weight. The Figure 3.29 below shows a mosaic of 1 h 
images of rigin with and without MN. The zone of penetration and hence separation 
of the penetration area post MN application was not clear. Figure 3.30 shows 1 h and 
24 h images from rigin treated skin after MN application. 
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Figure 3.29 Images of rigin with and without MN at 1 h 
 
Figure 3.30 Images from rigin treated skin after MN application 
The permeability results of rigin showed a longer lag time due to its higher molecular 
weight (Figure 3.31). Rigin with MN showed a 1.8-fold increase in the area (Rigin 1 
h with MN: 314847; Rigin 1 h without MN: 173020) and 1.7-fold increase in the ID 
in the viable epidermis at 1 h (p < 0.05). At 24 h the penetration areas were identical 
(Rigin 24 h with MN: 294090; Rigin 24 h without MN: 290515). The results were 
similar in comparison in the dermis though the area was 6-fold less than that in the 
viable epidermis. These results suggest that not only was the lateral penetration of 
rigin lower; its axial penetration was substantially reduced.  After MN treatment, 
rigin penetrated better than both rigin without MN and NaFsc without MN. In this 
study I have shown that the MN can deliver the molecule down to the dermis, from 
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there it is the optimisation of drug characteristics like hydrophilicity, partitioning and 
protein binding that will enhance its lateral diffusion.   
 
Figure 3.31 Penetration of rigin through human skin (n=3, results are expressed as ± SEM) 
Rigin (Gly–Gln–Pro–Arg) is a tetrapeptide originated from immunoglobulin g (IgG), 
which is found to be immunostimulatory.
268,364
 Immunoglobulins, interferons, 
interleukins, growth factors, and other biologically active proteins and peptides like 
rigin are the precursors of tetins.
270
 Rigin is very similar in structure and action to 
tuftsin another tetrapeptide which has been widely researched for its 
immunomodulatory effects in a range of disease conditions including parasitic 
infections, AIDS, cancer and other autoimmune diseases.
365-368
 Rigin though has not 
been as extensively studied.   
The chemistry of rigin has been studied well because of its similarities to tuftsin. 
Ashish et al. conducted the conformational analysis of rigin both theoretically and 
experimentally and found considerable similarity of spatial arrangement of tuftstin 
and rigin
369
 and Kumar et al. examined for its secondary structure preferences.
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Martinez et al. synthesised a decapeptide containing in its sequence the subunits of 
rigin and found it to have immunomodulatory effects.
370
 In a chemistry and activity 
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defining research Rocchi et al. studied binding of rigin to receptors and found it to 
bind to receptors that are unrelated to the tuftsin receptors.
269
 Apart from the above 
mentioned therapeutic potentials rigin is currently been marketed by Sederma
TM
 as 
Palmitoyl tetrapeptide-7 in their product Matrixyl
®
 3000 and Matrixyl
®
 synthe’6™. 
It is promoted as an enhancer of skin elasticity via interleukin (IL)-6 reduction. Rigin 
is also marketed by Microneedle therapy system (MTSTM) as MTS VitaPep Serum in 
conjunction with a microneedle roller MTS-ROLLER
TM 
as a part of the MTS Anti-
Aging Complex™.371 Though the MTS-ROLLERTM has been used to stimulate the 
skin to produce new collagen formation and not transdermal delivery of the active 
formulations, in my project I have shown that MN can deliver rigin into the viable 
epidermis. The ability of rigin to down-regulate IL-6 in resting and inflamed cells 
was compared with dehydroepiandrosterone (DHEA) in vitro, and the two actives 
were comparable. Marketing materials related to rigin indicate that this reduction in 
IL-6 can produce increased skin smoothness, firmness, and elasticity.
229,362
 In 
commercial cosmeceutical products rigin has been used at a dosage of 3% w/w as a 
part of the formulation. In the studies I have conducted, rigin at 0.05% was able to 
penetrate into the viable epidermis and dermis after MN based delivery within 1 h. 
Moreover, after 24 h the penetration area of rigin passively (without MN) in the VE 
was 290515 pixels. Perhaps the reports of rigin’s in vivo activity in the light of the 
penetration results shown in this project hold true and the use of MN would further 
increase its suitability for cosmetic purposes. 
3.4.5.3 Pal-KTTKS   
The last peptide studied in this project was the palmitoylated pentapeptide (Pal-
KTTKS/PAL-KTTKS; Pal-Lys-Thr-Thr-Lys-Ser). The molecular weight post 
palmitoylation and conjugation of FITC was 1191.06 Da and the log P of this native 
peptide was theoretically calculated as 3.32. This lipophilic peptide was not soluble 
in water and was hence expected to travel poorly in the dermis and epidermis 
laterally after MN treatment. The results showed no change in penetration area in the 
viable epidermis over 1 h (Pal-KTTKS 1 h with MN: 33268; Pal-KTTKS 1 h without 
MN: 33702). However, in the dermis a statistically significant enhancement was seen 
with the MN (Pal-KTTKS 1 h with MN: 2473; Pal-KTTKS 1 h without MN: 319; p 
< 0.05). Over 24 h the passive permeation of Pal-KTTKS in the VE was greater to 
the MN based permeation (Pal-KTTKS 24 h with MN: 44693; Pal-KTTKS 24 h 
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without MN: 116577).  We presumed that lipophilic Pal-KTTKS, penetrated better 
passively in the viable epidermis. In the hydrophilic dermis however, the effect of 
better lipophilicity may have little effect. The penetration area analysis in the dermis 
conformed this. There was a 6-fold enhancement in the area of permeation post MN 
treatment (Pal-KTTKS 24 h with MN: 31755; Pal-KTTKS 24 h without MN: 5389; p 
< 0.05) Figure 3.32 shows Pal-KTTKS penetration over 24 h; figure 3.33 shows 1 h 
and 24 h images from Pal-KTTKS treated skin after MN application 
 
Figure 3.32 Pal-KTTKS penetration after MN application in excised human skin over 24 h (n=3, 
results expressed as mean ± SEM) 
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Figure 3.33 Images from Pal-KTTKS treated skin after MN application (n=3, results expressed 
as ± SEM) 
Of the three peptides studied here palmitoyl pentapeptide or Pal-KTTKS is the most 
popular in cosmeceutical circles. Work by a group at the University of Tennessee in 
1993 identifying the activities of small peptide fragments within procollagen I 
resulted in the identification of KTTKS, a sub fragment within the carboxy-terminal 
propeptide (residues 197-241) capable of stimulating the production of both collagen 
and fibronectin.
249
 This peptide fragment dramatically augmented extracellular 
matrix (ECM) production in sub confluent fibroblasts.
233
 It also stimulated type I and 
type III collagens and fibronectin production in a dose and time-dependent manner 
with no effect on total protein synthesis or on the ratio of secreted proteins to cell-
associated proteins. Osborne
372
 et al. showed a robust result for this peptide in 
reducing bumpy texture and fine wrinkles compared with other baseline and 
comparators.
372
 Fu et al. conducted a long-term clinical study comparing a cosmetic 
anti-ageing regimen including Pal-KTTKS, against a recognized prescription topical 
treatment for improving the appearance of facial wrinkling.
373
  
In a study by Robinson et al. on 93 Caucasian female volunteers, Pal-KTTKS had 
significantly better scores than placebo for expert grader assessment and subject self-
assessment of age hyperpigmented spots.
234
 In another study Kaczvinsky et al. 
studied effects of cosmetic products containing Pal-KTTKS using 3-D imaging and 
concluded that four weeks of treatment showed improvement in the smoothness of 
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periorbital skin and reduced the apparent depth of larger wrinkles.
374
 Though there 
are numerous newsletters and promotional material highlighting in vivo case studies 
showing tremendous benefits from Pal-KTTKS, transdermal delivery studies have 
not been conducted to support that these peptides actually go in the skin.   Abu 
samah et al. conducted a review on topically applied KTTKS and remarked that 
“indeed, KTTKS and palmitoyl-KTTKS are unusual in that no supporting in vitro 
data has ever been published supporting their successful transcutaneous delivery”.375 
The positive results of passive permeation of Pal-KTTKS in the VE as shown above 
(Fig 3.32) are very encouraging. Hence, we presume that the penetration 
enhancement role of MN which now can be seen predominantly in the dermis would 
be more distinct if the pentapeptide was not palmitoylated.     
3.5 Future directions  
Peptides possess enormous potential for the treatment of various diseases.  In 
contrast to youthful skin, mature skin undergoes well-established clinical and 
microscopic changes, particularly after menopause. In particular, dermal thinning, 
loss of dermal collagen and decreased lipid production are complicated by the effects 
of life-long sun exposure.
376
 It is well-accepted that cosmeceuticals are topically 
applied products that are more than merely cosmetic, yet they are not true drugs that 
have undergone rigorous placebo controlled studies for safety and efficacy before 
they can be marketed.
377
 Peptides and proteins, frequently used in anti-aging 
regimens, are categorized into four groups: signal peptides, enzyme-inhibitor 
peptides, neurotransmitter- inhibitor peptides and carrier peptides.
378
 The peptides 
studied in this project have a multitude of therapeutic actions and have been 
researched for potential clinical uses. The success of MN to enhance transdermal 
penetration and intradermal accumulation of peptides in the skin opens new 
opportunities. In future studies, other non-invasive transdermal delivery techniques 
can be used synergistically with the microneedles used in this project. One potential 
synergistic technology is Magnetophoresis which is described in the next chapter. In 
the course of this project the group has applied and successfully achieved animal and 
human ethics approvals for the use of microneedles in various research projects. It 
will be a future direction of the group to apply for further ethics approvals to pursue 
advanced work on the fluorescently labelled peptides in vivo. In particular the 
tetrapeptide rigin and pentapeptide Pal-KTTKS have tremendous potential for in 
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vitro and in vivo transdermal delivery studies. These peptides are either precursors or 
fragments of naturally and endogenously occurring proteins and polypeptides and 
hence there use for in vivo research would hold key to unlocking further potential.    
3.6 Conclusions  
Development of effective and functional delivery systems for new active 
pharmaceutical and cosmeceutical ingredients is a challenging task.
379
 In this chapter 
I have demonstrated that microneedles are an effective way of delivering large and 
complex pharmaceutically active molecules deep into the skin.  Confocal laser 
scanning microscopy (CLSM) has provided a significant tool to visualize skin 
structure and the localization of fluorescent molecules within the skin tissue.
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CLSM has rendered it possible to visualise and quantify the penetration of the 
peptides studied in this project in a fast and efficient manner. The rationale for 
selection of the peptides in this research was a broad classification into an established 
transdermal stream and relatively smaller size. The project was designed to study 
peptides with similar biological activity and increasing chain length. It is a 
particularly difficult task to find peptides of increasing chain length which fall in the 
same therapeutic class. Moreover, it was a deliberate effort to work on peptides 
which act within the skin rather than systemic peptides. The peptides melanostatin, 
rigin and Pal-KTTKS are, as described in the sections before of a reasonable size (3, 
4 and 5 amino acid). In addition to a large number of other potential actions 
especially for melanostatin and rigin, their role as cosmeceuticals is of increasing 
importance. 
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Chapter 4  
Effect of low field strength magnets on the skin permeation 
of peptides and small molecules. Assessment of potential 
synergistic enhancement with microneedle pretreatment. 
 
 
 
Diamagnetism occurs because the external magnetic field alters the orbital velocity 
of electrons around their nuclei, thus changing the magnetic dipole moment. 
152  
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4.1 Introduction 
Magnetophoresis is the enhancement of drug permeation across biological barriers 
by application of an alternating or a fixed magnetic field.
6
 Although some 
mechanistic studies have been reported,
7, 154
 the precise mechanism of penetration 
enhancement is not yet clear. It has been postulated that magnetophoresis may act on 
diamagnetic drugs or can fluidize the skin lipids. It is also possible that 
magnetophoresis can act by both mechanisms. The effect on the active molecule may 
be attributed to the diamagnetic properties of the molecules,
152
 whilst the effect on 
the skin may be through perturbation of skin lipids due to the stationary magnetic 
fields.
7, 381
 
ETP (enhanced transdermal polymer) magnets and Dermaportation, an alternating 
magnetic field electromagnetic coil system, were provided as a gift from OBJ Ltd, a 
Perth based biotechnology firm.  To investigate the potential diamagnetic effect of 
ETP on small molecules, experiments were conducted on a non-membrane model 
that showed predictable resistance. The agar gel based model provided easy study of 
the movement of dye molecules, presumably following first order kinetics. This was 
advantageous when compared to skin, where compartmentalisation and complex 
kinetics make it very unpredictable and there is the potential for interaction of the 
magnetic field with the skin barrier structure.  Experiments were then conducted in 
vitro, across human epidermis with diclofenac sodium in a carbopol gel formulation. 
In this study Dermaportation was compared to ETP and passive permeation of 
diclofenac sodium. Finally, to assess whether magnetophoresis using ETP had any 
membrane perturbation effect, experiments were carried out in vivo on human 
volunteers with a model small molecule, curcumin, which facilitated skin 
visualisation.  
Further, the successful enhancement of transdermal permeation and intradermal 
accumulation of peptides achieved with microneedles (Chapter 3) prompted me to 
explore the synergistic potential of skin pretreatment with microneedles with 
magnetophoresis. Although transdermal permeation enhancers have been 
individually shown to enhance drug transport, their combinations can be significantly 
more effective.
382
 Consequently microneedles have been used in conjunction with 
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other transdermal delivery techniques like iontophoresis
383
, electrophoresis
384
, 
nanoparticles
52
 and chemical enhancers.
385
   
In this chapter by utilising different skin and non-skin models I aim to elucidate and 
comment on the mechanism of magnetophoretic drug delivery alone and in 
combination with microneedle pretreatment.  
4.2 Aims 
The aims of this study were: 
1. To assess the permeation of a dye (brilliant blue) through a non-membrane 
agar gel model.  
2. To study the penetration enhancement effects of ETP on diclofenac sodium 
across human epidermis in vitro and to compare the skin permeation achieved 
with ETP magnets to that with Dermaportation. 
3. To examine the penetration enhancing effects of 2 fixed magnetic arrays 
(ETP008 and ETP012) on in vivo permeation of Curcumin by multi photon 
tomography/ microscopy. 
4.  To investigate the permeation and distribution of a model tripeptide across 
full thickness human skin ex vivo. To assess effects of ETP magnets on 
peptide permeation and to explore the possible synergistic effects on skin 
diffusion of the peptide with microneedles. 
4.3 Materials and Methods  
4.3.1 Chemicals  
Melanostatin, a tripeptide conjugated to FITC (MW = 803.92) was purchased from 
Genscript, USA. Curcumin and diclofenac sodium, model small molecules with a 
molecular weight of 368.38 and 318.13 respectively were purchased from Sigma 
Aldrich (USA). HPLC grade acetonitrile was supplied by JT Baker (USA) and all 
other chemicals including brilliant blue dye and carbopol were of analytical grade 
and were purchased from Sigma Aldrich (Australia). Phosphate buffered saline 
solution (PBS) was prepared according to the United States Pharmacopoeia. 
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4.3.2 Instrumentation 
4.3.2.1 Magnetic film arrays (ETP) 
Magnetic film array material consisted of 35 mm × 35 mm sections of unpowered 
flexible array matrix ETP (008 and 012), a proprietary enhanced transdermal 
delivery array film developed by OBJ Ltd (Perth, WA, Australia) was a gift from the 
company. The magnetic film arrays are thin flexible polymer matrix containing 
multiple magnetic elements arranged to produce complex 3-dimensional magnetic 
gradients. The material has a peak magnetic field strength of 40 mT. However, the 
arrangement and distribution of alternating poles across the surface of the material 
results in a total magnetic gradient of 2 T/m
2
. Figure 4.1 illustrates the magnetic 
fields using a metal dust polymer strip: a) ETP 008 magnetic field and b) ETP 012 
magnetic field. 
 
Figure 4.1 a) ETP 008 magnetic field and b) ETP 012 magnetic field as observed on a metal dust 
polymer strip 
4.3.2.2 Microneedles and Microneedle applicator 
The microneedle arrays were cut using laser etcher (LaserPro 5290) onto a single 
plate of 50 μm stainless steel with a 700 μm length × 250 μm width. Each plate 
consisted of 3 microneedles separated by a 5 mm distance. These plates were then 
assembled in banks of 2 with 3 mm spacing. The applicator used in this study had an 
impact velocity of 1.5 m/s. Figure 4.2 shows a microneedle plate on a fingertip. 
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Figure 4.2 A microneedle plate on finger tip 
4.3.2.3 Reflectance confocal microscopy and imaging parameters 
RCM (VivaScope 2500) has been described in chapter 3 section 3.3.2.1. For this 
study we used L1 (454 nm) to image the FITC conjugated fluorescent peptide 
melanostatin. The confocal microscope was used with 488 nm excitation and 550 ± 
88 nm emission bands to record images. Reflectance mode was first used for 
orientation. 
4.3.2.4 UV spectrophotometry 
Fluorimeteric analysis of dye samples was performed in a UV-Vis spectrophotometer 
(UV mini-1240) that allows for full spectral data acquisition over the wavelength 
range of 190 nm to 1100 nm. Linear dilution was performed with water and 
calibration curves were obtained at 5×10
-3
, 2.5×10
-3
, 1.25×10
-3
, 6.25×10
-4
, 3.125×10
-
4
, 1.5625×10
-4
, 7.8125 ×10
-5
 and 3.90× 10
-5 μg/mL of the dye solution. 
4.3.2.5 HPLC instrumentation and conditions 
High performance liquid chromatography was used for analysis of samples obtained 
in the in vitro skin diffusion studies undertaken with diclofenac in carbopol gel. The 
samples were analysed by reverse phase HPLC Agilent 1100 system which consisted 
of a quaternary pump (G1311A), autosampler (G1313A), degasser (G1312A) and 
photo diode array detector (G1321A). Separation was achieved on a Phenomenex 
Jupiter C18, 300A column (5 μm, 4.6mm×150mm). Integration was undertaken 
using Chemstation software B.03.01. Elution was performed at ambient temperature 
using a mobile phase gradient at a flow rate of 1 mL/min and the wavelength of 
detection was 278 nm. Buffer B was 0.036% TFA in acetonitrile and Buffer A was 
0.045% TFA in water. The peptide was eluted using a linear gradient protocol; 
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Buffer B was held at a linear gradient from 10 to 100% over 10 min. All samples 
were analysed by HPLC using injection volumes of 20 μL. 
4.3.2.6 HPLC analysis and validation 
4.3.2.6.1 Linearity 
A 1 mg/mL stock solution of diclofenac sodium was prepared by dissolving 5 mg of 
the compound in 5 mL water. Linear dilution was performed and calibration curves 
were obtained using 3.9, 7.80, 15.75, 31.5, 63.0 and 126 μg/mL for diclofenac 
sodium. Linearity (quoted as R
2
) was evaluated by linear regression analysis, which 
was calculated by the least square regression method.  
4.3.2.6.2 Precision, Intra and Inter-day repeatability 
The precision of the assay was determined by injecting three standard concentrations 
of 7.80, 15.75 and 63.0 μg/mL diclofenac six times on the HPLC. The intra-day 
repeatability was assessed by injecting 3.90 and 15.75 μg/mL diclofenac standards 
six times at different times in a day. The inter-day repeatability was determined by 
injecting 3.90 and 15.75 μg/mL diclofenac standards six times on 3 different days. 
The intra- and inter-day repeatabilities were quoted as the coefficient of variance. 
4.3.2.6.3 Lower limit of detection (LOD) 
The minimum detectable and quantifiable limits (LOD and LOQ) were measured by 
diluting the stock solution of diclofenac to give a concentration range from 3.9 to126 
μg/mL and then injected on the HPLC. The LOD was calculated as greater than 3 
times the baseline noise level by the following formula: LOD = 3 × SD of peak area 
of standard / slope. 
4.3.2.6.4 Lower limit of quantification (LOQ) 
The LOQ was calculated as 10 times the baseline noise level by the following 
formula:  
LOQ = 10 × SD of peak area of standard / slope. 
4.3.2.7 Multi photon tomography 
Multiphoton images for the in vivo experiments were collected on a DermaInspect 
system (JenLab GmbH, Jena, Germany) with an ultra-short pulsed mode-locked 80 
MHz Titanium Sapphire MaiTai laser (Spectra Physics, Mountain View, CA, USA) 
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which has a tuning range of 710 – 920 nm with an 85 femtosecond pulse width. The 
tomography system had an integrated time correlated single photon counting 
(TCSPC Becker and Hickl, Berlin, Germany) 830 detector to enable fluorescence-
lifetime imaging microscopy (FLIM) measurements. Figure 4.3 illustrates the 
schematics of a MPT system. The excitation wavelength was 740 nm, and the 
average incident optical power was 23 mW. Treated skin was optically sectioned 
using MPT-FLIM with a 740 nm excitation wavelength from just above the stratum 
corneum to below the dermis (total 100 μm) in 5 μm increments using a Zeiss Plan-
Neoflour oil-immersion 40X objective lens, resulting in an image size of 210×210 
μm2. 
 
Figure 4.3 Schematic showing a typical MPT set-up  
4.3.3 Study design 
The scheme below shows an overview of the various models used and experiments 
conducted to investigate the possible skin permeation enhancement effect of 
magnetophoresis. 
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Figure 4.4 Overview of experimentation 
4.3.3.1 Studies on permeation of brilliant blue dye in Agar gel syringes 
A 0.8% agar gel was prepared by dissolving 0.8 g agar in 100 mL water and by 
gentle warming to 60 ºC. The warm agar gel was then poured into a 20 mL syringe 
that had its top cut. The plunger of the syringe was moved up with the agar still in 
liquid form to make a donor well on the top end of the syringe. The agar was then 
allowed to solidify. Brilliant blue dye solution was placed in the donor well. An ETP 
magnet or dummy non-magnetic film was then lowered into place on top of the 
donor solution so that it was in contact with the solution but not submerged in it. The 
experimental set-up is shown below in Figure 4.5. The experiments were carried out 
for 2 hours after which the excess dye was removed. The plunger was moved up to 
bring the agar gel to the surface, from where it was cut into discs of equal height 
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using a thin wire. Each agar disc was weighed and dissolved in 10 mL of water. The 
absorbance of the solution was measured at 630 nm using a UV/Vis.  The 
experiments were conducted in quadruplicates. 
 
Figure 4.5 Study setup for Agar gel pilot studies 
4.3.3.2 Studies on permeation of diclofenac gel through human skin 
4.3.3.2.1 Preparation of diclofenac gel  
A 0.5% carbopol gel was prepared and homogenised with 250 mg of diclofenac 
sodium per 50 g of gel. The gel formulation allowed for the ETP magnets to be 
placed with ease, without being in touch with the skin. 
4.3.3.2.2 Human skin preparation 
Full thickness human skin samples excised from patients (30-50 year old female 
abdominal sections) undergoing abdominoplasty were refrigerated immediately after 
surgery. Sampling was approved by the Human Research Ethics Committee of 
Curtin University (Approval numbers HR132/2001, HR 70/2007 and HR 129/2008) 
and was conducted in compliance with the guidelines of the National Health and 
Medical Research Council of Australia. The following procedure was used to obtain 
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epidermal sheets. The subcutaneous fat was removed by dissection, the full thickness 
skin then immersed in water at 60 °C for 1 min, allowing the epidermis to be lifted 
off the dermis.
277
 The epidermis was placed onto aluminium foil, air dried, then 
placed in a sealed bag and stored at –20 °C until required. 
4.3.3.2.3 Skin permeation of diclofenac sodium across human skin 
 In vitro permeation studies across human epidermis were performed in Pyrex glass 
Franz-type diffusion cells (enabling permeation across skin sections of cross 
sectional area 1.18 cm
2
; receptor volume approximately 3.5 mL). Epidermal 
membrane was placed between the donor and receptor compartments and allowed to 
equilibrate for 1 h with the receptor solution (PBS pH 7.4) which was stirred 
continuously with a magnetic stirrer bar. The receptor compartment of the cell was 
immersed in a water bath at 37 ± 0.5 °C. PBS (1 mL) was placed in the donor 
compartment, allowed to equilibrate for 1 h and the conductivity and resistance 
across the epidermis was measured using a digital multimeter to determine 
membrane integrity. Membranes exhibiting an electrical resistance of less than 20 kΩ 
were rejected from the study. The PBS solutions were then removed from the donor 
and receptor compartments and the receptor refilled with approximately 3 mL of 
fresh pre-warmed PBS. The donor consisted of 1 g of 0.5% diclofenac sodium in a 
carbopol gel. Two hundred μL samples of the receptor phase were withdrawn and 
replaced with an equal volume of fresh pre-warmed (37 °C) PBS over a 6 h period to 
maintain sink conditions. The diclofenac content in the samples was determined 
using HPLC. 
Sections of magnetic film array (ETP 012) were cut to a size suitable for insertion 
into the donor compartment of the Franz-type cell and suspended on the surface of 
the gel, while passive cells had a non-magnetic polymer film of similar dimensions 
and material placed on the gel surface. (Figure 4.6)  
146 
 
 
Figure 4.6 Set-up for diclofenac gel studies 
In the Dermaportation cells, the Dermaportation coils were added to the exterior of 
the donor compartment and energy applied for 6 h, whilst other cells had no external 
Dermaportation energy applied. All cells were also occluded by sealing the top of the 
donor compartment of the cell with Parafilm
TM
. After 6 h the donor and receptor 
fluids were recovered, the cell disassembled and the skin epidermal membrane 
examined for obvious tears (any cells with torn membranes were rejected). At least 6 
replicates were conducted for ETP, Dermaportation and for passive diffusion 
experiments. 
4.3.3.2.4 Data Analysis 
The cumulative amount of drug permeated through the epidermis (μg/cm2) versus 
time (h) was plotted. The flux of diclofenac sodium through the human epidermis 
was determined from the slope of the plot of cumulative amount versus time and 
expressed as μg/cm2/h. Permeability coefficients (cm/h) were calculated for 
diclofenac in all the study arms. 
4.3.3.3 Studies on permeation of Curcumin through human volunteer skin 
For in vivo transdermal delivery studies, Curcumin in mineral oil was used as a 
model fluorescent molecule which could be easily imaged.  Curcumin has molecular 
formula of C21H20O6 and a molecular weight of 368.38. The structure of curcumin (a) 
and its fluorescence spectrum (b) is described below Figure 4.7. 
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Figure 4.7 a) Structure and b) fluorescence spectrum of curcumin in different solvents
386
 
The in vivo penetration experiments were carried out on healthy human volunteers, 
with approval of Princess Alexandra Hospital Research Committee Approval No. 
2007/197, administrated by the University of Queensland Human Ethics Committee. 
The intervention was carried out by applying the curcumin and occluding the spot on 
the forearm with either the magnet or dummy material, followed by imaging.  Three 
spots were located on the forearm, marked and cleaned on each hand of the 
volunteers (described in Figure 4.8 a). An initial measure of the Trans Epidermal 
Water Loss (TEWL) was recorded, which was used to include a correction factor for 
the variability in the different skin conditions within the same subject as well as 
inter-subject variability. 
 The skin spots selected for tape stripping were then stripped 20 times to remove 
approximately 5 µm of the stratum corneum. Tape stripped skin served as a positive 
control as the removal of stratum corneum was expected to have a much bigger 
permeation enhancing effect when compared to the active interventions of 
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magnetophoresis assisted delivery.  The tape stripped spots were measured for 
TEWL after stripping to account for the increased permeability, before the 
application of curcumin in mineral oil formulation. Negative controls consisting of 
mineral oil only and mineral oil with ETP magnets were used to account for the auto 
fluorescence encountered. The effect of tape stripping on fluorescence was assessed 
by applying only mineral oil to a separate tape stripped spot. 
Curcumin in mineral oil was then applied to the skin passively where the skin spot 
was occluded with a dummy non-magnetic occlusive strip. Curcumin was also 
applied actively, occluded with the ETP magnets. The experiments were designed to 
ensure that each spot with curcumin was isolated to avoid accidental contamination 
of the negative control spots. Figures 4.8 a) and b) show a volunteer during the study.  
 
Figure 4.8 a) Volunteer arm with ETP treatment b) Volunteer during the MPT imaging 
The skin delivery experiments were carried out with a 1 h treatment time. After 
completion of the treatment duration, Z-Stack images were generated to a depth of 
100 µm with each layer in the stack being 5 µm apart.  
The multi photon tomography (MPT) imaging was carried out on a DermInspect 
system (JenLab GmbH, Jena, Germany). All the fluorescence data was then analysed 
using SPC image and Image J software.  For the calculation and quantification of 
fluorescence intensity, intensity images were transformed from the grey scale images 
originally generated by the MPT and intensity was calculated in the appropriate 740 
nm channel 3. The fluorescence intensities in the study arms was then plotted against 
depth and compared. Other more accurate measures like fluorescence lifetime 
analysis were carried out at the pilot stages of experimentation. The fluorescence 
lifetime analysis is used to generate the amount of protein bound (1), unbound (2) 
drug and the metabolic ratio a1/a2. These values are characteristic of an individual 
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molecule and are generally used to separate the fluorescence signal of an externally 
applied substance from the auto fluorescence. For this study the curcumin signal was 
gathered from a dedicated channel (C3) and hence the lifetime data was not used.    
4.3.3.4 Studies on florescent tagged melanostatin 
The study was designed to investigate the penetration enhancement effects in the 
peptide as a function of the combined effect of the microneedle and the magnets. The 
experimental protocol was similar to the studies described in Chapter 3 (Section 
3.4.5.1). The peptide was first dissolved in water. The study arms were:  
• A negative control - solvent with magnet post MN application to account for 
any auto fluorescence encountered  
• Peptide with magnet and no MN 
• Peptide with magnet post MN application 
• Peptide with a non-magnetic occlusive strip made of the same material as the 
ETP magnets (DUMMY) and no MN 
• Peptide with DUMMY post MN application 
The treatment duration of the study was 1 h for all interventions. Different skin 
donors were used for carrying out the replicates on each peptide. Figure 4.9 below 
shows the experimental set-up. The peptide, which has also been described in the 
previous chapter, melanostatin, a tripeptide (Pro-Leu-Gly) with molecular weight 
803.92 when conjugated with FITC and a log P of -0.485 (native peptide only) was 
selected based on its favourable penetration profile. Previously melanostatin showed 
good penetration both passively as well as with the aid of microneedles. It was hence 
expected that magnetophoresis would further enhance its penetration beyond the 
effect of microneedles themselves. Moreover, of particular interest to us was the 
stratum corneum (SC) breaching capacity of magnetophoresis where no MNs were 
used.  ETP magnet, ETP 012 was used with and without MN; dummy non-magnetic 
strips were used as controls to demonstrate that there was no penetration 
enhancement due to the material itself or due to simple occlusion with any non-
magnetic substance. After the completion of the treatment duration of 1 h, images 
were captured with the VivaScope 2500. For the analysis of the RCM images, image 
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J software was used as per the methods described in Chapter 3 section 3.3.5. 
 
 
Figure 4.9 Set-up for studies on Melanostatin 
4.3.4 Statistical analysis  
Skin permeation data from the in vitro study consisted of cumulative amount 
measurements of passive, ETP and Dermaportation taken at various times (1 to 24 h).  
A random effects regression model was used to compare the treatments at various 
time points, with the timings treated as categorical variables (so that no linear 
relationship was assumed between permeation and time).  This type of regression 
model is equivalent to a repeated measures analysis of variance, in that it properly 
takes into account correlations between measurements made on the same sample at 
different time points.  If the standard deviations of the permeation appeared to differ 
widely for different time periods, a logarithmic transformation was performed on the 
permeation before analysis. 
Pairwise comparisons were calculated from the regression model by requesting 
certain ‘contrasts’ as required.  Contrasts were tailored to make specific comparisons, 
and obtain the p-values for them.  The standard errors on which the contrasts were 
based were estimated from the regression model which was based on all the available 
data.  If the analysis was performed on the log-transformed data, the p-values for the 
pairwise comparisons were based on this analysis, but the mean permeation was 
quoted on the original scale (to simplify interpretation). 
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For the analysis of area and integrated density in the ex vivo study, there were no 
repeated measurements, so a straightforward analysis of variance (ANOVA) was 
performed to compare results between treatments.   
The data for the in vivo study consisted of 6 different exposures applied to each of 6 
different subjects.  The data were then observed at different skin depths varying from 
5 to 55 µm. All the data was fitted into a single (random effects) regression model 
similar to the in vitro study. 
All statistical analyses were performed using the SAS version 9.2 statistical software 
(SAS Institute Inc, Cary, NC, USA, 2008).  A p-value <0.05 was taken to indicate a 
statistically significant association. 
4.4 Results and Discussion 
4.4.1 Studies on agar gel   
In the initial pilot studies, the ETP 012 magnets (cumulative amount - 3.40 µg/mL) 
showed a 33% increase in permeation when compared to the dummy magnets 
(cumulative amount - 2.40 µg/mL). Figure 4.10 below shows the results obtained 
after the permeation of brilliant blue in the agar gel (n=4). 
 
Figure 4.10 Permeation of Brilliant blue dye in the agar gel (n=4). Results are expressed as mean 
± SEM 
The agar gel syringe model followed the studies described by Schantz et al.
387
 and 
Lauffer et al.
388
 At completion of the 2 h application time, the agar gel was pushed 
up out of the syringe and discs were cut and weighed. This protocol was reasonably 
reproducible with the weight of the agar discs being within 10% of the 1 g mean 
weight. The agar disc was then dissolved in 10 mL of water in bottles that were 
152 
 
labelled according to their distance from the top of the syringe. Absorbance was 
measured at 630 nm and corrected for the weight difference. Linearity was conducted 
on a series of standard dye solutions. The observed linearity of the standards was 
0.99. Though these study results did not show a statistically significant penetration 
enhancement, the positive trend combined with results of previous studies from our 
group
7,153,157
 provided with an impetus to continue the work further.    
This experimental set up is prone to some technical flaws. Schantz et al. had reported 
that if the gel is pulled away from the wall of the syringe after it is set, erratic results 
might be obtained because of the solution containing the solute creeping into the 
capillary space created. We countered this problem by moving the gel into the 
desired position to create a donor chamber by moving the plunger of the syringe 
while the gel was still in a liquid state. A problem we encountered was that the 
surface layer of the gel that was in contact with air was more “hardened” and thus 
more resistant to diffusion that the bulk of the agar gel. To prevent this problem 
Schantz et al. had cut of the top part of the hardened gel while the gel was still at the 
tip of the syringe and lowered the plunger after the gel was formed. However, as we 
had allowed the gel to solidify below the syringe surface it was not possible to 
simply remove the surface. Therefore, the pouring of the agar was accurately timed 
throughout all replicates to make this model consistent.  
4.4.2 In vitro studies on excised human skin/ Magnetophoretic delivery of 
diclofenac sodium in carbopol gel formulation.   
4.4.2.1 Chromatography 
Diclofenac sodium was analysed by UV detection using HPLC. The active eluted 
without any interfering peaks at a retention time of 8.2 min. The linearity obtained by 
the HPLC method was 1.0 over the range of the calibration curve (1.9-125.0 μg/mL) 
for diclofenac sodium standard solutions. Figure 4.11 shows a typical HPLC 
chromatogram of diclofenac sodium at 31.25 μg/mL.  
153 
 
 
Figure 4.11 HPLC chromatogram of diclofenac sodium at 31.25 μg/mL 
A calibration curve was obtained by plotting the peak area versus concentration of 
standards injected. The CV for precision, determined from the relative standard 
deviation (n = 5), was 0.75% for 3.9 μg/mL, 0.65% for 15.75 μg/mL and 0.57% for 
63.0 μg/mL diclofenac sodium standard solutions in PBS. The intra-day variation 
was 0.78% and 0.69% and the inter-day variation was 0.96% and 0.73% at 3.9 and 
15.75 μg/mL of diclofenac sodium standard solutions in PBS, respectively. These are 
within the acceptable criteria for intra and inter-day repeatability of R.S.D < 2%. 
The limit of detection (LOD), calculated as greater than three times the baseline 
noise level in the assay, was 90 ng/mL. The limit of quantitation (LOQ), calculated 
as greater than 10 times the baseline noise level in the assay, was 300 ng/mL. 
4.4.2.2 Permeation of diclofenac sodium through human epidermis with ETP and 
Dermaportation 
HPLC analysis of samples post treatment with diclofenac passively and in the 
presence of ETP magnets and Dermaportation electromagnets showed there was a 
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substantial increase in mean cumulative permeation of diclofenac over 6 h for ETP 
application (34.17 ± 8.12 μg/cm2) as compared with passive application (14.47 ± 
3.27 μg/cm2) and Dermaportation (16.5 ± 7.01 μg/cm2).  All permeation parameters 
were enhanced by magnetic application (ETP), the enhancement was statistically 
significant (p < 0.05) from 4h onwards when compared to both passive and 
Dermaportation. The steady state flux increased from 0.0398 to 0.0943 μg/cm2/h by 
administration of diclofenac sodium with ETP (Table 4.1). Dermaportation did not 
have a substantial effect on diclofenac sodium delivery across the epidermis.  
Table 4.1 Skin permeation results for diclofenac sodium post magnetophoretic 
treatment (n=8) 
Parameters Treatment 
Passive ETP Dermaportation 
Mean cumulative permeation 
(μg/cm2) 
14.47 ± 3.27 34.17 ± 8.12 16.50 ± 7.01 
Steady state flux (μg/cm2/h) 0.0398 0.0943 0.0451 
Permeability coefficient (cm/h) 7.9 × 10
-6
 19 × 10
-6
 9.0 × 10
-6
 
The in vitro permeation profiles of diclofenac sodium across human epidermis are 
presented in Figure 4.12. A comparison of the cumulative amount of diclofenac 
sodium penetrating the epidermis to the receptor solution versus time was plotted for 
passive, magnetic array enhanced applications and Dermaportation (Figure 4.12) As 
observed from the preliminary agar gel study, ETP magnets have demonstrated an 
ability to push drug molecules across membranes and gels due to diamagnetic 
properties of the drugs. Hence in this study, we tried to compare the diamagnetic 
repulsion of the ETP magnets to that of a pulsating electro-magnet. 
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Figure 4.12  Skin permeation of diclofenac sodium. Results are expressed as mean ±SEM (n=8)  
Benson et al. investigated the effect of magnetic film array technology on the skin 
permeation of urea in vitro and its effect on skin hydration in vivo. They found that 
under active occlusion (ETP 008), the epidermal thickness (as a measure of 
hydration) as determined by optical coherence tomography (OCT) increased by 16 
and 11% at 30 and 60 min, respectively. They concluded that administration with this 
novel magnetic film array technology provided enhanced skin penetration of urea 
and thus increased epidermal hydration when compared with administration under an 
occlusive film only. OCT measurements also revealed that the changes in the 
epidermal properties maximise after about 30 min and then stabilise or even decrease 
over longer periods of time. In our study a linear increase in diclofenac permeation 
was observed after 30 min until the termination of the experiment. 
We have previously demonstrated enhanced skin penetration of 5-aminolevulinic 
acid, a dipeptide and naltrexone hydrochloride by a pulsed electromagnetic 
field.
153,156,157
 In a preliminary investigation undertaken by our group to elucidate the 
mechanism of magnetic enhanced delivery, 10 nm gold nanoparticles were applied to 
human epidermis with and without electromagnetic fields.
381
 Multiphoton 
microscopy with fluorescent lifetime imaging showed skin permeation of the 
nanoparticles with the pulsed electromagnetic field with no evidence of passive 
permeation. It was thus hypothesized that the magnetic energy may induce channels 
within the stratum corneum of at least 10 nm in diameter.  
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The precise mechanism of skin permeation enhancement may vary with the magnetic 
field characteristics.
7
 Biological and therapeutic effects of electromagnetic fields and 
inductive effects on biological tissues have been widely reported, for example, 
enhancement of healing of venous ulcers and bone fractures and effects on a range of 
cellular functions.
146,299
  
The standard Dermaportation system (DP1001) generates a specific pattern of energy 
pulses that have been shown to induce transdermal flux increases during field 
exposure of a number of small molecules, such as 5-aminolevulinic acid,
157
 lidocaine 
hydrochloride
159
 and a model dipeptide Ala-Trp.
153
 It is proposed that the 
Dermaportation energy influences both the molecular movement of drug molecules 
in the epidermis and the ordered structure of the stratum corneum lipid bilayers. The 
precise mechanism of enhancement is an area of continuing investigation. 
Dermaportation was not used for subsequent studies as it failed to show a positive 
skin permeation enhancement effect, when compared to ETP magnets. 
4.4.3 In vivo studies on a model fluorescent compound (Curcumin) 
Figure 4.13 below presents the effects of tape stripping and magnetic array on the 
skin penetration of curcumin, expressed as mean intensity versus depth. As 
anticipated, tape stripping had the most profound effect on skin penetration and 
served as an effective positive control for the study. ETP 008 demonstrated enhanced 
curcumin penetration in the upper part of the skin. As the depth increased the effect 
of the magnets reduced and the intensity observed was similar to the auto 
fluorescence encountered in the negative controls. Overall the penetration of 
curcumin in the top layer of the skin was 1.4 times greater due to ETP 008 magnets 
when compared to the dummy non-magnetic strips.   
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Figure 4.13 ETP 008 induced skin penetration enhancement of curcumin 
The results of the ETP 012 studies are presented below in Figure 4.14 Similar to ETP 
008, ETP 012 showed enhanced penetration of curcumin in the top parts of the skin. 
The penetration of curcumin was enhanced by 1.5 times. ETP 012 showed enhanced 
penetration to deeper distance in the skin. (ETP 008: 20 µm; ETP 012: 30 µm; p < 
0.05) 
 
Figure 4.14  ETP 012 induced skin penetration enhancement of curcumin 
The studies conducted and described in this chapter were designed to examine 
magnetophoresis as a penetration enhancement technique in its own right as well as a 
potential synergistic skin penetration enhancement technology with microneedles. To 
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understand the mechanism of magnetophoretic drug delivery work done by Murthy’s 
group and previous work by our group are of utmost importance. As these are the 
only available sources for such work across skin (both human and non-human).  
The potential to increase diffusion or flow within the applied solvent possibly due to 
an interaction between the magnetic field and the diamagnetic properties of the 
molecules was investigated in agar gel, excised human epidermis and excised human 
full thickness skin. The former was chosen as a simple system, whereas in the skin 
the magnetic fields may also influence the skin structure. I have also attempted to 
look at differences in the skin lipid structure with the help of ATR-FTIR by applying 
ETP magnets to excised human skin mounted on an ATR-FTIR crystal (data not 
presented). The results of this preliminary study did not show any noticeable change 
to the primary and secondary structure of the skin. This is in agreement with Murthy 
et al.
154
 who examined the effect of more powerful magnets (30, 150 and 300 mT 
compared to ETP 5-40 mT) on skin using ATR-FTIR and reported no changes to the 
skin structure.  It is unclear if ATR-FTIR is the best system for these measurements 
and Raman spectroscopy may be a better analytical tool. In this study I attempted to 
gain more knowledge on the possible mechanism of the ETP magnets, by conducting 
studies on human volunteers. I expected that any effect of the magnets on skin 
structure would be better observed in vivo. The solvent mineral oil showed the least 
fluorescence with and without ETP magnets. It was also hypothesised that the 
removal of stratum corneum by tape stripping (TS) would increase the trans 
epidermal water loss (TEWL) reading and hence would enhance skin permeability to 
extraneously applied drug, curcumin (CUR). The results of TEWL before and after 
the study are presented in the figures below (Figure 4.15 and Figure 4.16). Tape 
stripping increased the TEWL by 3-6 times in all the subjects (p < 0.05). The reading 
after the study suggested further that the skin permeability remained high for a long 
duration.           
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Figure 4.15 TEWL readings before and after the treatment 
 
 
Figure 4.16 Average TEWL across subjects (n=6). Results are expressed as mean ± SD 
Figures 4.17 and 4.18 below show pseudo coloured images from channel 1 and 
channel 3 of the different sample points. Curcumin fluorescence can be observed in 
C 3 as bright orange colouration.     
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Figure 4.17 Pseudo coloured images from channel 1 and channel 3 –Negative control (MO) and 
positive control (TS + CUR) 
 
Figure 4.18  Pseudo coloured images from channel 1 and channel 3 – Passive (CUR) and active 
treatments (ETP 008, ETP 012) 
The premise that all cells produce a certain degree of autofluorescence, lead us to 
evaluate the effects of the magnets with a correction for the autofluorescence. 
Following the above described procedures form section 4.3.3.3, background 
fluorescence of the corresponding treatment arms was subtracted from all the 
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curcumin containing interventions. The resulting net intensity (δ) was graphed 
(Figure 4.19). Both magnets showed twice the intensity of that observed with 
curcumin and dummies (ETP 008 -8050; ETP 012 – 8950; Dummy – 4055). Tape 
stripping however, was by far, the most effective intervention in enhancing the skin 
permeation of curcumin. (TS – 15890) 
 
Figure 4.19 Net fluorescence intensity (δ) of curcumin following treatment with ETP 008, ETP 
012 and tape stripping 
4.4.4  Ex-vivo studies on a fluorescent peptide (Melanostatin) 
Average penetration area and average integrated density, calculated using image J 
were used to assess the penetration of melanostatin. Figure 4.20 shows the 
penetration of melanostatin after 1 h post treatment with MN and ETP magnets. In 
the absence of the MN the area of penetration was significantly low and the 
fluorescence was mostly accumulated in the skin furrows. The fluorescent intensity 
too was lower than that for the skin samples with MN treatment. However, both the 
indicators were significantly higher when compared to the negative control (MN + 
ETP + Solvent).  The average penetration area of melanostatin with MN and ETP 
012 was 1.48 times greater than that observed with MN and dummy non-magnetic 
strips (MN dummy: 103052 ± 37546 pixels; MN ETP 012: 153058 ± 48963 pixels; p 
< 0.05). This result was an average across all the three measured skin layers (SC, VE, 
and DER, Table 4.2). The area of penetration was larger and the measured intensity 
was greater in all three layers (Table 4.2). The most profound effect of the ETP 
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magnets when used in conjunction with the MN was seen in the dermis where the 
integrated density was 2.42 times higher than the ID of MN with dummy. The area of 
penetration as well was greater by a factor of 4.63 times in the dermis. The ETP 012 
magnets showed 7.12 times greater area of penetration when compared to dummy 
strips (Dummy-1091 vs. ETP012- 7775) when no MN were used, this comparison 
was statistically significant (p < 0.05). The average intensity of the penetration area 
represented by integrated density was also enhanced by 2.8 times (Dummy-133 vs. 
ETP012- 368) demonstrating that the ETP 012 magnets had the ability to transport 
the peptide across the SC, without the MN.  
 
Figure 4.20 Average penetration area and average integrated density of melanostatin after 1 h 
post treatment with MN and ETP magnets 
Table 4.2 Penetration area and fluorescence integrated density of melanostatin 
after MN and ETP treatment  
 MEL MN DUMMY MEL MN ETP 
 Nor Area  
(pixels) 
Nor ID Nor Area 
(pixels) 
Nor ID 
SC 91743 531 97273 629 
VE 191637 657 242548 987 
DER 25777 107 119355 260 
AVERAGE 103052 432 153059 625 
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It was observed that topical peptide application results in accumulation in the skin 
furrows. The average width of the furrows measured in pixels and the average 
intensity of the fluorescence signal present in the furrows was calculated in image J 
(Figure 4.21).  The difference in penetration and accumulation within the furrows of 
ETP treated and dummy treated skin samples were investigated. Figure 4.21 shows 
an example of the skin sample images showing the line profile of each of ETP and 
dummy treated skin samples. The cut-off intensity of 54 has been used as the lower 
threshold limit for all the analysis in chapter 3 as it is a positive indication of FITC 
fluorescence and not auto-fluorescence.  To measure the width of the furrows, 
consecutive pixels with intensity above 32/pixels was used (Figure 4.21). The 
average width of furrow fluorescence in the ETP 012 treated skin sample was 2.4 
times that observed in dummy strip treated skin (Dummy: 8.6 ± 5.47; ETP012: 20.6 
± 15.2 pixels). Further, the average intensity of fluorescence in these furrows was 1.2 
times that of the dummy strips (Dummy: 52.3 ± 12.4; ETP012: 67.3 ± 21.5).  Such 
an analysis of the fluorescent drug particles in the skin furrows has previously been 
reported with other topical products like sunscreens and heavy metal nano-
particles.
41,389,390
 Accumulation of drugs in the skin furrows can be advantageous, as 
it can act like a reservoir for drugs in solution. Form the furrows the drug can be 
taken up into the skin over time. Though the furrows contribute to only 0.1% of the 
total skin surface, once accumulated in the furrows, the drug is transported into the 
skin.
391,392
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Figure 4.21 Width and fluorescence intensity signal analysis within skin furrows (mean ± SD, 
n=3)  
4.5 Conclusions and future directions 
Though the magnets used in this project are of very weak field strength, they have 
shown to increase the permeation of a number of molecules here. In this project I 
have demonstrated a 33% increase in the permeation of a dye through an agar gel 
based model, a 200% increase in mean cumulative permeation of diclofenac sodium 
(gel formulation) through human epidermis in vitro and a 10 fold higher permeability 
coefficient when compared to passive diffusion. I have also demonstrated that the 
results of the in vitro studies were fully reproducible in an in vivo set-up. In the 
studies on human volunteers a 200% increase in the curcumin net intensity was 
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observed when compared to dummy non-magnetic strips of similar material. Further, 
the ETP magnets also showed an average 500-600% increase in the permeation of a 
tripeptide through full thickness human skin ex vivo. The ETP magnets can hence be 
of great value as transdermal permeation enhancers. Moreover, these ETP magnets 
have potential to be easily formulated into non-invasive transdermal patches. ETP 
magnets can also be used in synergistic combination with microneedles, especially 
dissolvable hollow microneedles to deliver drugs and vaccines transdermally through 
a reservoir patch. Further studies are required to understand the optimal performance 
of the magnets and their mechanism of transdermal delivery enhancement. 
Successful transformation of this technique can provide an inexpensive transdermal 
delivery system which can be used without the need of elaborate procedures and 
expert supervision.     
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Chapter 5  
Summary and future directions 
 
Figure 5.1 Skin penetration enhancement strategies used in this project
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Development of effective and functional delivery systems for new active 
pharmaceutical and cosmeceutical products is a challenging task and a long term 
goal of drug delivery research.
379
 In this PhD project efforts have been made to 
advance the science through three different methods. These approaches are 
highlighted in Figure 5.1 above. 
Chapter 2 describes the use of Cell penetrating peptides, in particular 
diketopiperazine (DKP) in penetration enhancement of a small dipeptide (Ala-Trp) 
and diclofenac. The physical admixture of these molecules with DKP enhanced their 
permeation across human epidermis in vitro by 9.15-fold and 1.9-fold respectively. 
These results were consistent with previous findings.
310,311
 Proteins and peptide 
delivery with the use of CPPs has gained a lot of attention. The major obstacles for in 
vivo clinical applications of peptides is their poor permeability through plasma 
membrane and their sensitivity to enzymatic degradation.
92
 Conjugation of DKP with 
diclofenac enhanced the transdermal flux of diclofenac 9-fold and significantly 
enhanced drug deposition into the skin (14-fold compared to passive diclofenac). A 
comparison with the well-established cell penetrating peptide TAT showed that DKP 
enhanced the permeation of diclofenac through the skin and the deposition of 
diclofenac in the skin, 5-fold and 6-fold greater than TAT respectively. Enzyme 
assay results demonstrated COX inhibition by the DKP-diclofenac conjugate, 
showing it retained its anti-inflammatory activity.  Further work needs to be 
undertaken to better understand the mode of skin penetration of the diketopiperazine 
based cell penetrating peptides. Fluorescence tagging of DKP would be of particular 
value for investigating its route of skin penetration. This information will be 
invaluable in optimization and accurate selection of the most suitable drugs for skin 
delivery using the DKP platform. The strategies used to deliver these peptides across 
the skin so as to ensure they are made available to the site of action in a non-invasive 
manner will govern the success of this approach.    
Chapter 3 demonstrated the enhanced delivery of three peptides by Microneedle pre-
treatment of the skin. Confocal laser scanning microscopy (CLSM) in conjunction to 
the reflectance mode available in the VivaScope 2500 rendered it possible to 
visualise and quantify the penetration of the peptides studied in this project in a rapid 
and efficient manner. The peptides selected for these studies were 3, 4 and 5 amino 
acids in length (melanostatin, rigin and palmitoyl pentapeptide). Melanostatin and 
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rigin are fairly water-soluble peptides whereas palmitoyl pentapeptide has the 
peptide conjugated to a lipophilic group that is designed to enhance stratum corneum 
permeability. The stratum corneum is generally regarded as relatively impermeable 
to hydrophilic molecules and hence preferentially permeable to reasonably lipophilic 
solutes. However it has recently been suggested that the skin permeability of highly 
hydrophilic drugs is generally under-predicted by 2–6 orders of magnitude.393 In this 
study, all peptides showed enhanced penetration with the microneedle pretreatment, 
although the enhancement varied considerably between the peptides. Melanostatin 
showed a 10-fold enhancement in penetration area in the viable epidermis at 1 h and 
a 22-fold increase in area in the dermis with microneedle pretreatment. Melanostatin 
is currently used in specific hyperpigmentary problems such as post inflammatory 
hyperpigmentation, solar lentigos, and melasma.
362,363
 Our research clearly shows 
that microneedle pretreatment is a useful method to enhance delivery and potentially 
improve clinical outcomes for these conditions.  
Rigin showed a 1.8-fold increase in the area at 1 h and no difference at 24 h with 
microneedle pretreatment. Sederma
TM
 markets rigin as Palmitoyl tetrapeptide-7 in 
their product Matrixyl
®
 3000 and Matrixyl
®
 synthe’6™. It is promoted as an 
enhancer of skin elasticity via interleukin (IL)-6 reduction. For the studies on rigin in 
this project the parent molecule was used rather than the palmitoylated tetrapeptide 
to manage the size of the molecule. To our knowledge skin permeation studies on 
these peptides have not been published and the manuscript prepared on this project 
could be the first publication reporting passive (without MN) and MN based skin 
delivery.  
Palmitoyl pentapeptide or Pal-KTTKS is a frequently used peptide in the 
cosmeceutical industry. At 1 h post administration there was no difference in 
penetration area in the viable epidermis with the use of microneedles, but over 24 h 
the passive permeation of Pal-KTTKS was increased 2.6-fold with microneedle 
pretreatment. Figure 5.2 below shows the comparative assessment of skin penetration 
area of all the peptides. 
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Figure 5.2 Comparison of penetration area of peptides after microneedle (MN) based 
application. Mean ±SEM (n=3) 
Pretreatment with a microneedle patch is not very uncommon and has been used 
indiscriminately for various transdermal drugs. 3M in 2011 have launched a stand-
alone microneedle based pretreatment device. 3M calls it, its “Microchannel Skin 
System,” and it consists of a sterile, single-use patch with hundreds of microneedles 
that create “micro channels” to administer the drug.394 Currently available only for 
dermatologists, through dedicated dealers, this device is touted to be made available 
for the patients in the near future. However, debate regarding safety and efficacy is 
bound to stretch far and long.  
 
Figure 5.3 3M - Microchannel Skin System 
Successful application of microneedles depends on the applicator device that 
facilitates microneedle insertion and possible infusion of drugs into the skin, skin 
recovery and regeneration after microneedle insertion. Other important factors 
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include drug efficacy, safety, stability during manufacturing and patient outcomes 
such as lack of pain, skin irritation and skin infection.
395
 In order to get a particular 
design of microneedles approved to be marketed for transdermal drug delivery, it is 
very important to properly choose the type of microneedle (e.g., hollow, solid, 
geometry, material, density, length). Furthermore, to obtain sufficient and 
reproducible penetration and a possibility of self-administration by the patient, the 
right microneedle application devices must be used. Therefore, new microneedle-
based products for transdermal drug delivery usually need to be a complete package 
for each type of drug.
396
 Microneedles have been shown to enhance the skin 
diffusion of various drugs including peptides and vaccines.
5, 186, 187, 199-201, 350, 395
 In 
this project microneedles were used to enhance skin diffusion and penetration of 
small peptides. Further work needs to be undertaken to compare different 
microneedle designs before an optimised model can be generated. 
Chapter 4 describes the novel skin penetration enhancement technique of 
Magnetophoresis. Magnetophoresis is a recently introduced technique to be used in 
transdermal delivery that involves the application of a magnetic field to the skin. 
Previous research by our group and Murthy’s group has shown skin delivery of 
various molecules with the use of fixed and pulsating magnets.
6,7,153-155,157,381
 The 
influence of magnetic field strength on diffusion flux was determined by Murthy et 
al. and reported to increase with an increase in the applied field strength.
6
 
The magnets used in this project are of comparatively weak field strength but were 
found to significantly enhance skin penetration alone and in combination with 
microneedles. A series of experiments was designed to assess magnetophoresis 
compared to passive permeation. In the first study, ETP 012 showed a 2.4-fold 
increase in diclofenac permeation in vitro across human epidermis when compared to 
passive treatment. In the studies on human volunteers we also showed a 200% 
increase in the net fluorescence intensity generated by curcumin when compared to 
passive (dummy non-magnetic strips of similar material). When investigated for their 
use in combination with microneedles, the magnetic film array (ETP 012) showed a 
5-fold increase in skin diffusion of melanostatin in full thickness human skin ex vivo 
when compared to microneedles alone. In CLSM generated image analysis, in 
addition to the increase in area and fluorescence intensity, the average width of 
furrow fluorescence in the ETP 012 treated skin sample was 2.4 times that observed 
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for microneedle pretreatment alone. These experiments suggest that magnetophoresis 
is worthy of further investigation as a stand-alone enhancement technology and may 
also be useful in driving drug into the skin via pores generated by microneedles. The 
small field magnets used in this project are a unique and non-invasive skin delivery 
approach. Further work needs to be undertaken to better understand the mode of 
action of these magnets.  
Overall, it can be concluded that all three approaches to enhance transdermal 
delivery that were investigated in this project have shown improved permeation and 
diffusion of peptides and small drugs after topical application.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
172 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6  
References 
 
 
 
 
 
 
 
 
 
 
173 
 
 
1. Amsden BG, Goosen MFA. Transdermal delivery of peptide and protein 
drugs: an overview. Bioengineering, Food and Natural products. 1995; 41(8):1972-
1997.  
2. Benson HAE, Watkinson AC. Topical and Transdermal Drug Delivery: 
Principles and Practice. New Jersey: John Wiley & Sons; 2012. 
3. Benson HAE, Namjoshi S. Proteins and peptides: Strategies for delivery to 
and across the skin. Journal of Pharmaceutical Sciences. 2008; 97(9):3591-10.  
4. Hällbrink M, Florén A, Elmquist A, Pooga M, Bartfai T, Langel Ü. Cargo 
delivery kinetics of cell-penetrating peptides. Biochimica et Biophysica Acta (BBA) 
- Biomembranes. 2001; 1515(2):101-109.  
5. Prow TW, Chen X, Prow NA, Fernando GJP, Tan CSE, Raphael AP, et al. 
Nanopatch-targeted skin vaccination against west nile virus and chikungunya virus in 
mice. Small. 2010; 6(16):1776-1784.  
6. Murthy SN. Magnetophoresis: an approach to enhance transdermal drug 
diffusion. Pharmazie. 1999; 54(5):377-409.  
7. Benson HAE, Krishnan G, Edwards J, Liew YM, Wallace VP. Enhanced skin 
permeation and hydration by magnetic field array: preliminary in-vitro and in-vivo 
assessment. Journal of Pharmacy and Pharmacology. 2010; 62(6):696-701.  
8. Bolzinger M-A, Briançon S, Pelletier J, Chevalier Y. Penetration of drugs 
through skin, a complex rate-controlling membrane. Current Opinion in Colloid 
&amp; Interface Science. 2012; 17(3):156-165.  
9. Troy D, editor. Principals of Drug Discovery. Fifth edition ed: Lippincott 
Williams and Wilkins; 2002. 
10. Banga AK, Chien YW. Systemic delivery of therapeutic peptides and 
proteins. International Journal of Pharmaceutics. 1988; 48(1-3):15-50.  
11. Siddiqui, Chien YW. Non-parental administration of peptide and protein 
drugs. Critical Reviews in Therapeutic Drug Carrier Systems. 1987; 3(3):195.  
12. Namjoshi S, Caccetta R, Benson HAE. Skin peptides: biological activity and 
therapeutic opportunities. Journal of Pharmaceutical Sciences. 2008; 97(7):2524-42.  
174 
 
13. Williams AC. Structure and function of human skin. In: Transdermal and 
Topical Drug delivery: Pharmaceutical Press; 2003. 
14. Mills PC, Cross SE. Transdermal drug delivery: Basic principles for the 
veterinarian. The Veterinary Journal. 2006; 172(2):218-233.  
15. Wilkes GL, Brown IA, Wildnauer RH. The biomechanical properties of skin. 
CRC Critical Reviews in Bioengineering. 1973; 62:453 - 495.  
16. Holbrook KA, Odland GF. Regional differences in the thickness (cell layers) 
of the human stratum corneum : An ultrastructural analysis. The Journal of 
Investigative Dermatology. 1974; 62:415 - 422.  
17. Benson HAE. Transdermal drug delivery:Penetration enhancement 
techniques. Current Drug Delivery. 2005; 2(1):23 - 33.  
18. Barry BW. Novel mechanisms and devices to enable successful transdermal 
drug delivery. European Journal of Pharmaceutical Sciences. 2001; 14:101 - 114.  
19. Swartzendruber D, Wertz P, Madison K, Downing D. Evidence that the 
corneocyte has a chemically bound lipid envelope. Journal of Investigative 
Dermatology. 1987; 88:709 - 713.  
20. Potts RO, Francoeur ML. The influence of stratum corneum morphology on 
water permeability. The Journal of Investigative Dermatology. 1991; 96:495 - 499.  
21. Bouwstra JA, Gooris GS, spek Vd, Bras JA. Structural investigations of 
human stratum corneum by small-angle X-Ray scattering. Journal of Investigative 
Dermatology. 1991; 97:1005 - 1012.  
22. Anderson RL, Cassidy JM. Variations in physical dimensions and chemical 
composition of human stratum corneum. The Journal of Investigative Dermatology. 
1973; 61:30 - 32.  
23. Senti G. Epicutaneous allergen administration: Is this the future of allergen-
specific immunotherapy? Allergy. 2011; 66(6):798-809.  
24. Hata M, Tokura Y, Takigawa M, Sato M, Shioya Y, Fujikura Y, et al. 
Assessment of epidermal barrier function by photoacoustic spectrometry in relation 
to its importance in the pathogenesis of atopic dermatitis. Laboratory Investigation. 
2012; 82(11):1451-1461.  
175 
 
25. Watanabe M, Tagami H, Horii I, Takahashi M, Kligman AM. Functional 
analyses of the superficial stratum corneum in atopic xerosis. Archives of 
Dermatology. 1991; 127(11):1689-1692.  
26. Wertz PW. Stratum Corneum : Biological and Biochemical Considerations. 
In: Hadgraft J, guy RH, editors. Transdermal drug delivery : developmental issues 
and research initiatives. New York: Marcel Dekker Inc; 1989. p. 1 - 22. 
27. Barry BW. Drug delivery routes in skin : a novel approach. Advanced Drug 
Delivery Reviews. 2002; 54(Suppl 1):S 31 - S 40.  
28. Trommer H, Neubert RHH. Overcoming the stratum corneum: The 
modulation of skin penetration. Skin Pharmacology and Physiology. 2006; 
19(2):106-121.  
29. Williams AC. Theoretical aspects of transdermal drug delivery. In: 
Transdermal and Topical drug delivery. London: Pharmaceutical Press; 2003. p. 26-
49. 
30. Sloan KB. Prodrugs: Topical and ocular drug delivery. Marcel Dekker Inc: 
New York; 1992. 
31. Williams A. Chemical modulation of topical and transdermal permeation. In: 
Transdermal and topical drug delivery: Pharmaceutical Press; 2003. 
32. Megwa SA, Cross SE, Benson HA, Roberts MS. Ion-pair formation as a 
strategy to enhance topical delivery of salicylic acid. Journal of Pharmacy and 
Pharmacology. 2000; 52(8):919-28.  
33. Larsen SW. Kinetics of degradation and oil solubility of ester prodrugs of a 
model dipeptide (Gly-Phe). European Journal of Pharmaceutical Sciences. 2004; 
22(5):399-408.  
34. Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes — novel 
vesicular carriers for enhanced delivery: characterization and skin penetration 
properties. Journal of Controlled Release. 2000; 65(3):403-418.  
35. Gupta PN. Non invasive vaccine delivery in transferosomes, niosomes and 
liposomes: a comparative study. International Journal of Pharmaceutics. 2005; 
293(1-2):73-82.  
176 
 
36. Benson HAE. Transfersomes for transdermal drug delivery. Expert Opinion 
on drug Delivery. 2006; 3(6):727-737.  
37. Manconi M. Niosomes as carriers for tretinoin III. A study into the in vitro 
cutaneous delivery of vesicle-incorporated tretinoin International Journal of 
Pharmaceutics. 2006; 311(1-2):11-19.  
38. Arruebo M, Fernández-Pacheco R, Ibarra MR, Santamaría J. Magnetic 
nanoparticles for drug delivery. Nanotoday 2007; 2(3):22-32.  
39. Soares AF, Carvalho RdA, Veiga F. Oral administration of peptides and 
proteins: nanoparticles and cyclodextrins as biocompatible delivery systems. 
Nanomedicine. 2007; 2(2):183-202.  
40. Robertson TA, Sanchez WY, Roberts MS. Are commercially available 
nanoparticles safe when applied to the skin? Journal of Biomedical Nanotechnology. 
2010; 6(5):452-468.  
41. Prow TW, Grice JE, Lin LL, Faye R, Butler M, Becker W, et al. 
Nanoparticles and microparticles for skin drug delivery. Advanced Drug Delivery 
Reviews. 2011; 63(6):470-491.  
42. Webster TJ. Safety of Nanoparticles: From Manufacturing to Medical 
Applications. Springer; 2008. 
43. Nohynek GJ, Lademann J, Ribaud C, Roberts MS. Grey Goo on the Skin? 
Nanotechnology, Cosmetic and Sunscreen Safety. Critical Reviews in Toxicology. 
2007; 37(3):251-277.  
44. Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and 
nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. 
Advanced Drug Delivery Reviews. 2002; 54:S131-S155.  
45. Wissing SA, Muller RH. Cosmetic applications for solid lipid nanoparticles 
(SLN). International Journal of Pharmaceutics. 2003(254);65 - 68.  
46. Malavolta L. Peptides: Important tools for the treatment of central nervous 
system disorders. Neuropeptides. 2011; 45(5):309-316.  
177 
 
47. Lucke A, Fustella E, Teßmar J, Gazzaniga A, Göpferich A. The effect of 
poly(ethylene glycol)–poly(d,l-lactic acid) diblock copolymers on peptide acylation. 
Journal of Controlled Release. 2002; 80(1-3):157-168.  
48. Fraysse-Ailhas C, Graff-Meyer A, Rigler P, Mittelhozer C, Raman S, Aebi U, 
et al. Peptide nanoparticles for drug delivery applications. European Cells and 
Materials. 2007; 14(3):115.  
49. Gareth A H. Nanostructure-mediated drug delivery. Nanomedicine: 
Nanotechnology, Biology and Medicine. 2005; 1(1):22-30.  
50. Lee P-W, Peng S-F, Su C-J, Mi F-L, Chen H-L, Wei M-C, et al. The use of 
biodegradable polymeric nanoparticles in combination with a low-pressure gene gun 
for transdermal DNA delivery. Biomaterials. 2008; 29(6):742-751.  
51. Coulman SA, Anstey A, Gateley C, Morrissey A, McLoughlin P, Allender C, 
et al. Microneedle mediated delivery of nanoparticles into human skin. International 
Journal of Pharmaceutics. 2009; 366(1-2):190-200.  
52. Lee SH. Nanoparticle popsicle: Transdermal delivery of nanoparticles using 
polymeric microneedle array. Korean Journal of Chemical Engineering. 2011; 
28(9):1913-1917.  
53. Ali M, Manolios N. Peptide delivery systems. Letters in Peptide Science. 
2002; 8:289–294.  
54. Setoh K, Murukami M, Araki N, Fujita T, Yamamoto A, Muranishi S. 
Improvement of transdermal delivery of tetragastrin by lipophilic modification with 
fatty acids Journal of Pharmacy and Pharmacology. 1995; 47(10):808-811.  
55. Toth I, Danton M, Flinn N, Gibbons WA. A combined adjuvant and carrier 
system for enhancing synthetic peptides immunogenicity utilising lipidic amino 
acids. Tetrahedron Letters. 1993; 34(24):3925-3928.  
56. Staffan T, Hashimoto K, Malkinson J, Lazorova L, Toth I, Artursson P. A 
new principal for tight junction modulation based on occludin peptides. Molecular 
Pharmacology. 2003; 64(6):1530-1540.  
57. Yamamoto A, Setoh K, Murakami M, Shironoshita M, Kobayashi T, 
Fujimoto K, et al. Enhanced transdermal delivery of phenylalanyl-glycine by 
178 
 
chemical modification with various fatty acids. International Journal of 
Pharmaceutics. 2003; 250(1):119-128.  
58. Fujita T, Fujita T, Morikawa K, Tanaka H, Iemura O, Yamamoto A, et al. 
Improvement of intestinal absorption of human calcitonin by chemical modification 
with fatty acids: Synergistic effects of acylation and absorption enhancers. 
International Journal of Pharmaceutics. 1996; 134(1-2):47-57.  
59. Linter K, Peschard O. Biologically active peptides: From a laboratory bench 
curiosity to a functional skin care product International Journal of Cosmetic Science. 
2000; 22:207-218.  
60. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human 
immunodeficiency virus. Cell. 1988; 55(6):1189-1193.  
61. Green M, Loewenstein PM. Autonomous functional domains of chemically 
synthesized human immunodeficiency virus tat trans-activator protein. Cell. 1988; 
55(6):1179-1188.  
62. André Z. Thermodynamic studies and binding mechanisms of cell-
penetrating peptides with lipids and glycosaminoglycans. Advanced Drug Delivery 
Reviews. 2008; 60(4–5):580-597.  
63. Zorko M, Langel Ü. Cell-penetrating peptides: mechanism and kinetics of 
cargo delivery. Advanced Drug Delivery Reviews. 2005; 57(4):529-545.  
64. Dietz GPH, Bδhr M. Delivery of bioactive molecules into the cell: The trojan 
horse approach. Molecular and Cellular Neuroscience. 2004; 27(2):85-131.  
65. Madani F, Lindberg S, Langel, Futaki S, Slund A. Mechanisms of cellular 
uptake of cell-penetrating peptides. Journal of Biophysics. 2011.  
66. Hansen M, Kilk K, Langel Ü. Predicting cell-penetrating peptides. Advanced 
Drug Delivery Reviews. 2008; 60(4–5):572-579.  
67. Sandberg M, Eriksson L, Jonsson J, Sjöström M, Wold S. New chemical 
descriptors relevant for the design of biologically active peptides. A multivariate 
characterization of 87 amino acids. Journal of Medicinal Chemistry. 1998; 
41(14):2481-2491.  
179 
 
68. Lundberg P, Langel Ü. A brief introduction to cell-penetrating peptides. 
Journal of Molecular Recognition. 2003; 16(5):227-233.  
69. Alain P. Protein and peptide transduction, twenty years later a happy 
birthday. Advanced Drug Delivery Reviews. 2008; 60(4–5):448-451.  
70. Arwyn T J. Gateways and tools for drug delivery: Endocytic pathways and 
the cellular dynamics of cell penetrating peptides. International Journal of 
Pharmaceutics. 2008; 354(1–2):34-38.  
71. Tyagi M, Rusnati M, Presta M, Giacca M. Internalization of HIV-1 tat 
requires cell surface heparan sulfate proteoglycans. Journal of Biological Chemistry. 
2001; 276(5):3254-3261.  
72. Wender PA. The design, synthesis, and evaluation of molecules that enable or 
enhance cellular uptake: Peptoid molecular transporters. Proceedings of the National 
Academy of Sciences of the United States of America. 2000; 97(24):13003-13008.  
73. Magzoub M, Gräslund A. Cell-penetrating peptides: small from inception to 
application. Quarterly Reviews of Biophysics. 2004; 37(02):147-195.  
74. Järver P, Langel Ü. Cell-penetrating peptides—A brief introduction. 
Biochimica et Biophysica Acta (BBA) - Biomembranes. 2006; 1758(3):260-263.  
75. Pooga M. Cell penetration by transportan. The FASEB Journal. 1998; 
12(1):67-77.  
76. Vladimir P T. Multifunctional nanocarriers. Advanced Drug Delivery 
Reviews. 2006; 58(14):1532-1555.  
77. Bárány-Wallje E, Keller S, Serowy S, Geibel S, Pohl P, Bienert M, et al. A 
critical reassessment of renetratin translocation across lipid membranes. Biophysical 
journal. 2005; 89(4):2513-2521.  
78. Saar K, Lindgren M, Hansen M, Eiríksdóttir E, Jiang Y, Rosenthal-Aizman 
K, et al. Cell-penetrating peptides: A comparative membrane toxicity study. 
Analytical Biochemistry. 2005; 345(1):55-65.  
79. Vivès E, Brodin P, Lebleu B. A truncated HIV-1 tat protein basic domain 
rapidly translocates through the plasma membrane and accumulates in the cell 
nucleus. Journal of Biological Chemistry. 1997; 272(25):16010-16017.  
180 
 
80. Vivès E, Schmidt J, Pèlegrin A. Cell-penetrating and cell-targeting peptides 
in drug delivery. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2008; 
1786(2):126-138.  
81. Cardozo AK, Buchillier V, Mathieu M, Chen J, Ortis F, Ladrière L, et al. 
Cell-permeable peptides induce dose- and length-dependent cytotoxic effects. 
Biochimica et Biophysica Acta (BBA) - Biomembranes. 2007; 1768(9):2222-2234.  
82. Tréhin R, Merkle HP. Chances and pitfalls of cell penetrating peptides for 
cellular drug delivery. European Journal of Pharmaceutics and Biopharmaceutics. 
2004; 58(2):209-223.  
83. Brooks NA, Pouniotis DS, Tang C-K, Apostolopoulos V, Pietersz GA. Cell-
penetrating peptides: Application in vaccine delivery. Biochimica et Biophysica Acta 
(BBA) - Reviews on Cancer. 2010; 1805(1):25-34.  
84. Räägel H, Pooga M. Chapter 10 - Peptide and Protein Delivery with Cell-
penetrating Peptides. In: Chris Van Der W, editor. Peptide and Protein Delivery. 
Boston: Academic Press; 2011. p. 221-246. 
85. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald 
DR, et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of 
cancer drugs. Science. 2010; 328(5981):1031-1035.  
86. Chugh A, Eudes F, Shim Y-S. Cell-penetrating peptides: Nanocarrier for 
macromolecule delivery in living cells. IUBMB Life. 2010; 62(3):183-193.  
87. Järver P, Mäger I, Langel Ü. In vivo biodistribution and efficacy of peptide 
mediated delivery. Trends in Pharmacological Sciences. 2010; 31(11):528-535.  
88. Laakkonen P, Åkerman ME, Biliran H, Yang M, Ferrer F, Karpanen T, et al. 
Antitumor activity of a homing peptide that targets tumor lymphatics and tumor 
cells. Proceedings of the National Academy of Sciences of the United States of 
America. 2004; 101(25):9381-9386.  
89. Gius DR, Ezhevsky SA, Becker-Hapak M, Nagahara H, Wei MC, Dowdy SF. 
Transduced p16INK4a peptides Inhibit hypophosphorylation of the retinoblastoma 
protein and cell cycle progression prior to activation of Cdk2 complexes in late G1. 
Cancer Research. 1999; 59(11):2577-2580.  
181 
 
90. Ward B, Seal BL, Brophy CM, Panitch A. Design of a bioactive cell-
penetrating peptide: when a transduction domain does more than transduce. Journal 
of Peptide Science. 2009; 15(10):668-674.  
91. Temsamani J, Vidal P. The use of cell-penetrating peptides for drug delivery. 
Drug Discovery Today. 2004; 9(23):1012-1019.  
92. Margus H, Padari K, Pooga M. Cell-penetrating peptides as versatile vehicles 
for oligonucleotide delivery. Molecular Therapy. 2012.  
93. Mäe M, Langel Ü. Cell-penetrating peptides as vectors for peptide, protein 
and oligonucleotide delivery. Current Opinion in Pharmacology. 2006; 6(5):509-514.  
94. Räägel H, Säälik P, Pooga M. Peptide-mediated protein delivery—Which 
pathways are penetrable? Biochimica et Biophysica Acta (BBA) - Biomembranes. 
2010; 1798(12):2240-2248.  
95. Mark A L. Peptide-mediated cell delivery: application in protein target 
validation. Current Opinion in Pharmacology. 2002; 2(5):587-594.  
96. Myou S, Zhu X, Myo S, Boetticher E, Meliton AY, Liu J, et al. Blockade of 
airway inflammation and hyperresponsiveness by HIV-TAT-dominant negative Ras. 
The Journal of Immunology. 2003; 171(8):4379-4384.  
97. Fujimoto K, Hosotani R, Miyamoto Y, Doi R, Koshiba T, Otaka A, et al. 
Inhibition of pRb phosphorylation and cell cycle progression by an antennapedia-
p16INK4A fusion peptide in pancreatic cancer cells. Cancer letters. 2000; 
159(2):151-158.  
98. Snyder EL, Meade BR, Saenz CC, Dowdy SF. Treatment of terminal 
peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biology. 
2004; 2(2):e36.  
99. Teixidó M, Zurita E, Malakoutikhah M, Tarragó T, Giralt E. 
Diketopiperazines as a sool for the study of transport across the Blood−Brain Barrier 
(BBB) and their potential yse as BBB-shuttles. Journal of the American Chemical 
Society. 2007 [cited 2012/01/14]; 129(38):11802-11813.  
100. William M P. Blood–brain barrier delivery. Drug Discovery Today. 2007; 
12(1–2):54-61.  
182 
 
101. Kumar P, Wu H, McBride JL, Jung K-E, Hee Kim M, Davidson BL, et al. 
Transvascular delivery of small interfering RNA to the central nervous system. 
Nature [10.1038/nature05901]. 2007; 448(7149):39-43.  
102. Rousselle C, Clair P, Lefauconnier J-M, Kaczorek M, Scherrmann J-M, 
Temsamani J. New advances in the transport of doxorubicin through the Blood-Brain 
Barrier by a peptide vector-mediated strategy. Molecular Pharmacology. 2000; 
57(4):679-686.  
103. Fischer PM. Diketopiperazines in peptide and combinatorial chemistry. 
Journal of Peptide Science. 2003; 9(1):9-35.  
104. Bolognesi ML, Ai Tran HN, Staderini M, Monaco A, López-Cobeñas A, 
Bongarzone S, et al. Discovery of a class of diketopiperazines as antiprion 
compounds. ChemMedChem. 2010; 5(8):1324-1334.  
105. Martins MB, Carvalho I. Diketopiperazines: biological activity and synthesis. 
Tetrahedron. 2007; 63(40):9923-9932.  
106. Malakoutikhah M, Teixidó M, Giralt E. Toward an optimal Blood−Brain 
Barrier shuttle by synthesis and evaluation of peptide libraries. Journal of Medicinal 
Chemistry. 2008 [cited 2012/01/14]; 51(16):4881-4889.  
107. Rothbard JB, Garlington S, Lin Q, Kirschberg T, Kreider E, McGrane PL, et 
al. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery 
and inhibition of inflammation. Nature Medicine. 2000; 6(11):1253-1257.  
108. Hou Y-W, Chan M-H, Hsu H-R, Liu BR, Chen C-P, Chen H-H, et al. 
Transdermal delivery of proteins mediated by non-covalently associated arginine-
rich intracellular delivery peptides. Experimental Dermatology. 2007; 16(12):999-
1006.  
109. Jin LH, Bahn JH, Eum WS, Kwon HY, Jang SH, Han KH, et al. Transduction 
of human catalase mediated by an HIV-1 TAT protein basic domain and arginine-
rich peptides into mammalian cells. Free Radical Biology and Medicine. 2001; 
31(11):1509-1519.  
110. Wender PA, Rothbard JB, Jessop TC, Kreider EL, Wylie BL. Oligocarbamate 
molecular transporters:  design, synthesis and biological evaluation of a new class of 
183 
 
transporters for drug delivery. Journal of the American Chemical Society. 2002 
[cited 2012/01/19]; 124(45):13382-13383.  
111. Lim JM, Chang MY, Park SG, Kang NG, Song YS, Lee YH, et al. 
Penetration enhancement in mouse skin and lipolysis in adipocytes by TAT-GKH, a 
new cosmetic ingredient. Journal of Cosmetic Sciences. 2003; 54(5):483-91.  
112. Hsu T, Mitragotri S. Delivery of siRNA and other macromolecules into skin 
and cells using a peptide enhancer. Proceedings of the National Academy of 
Sciences. 2011.  
113. Lee JN. The effects of depilatory agents as penetration enhancers on human 
stratum corneum structures. Journal of investigative dermatology. 2008; 
128(9):2240-2247.  
114. Tsai TH. Multiphoton microscopy in dermatological imaging. Journal of 
Dermatological Science. 2009; 56(1):1-8.  
115. Kumar R, Philip A. Modified transdermal technologies: Breaking the barriers 
of drug permeation via the skin. Tropical Journal of Pharmaceutical Research. 2007; 
6(1):633-644.  
116. Magnusson BM, Runn P. Effect of penetration enhancers on the permeation 
of the thyrotropin releasing hormone analogue pGlu-3-methyl-His- Pro amide 
through human epidermis. International Journal of Pharmaceutics. 1999; 178(2):149-
159.  
117. Kanikkannan N, Kandimalla K, Lamba S, Singh M. Structure-activity 
relationship of chemical penetration enhancers in transdermal drug delivery. Current 
Medicinal Chemistry. 2000; 6:593-608.  
118. Wang Y, Thakur R, Fan Q, Michniak B. Transdermal iontophoresis: 
combination strategies to improve transdermal iontophoretic drug delivery. European 
Journal of Pharmaceutics and Biopharmaceutics. 2005; 60(2):179-191.  
119. Michael J P. The role of electroosmotic flow in transdermal iontophoresis. 
Advanced Drug Delivery Reviews. 2001; 46(1-3):281-305.  
120. Schuetz YB, Naik A, Guy RH, Kalia YN. Emerging strategies for the 
transdermal delivery of peptide and protein drugs. Expert Opinion on Drug Delivery. 
2005; 2(3):533-548.  
184 
 
121. Naik A, Kalia YN, Guy RH. Transdermal drug delivery: overcoming the 
skin’s barrier function. Pharmaceutical Science &amp; Technology Today. 2000; 
3(9):318-326.  
122. Hirvonen J, Kalia YN, Guy RH. Transdermal delivery of peptides by 
iontophoresis. Nature Biotechnology. 1996; 14(13):1710-1713.  
123. Schuetz YB, Naik A, Guy RH, Kalia YN. Effect of amino acid sequence on 
transdermal iontophoretic peptide delivery. European Journal of Pharmaceutical 
Sciences. 2005; 26(5):429–437.  
124. Kochhar C, Imanidis G. In vitro transdermal iontophoretic delivery of 
leuprolide under constant current application. Journal of Controlled Release. 2004; 
98(1):25-35.  
125. Robert Meyer B, Kreis W, Eschbach J, Omara V, Rosen S, Sibalis D. 
Transdermal versus subcutaneous leuprolide: A comparison of acute 
pharmacodynamic effect. Clinical Pharmacology and Therapeutics. 1990; 48(4):340-
345.  
126. Green PG. Iontophoretic delivery of peptide drugs. Journal of Controlled 
Release. 1996; 41:33-48.  
127. Banga AK, Chien YW. Hydrogel-based iontotherapeutic delivery devices for 
transdermal delivery of peptide/protein drugs. Pharmaceutical Research. 1993; 
10(5):697-702.  
128. Pillai O, Kumar N, Dey CS, Borkute S, Nagalingam S, RPanchagnula. 
Transdermal iontophoresis of insulin. Part 1: A study on the issues associated with 
the use of platinum electrodes on rat skin. Journal of Pharmacy and Pharmacology. 
2003; 55(11):1505-13.  
129. Tokumoto S, Higo N, Sugibayashi K. Effect of electroporation and pH on the 
iontophoretic transdermal delivery of human insulin. International Journal of 
Pharmaceutics. 2006; 326(1-2):13-19.  
130. Bhatia KS, Singh J. Effect of linolenic acid/ethanol or limonene/ethanol and 
iontophoresis on the in vitro percutaneous absorption of LHRH and ultrastructure of 
human epidermis. International Journal of Pharmaceutics. 1999; 180(2):235-250.  
185 
 
131. Boinpally RR, Zhou SL, Devraj G, Anne PK, Poondru S, Jasti BR. 
Iontophoresis of lecithin vesicles of cyclosporin A. International Journal of 
Pharmaceutics. 2004; 274(1-2):185-190.  
132. Williams A, editor. Physical and Technological Modulation of Topical and 
Transdermal Drug Delivery. London: Pharmaceutical Press; 2003. 
133. Vanbever R, De Morre N, Préat V. Transdermal delivery of fentanyl by 
electroporation II. Mechanisms involved in drug transport. Pharmaceutical Research. 
1996; 13(9):1360-1366.  
134. Prausnitz MR, Bose VG, Langer R, Weaver JC. Electroporation of 
mammalian skin: A mechanism to enhance transdermal drug delivery. Proceedings 
of the Natural Academy of Sciences of the United States of America. 1993; 
70(22):10504–10508.  
135. Edwards DA, Prausnitz MR, Langer R, Weaver JC. Analysis of enhanced 
transdermal transport by skin electroporation. Journal of Controlled Release. 1995; 
34(3):211-221.  
136. Prausnitz MR, Edelman ER, Gimm JA, Langer R, Weaver JC. Transdermal 
delivery of heparin by skin electroporation. Biotechnology (NY). 1995; 13:1205-
1209.  
137. Regnier V, Doan TL, Préat V. Parameters controlling topical delivery of 
oligonucleotides by electroporation. Journal of Drug Targeting. 1998; 5(4):275-289.  
138. Vanbever R, Boulange´ EL, Pre´at V. Transdermal delivery of fentanyl by 
electroporation I. Influence of electrical factors. Pharmaceutical Research. 1996; 
13:559-565.  
139. Gaudy C, Richard MA, Folchetti G, Bonerandi JJ, Grob JJ. Randomized 
controlled study of electrochemotherapy in the local treatment of skin metastases of 
melanoma. Journal of Cutaneous Medicine and Surgery. 2006; 10:115-121.  
140. Lombry C, Dujardin N, Préat V. Transdermal delivery of macromolecules 
using skin electroporation. Pharmaceutical Research. 2000; 17(1):32-37.  
141. Wang S, Kara M, Krishnan TR. Transdermal delivery of cyclosporin-A using 
electroporation. Journal of Controlled Release. 1998; 50(1-3):61-70.  
186 
 
142. Sen A, Daly ME, Hui SW. Transdermal insulin delivery using lipid enhanced 
electroporation. Biochimica et Biophysica Acta (BBA) - Biomembranes. 2002; 
1564(1):5-8.  
143. Medi BM, Singh J. Electronically facilitated transdermal delivery of human 
parathyroid hormone (1–34). International Journal of Pharmaceutics. 2003; 263(1-
2):25-33.  
144. Vanbever R, Preat V. In vivo efficacy and safety of skin electroporation. 
Advanced Drug Delivery Reviews. 1999; 35:77 - 88.  
145. Philpott WH, Kalita DK, Goldberg B. Innerself [In: A Brief History of 
Magnet Therapy. 2000. Tiburon, CA, USA.: 
146. Mooney V. A randomized double-blind prospective study of the efficacy of 
pulsed electromagnetic fields for interbody lumbar fusions. Spine. 1990; 15(7):708-
12.  
147. Simko M, Mattsson MO. Extremely low frequency electromagnetic fields as 
effectors of cellular responses in vitro: possible immune cell activation. J Cell 
Biochem. 2004; 93(1):83-92.  
148. Santini JT, Cima MJ, Langer R. A controlled-release microchip. Nature. 
1999; 397(28):335-338.  
149. Nishijima S, Mishima F, Terada T, Takeda S. A study on magnetically 
targeted drug delivery system using superconducting magnet. Physica C: 
Superconductivity. 2007; 463–465(1):1311-1314.  
150. Grief AD, Richardson G. Mathematical modelling of magnetically targeted 
drug delivery. Journal of Magnetism and Magnetic Materials. 2005; 293(1):455-463.  
151. Huang W-C, Hu S-H, Liu K-H, Chen S-Y, Liu D-M. A flexible drug delivery 
chip for the magnetically-controlled release of anti-epileptic drugs. Journal of 
Controlled Release. 2009; 139(3):221-228.  
152.  In: Diamagnetism. Wikipedia. 
153. Namjoshi S, Chen Y, Edwards J, Benson HAE. Enhanced transdermal 
delivery of a dipeptide by dermaportation. Biopolymers Peptide Science. 2008; 
90(5):655-662.  
187 
 
154. Murthy SN, Sammeta SM, Bowers C. Magnetophoresis for enhancing 
transdermal drug delivery: Mechanistic studies and patch design. Journal of 
Controlled Release. 2010; 148(2):197-203.  
155. Sammeta SM, Repka MA, Narasimha Murthy S. Magnetophoresis in 
combination with chemical enhancers for transdermal drug delivery. Drug 
Development and Industrial Pharmacy. 2011; 37(9):1076-1082.  
156. Krishnan G. Enhanced skin permeation of naltrexone by pulsed 
electromagnetic fields in human skin in vitro. Journal of Pharmaceutical Sciences. 
2010; 99(6):2724-2731.  
157. Namjoshi S, Caccetta R, Edwards J, Benson HAE. Liquid chromatography 
assay for 5-aminolevulinic acid: Application to in vitro assessment of skin 
penetration via Dermaportation. Journal of Chromatography B. 2007; 852(1-2):49-
55.  
158. Benson HAE, Caccetta R, Eijkenboom M. 8th World Congress on 
Inflammation [2007]. Copenhagen, Denmark: 
159. Benson HAE, Caccetta R, Namjoshi S, Edwards J, Eijkenboom M. World 
Congress on Pain [2005]. Sydney: 
160. Mitragotri S, Blankschtein D, Langer R. Ultrasound-mediated transdermal 
protein delivery. Science. 1995; 269(5225):850-853.  
161. Pitt WG, Husseini GA, Staples BJ. Ultrasonic drug delivery—A general 
review. Expert Opinion on drug Delivery. 2004; 1(1):37-56.  
162. Mitragotri S. A mechanistic study of ultrasonically-enhanced transdermal 
drug delivery. Journal of Pharmaceutical Sciences. 1995; 84(6):697-706.  
163. Cross SE, Roberts MS. Physical enhancement of transdermal drug 
application: is delivery technology keeping up with pharmaceutical development? 
Current drug delivery. 2004; 1(1):81-92.  
164. Gaertner W. Frequency dependence of ultrasonic cavitation. The Journal of 
the Acoustical Society of America. 1954; 26(6):977-980.  
188 
 
165. Alvarez-Roman R, Merino G, Kalia YN, Naik A, Guy RH. Skin permeability 
enhancement by low frequency sonophoresis: Lipid extraction and transport 
pathways. Journal of Pharmaceutical Sciences. 2003; 92(6):1138-46.  
166. Tezel A, Sens A, Mitragotri S. Description of transdermal transport of 
hydrophilic solutes during low-frequency sonophoresis based on a modified porous 
pathway model. Journal of Pharmaceutical Sciences. 2003; 92(2):381-393.  
167. Liu H, Li S, Pan W, Wang Y, Han F, Yao H. Investigation into the potential 
of low-frequency ultrasound facilitated topical delivery of Cyclosporin A. 
International Journal of Pharmaceutics. 2006; 326(1-2):32-38.  
168. Le L, Kost J, Mitragotri S. Combined effect of low-frequency ultrasound and 
iontophoresis: applications for transdermal heparin delivery. Pharmaceutical 
Research. 2000; 17(9):1151-1154.  
169. Brown MB, Traynor MJ, Martin GP, Akomeah FK. Transdermal Drug 
Delivery Systems: Skin Perturbation Devices Totowa, NJ: Humana Press; 2008. 
170. Schramm J, Mitragotri S. Transdermal drug delivery by jet injectors: 
energetics of jet formation and penetration. Pharmaceutical Research. 2002; 
19(11):1673-1679.  
171. Sarno MJ. Clinical immunogenicity of measles, mumps and rubella vaccine 
delivered by the Injex jet injector: comparison with standard syringe injection. The 
Pediatric Infectious Disease Journal. 2000; 19(9):839-42.  
172. Jackson L. Safety and immunogenicity of varying dosages of trivalent 
inactivated influenza vaccine administered by needle-free jet injectors. Vaccine. 
2001; 19(32):4703-4709.  
173. Resman E. The application of insulin using the jet injector DG-77. Acta 
Diabetologica Latina. 1985; 22(2):119-125.  
174. Dean H. Powder and particle-mediated approaches for delivery of DNA and 
protein vaccines into the epidermis. Comparative Immunology, Microbiology and 
Infectious Diseases. 2003; 26(5-6):373-388.  
175. Kendall M. Engineering of needle-free physical methods to target epidermal 
cells for DNA vaccination. Vaccine. 2006; 24(21):4651-4656.  
189 
 
176. Doukas A. Physical characteristics and biological effects of laser-induced 
stress waves. Ultrasound in Medicine & Biology. 1996; 22(2):151-164.  
177. Haar T. Biological effects of ultrasound in clinical applications. New York: 
VCH Publishers; 1988. 
178. Doukas AG, McAuliffe DJ, Lee S, Venugopalan V, Flotte TJ. Physical 
factors involved in stress-wave-induced cell injury: the effect of stress gradient. 
Ultrasound in Medicine & Biology. 1995; 21(7):961-967.  
179. Lee S, Anderson T, Zhang H, Flotte TJ, Doukas AG. Alteration of cell 
membrane by stress waves in vitro. Ultrasound in Medicine & Biology. 1996; 
22(9):1285-1293.  
180. Lee S, Kollias N, McAuliffe DJ, Flotte TJ, Doukas AG. Topical drug delivery 
in humans with a single photomechanical wave. Pharmaceutical Research. 1999; 
16(11):1717-1721.  
181. Lee S, McAuliffe DJ, Flotte TJ, Kollias N, Doukas AG. Photomechanical 
transcutaneous Delivery of macromolecules. Journal of Investigative Dermatology. 
1998; 111(6):925-929.  
182. Lee S, McAuliffe DJ, Mulholland SE, Doukas AG. Photomechanical 
transdermal delivery of insulin in vivo. Lasers in Surgery and Medicine. 2001; 
28(3):282-285.  
183. Doukas AG, Kollias N. Transdermal drug delivery with a pressure wave. 
Advanced Drug Delivery Reviews. 2004; 56(5):559-579.  
184. Gerstel MS, Place VA, inventors; Drug delivery device. United States of 
America. U.S. Patent 3,964,482. June 22, 1976. 
185. Prausnitz M. Current status and future potential of transdermal drug delivery. 
Nature reviews. Drug discovery. 2004; 3(2):115-24.  
186. Henry S, McAllister DV, Allen MG, Prausnitz MR. Microfabricated 
Microneedles : A novel approach to transdermal drug delivery. Journal of 
Pharmaceutical Sciences. 1998; 87(8):922 - 925.  
187. Prausnitz MR. Microneedles for transdermal drug delivery. Advanced Drug 
Delivery Reviews. 2004; 56(5):581 - 587.  
190 
 
188. Chen X. Dry-coated microprojection array patches for targeted delivery of 
immunotherapeutics to the skin. Journal of Controlled Release. 2009; 139(3):212-
220.  
189. Champion RH, Burton JL, Burns T, Breathnach SM, Burns DA. Textbook of 
Dermatology. John Wiley & Sons, Limited; 1998. 
190. Martanto W, Moore JS, Couse T, Prausnitz MR. Mechanism of fluid infusion 
during microneedle insertion and retraction. Journal of Controlled Release. 2006; 
112(3):357-361.  
191. Bal SM, Kruithof AC, Zwier R, Dietz E, Bouwstra JA, Lademann J, et al. 
Influence of microneedle shape on the transport of a fluorescent dye into human skin 
in vivo. Journal of Controlled Release. 2010; 147(2):218-224.  
192. Bal S, Kruithof AC, Liebl H, Tomerius M, Bouwstra J, Lademann J, et al. In 
vivo visualization of microneedle conduits in human skin using laser scanning 
microscopy. Laser Physics Letters. 2010; 7(3):242-246.  
193. Banks SL, Pinninti RR, Gill HS, Paudel KS, Crooks PA, Brogden NK, et al. 
Transdermal delivery of naltrexol and skin permeability lifetime after microneedle 
treatment in hairless guinea pigs. Journal of Pharmaceutical Sciences. 2010; 
99(7):3072-3080.  
194. Banks S, Paudel K, Brogden N, Loftin C, Stinchcomb A. Diclofenac enables 
prolonged delivery of naltrexone through microneedle-treated skin. Pharmaceutical 
Research. 2011; 28(5):1211-1219.  
195. Hashmi S. Genetic transformation of nematodes using arrays of 
micromechanical piercing structures. BioTechniques. 1995; 19(5):766-770.  
196. Lin W. Transdermal delivery of antisense oligonucleotides with 
microprojection patch (Macroflux®) technology. Pharmaceutical Research. 2001; 
18(12):1789-1793.  
197. Donnelly RF, Morrow DIJ, McCarron PA, Woolfson AD, Morrissey A, 
Juzenas P, et al. Microneedle-mediated intradermal delivery of 5-aminolevulinic 
acid: Potential for enhanced topical photodynamic therapy. Journal of Controlled 
Release. 2008; 129(3):154-162.  
191 
 
198. Park J-H, Allen MG, Prausnitz MR. Biodegradable polymer microneedles: 
Fabrication, mechanics and transdermal drug delivery. Journal of Controlled Release. 
2005; 104(1):51-66.  
199. Lee JW, Park J-H, Prausnitz MR. Dissolving microneedles for transdermal 
drug delivery. Biomaterials. 2008; 29(13):2113-2124.  
200. Raphael AP, Prow TW, Crichton ML, Chen X, Fernando GJP, Kendall MAF. 
Targeted, needle-free vaccinations in skin using multilayered, densely-packed 
dissolving microprojection arrays. Small. 2010; 6(16):1785-1793.  
201. Chen X, Corbett HJ, Yukiko SR, Raphael AP, Fairmaid EJ, Prow TW, et al. 
Site-selectively coated, densely-packed microprojection array patches for targeted 
delivery of vaccines to skin. Advanced Functional Materials. 2011; 21(3):464-473.  
202. Chen X, Fernando GJP, Raphael AP, Yukiko SR, Fairmaid EJ, Primiero CA, 
et al. Rapid kinetics to peak serum antibodies is achieved following influenza 
vaccination by dry-coated densely packed microprojections to skin. Journal of 
Controlled Release. 2011; 158(1):78-84.  
203. Lee K, Lee CY, Jung H. Dissolving microneedles for transdermal drug 
administration prepared by stepwise controlled drawing of maltose. Biomaterials. 
2011; 32(11):3134-3140.  
204. Kommareddy S, Baudner BC, Oh S, Kwon S-y, Singh M, O'Hagan DT. 
Dissolvable microneedle patches for the delivery of cell-culture-derived influenza 
vaccine antigens. Journal of Pharmaceutical Sciences. 2012; 101(3):1021-1027.  
205. Michel C, Peter D. Macroflux Technology for Transdermal Delivery of 
Therapeutic Proteins and Vaccines. In: Modified-Release Drug Delivery 
Technology: Informa Healthcare; 2002. p. 589-598. 
206. Chen X  Novel coating of micro-nanoprojection patches for targeted vaccine 
delivery to skin. International Conference on Nanoscience and Nanotechnology; 
2008 p. 105-108. 
207. Cormier M, Johnson B, Ameri M, Nyam K, Libiran L, Zhang DD, et al. 
Transdermal delivery of desmopressin using a coated microneedle array patch 
system. Journal of Controlled Release. 2004; 97(3):503-511.  
192 
 
208. Gomaa YA. Effects of microneedle length, density, insertion time and 
multiple applications on human skin barrier function: Assessments by transepidermal 
water loss. Toxicology In Vitro. 2010; 24(7):1971-1978.  
209. Al Qallaf B. Modelling transdermal delivery of high molecular weight drugs 
from microneedle systems. Philosophical transactions - Royal Society. Mathematical, 
Physical and engineering sciences. 2007; 365(1861):2951-2967.  
210. Al-Qallaf B, Moriy D, Olatunjiz L, Das DB, Cuiyy Z. Transdermal drug 
delivery by microneedles: Does skin metabolism matter? International Journal of 
Chemical Reactor Engineering. 2009; 7:1-23.  
211. Mitragotri S, Anissimov YG, Bunge AL, Frasch HF, Guy RH, Hadgraft J, et 
al. Mathematical models of skin permeability: An overview. International Journal of 
Pharmaceutics. 2011; 418(1):115-129.  
212. Nelson JS, McCullough JL, Glenn TC, Wright WH, Liaw LH, Jacques SL. 
Mid-infrared laser ablation of stratum corneum enhances in vitro percutaneous 
transport of drugs. Journal of Investigative Dermatology. 1991; 97(5):874-879.  
213. Furness G. Global overview of the active transdermal drug delivery market 
Drug Development and Delivery. 2003; 4(3).  
214. Birchall J. Cutaneous gene expression of plasmid DNA in excised human 
skin following delivery via microchannels created by radio frequency ablation. 
International Journal of Pharmaceutics. 2006; 312(1-2):15-23.  
215. Sintov A. Radiofrequency-driven skin microchanneling as a new way for 
electrically assisted transdermal delivery of hydrophilic drugs. Journal of Controlled 
Release. 2003; 89(2):311-320.  
216. Levin G. Transdermal delivery of human growth hormone through RF-
microchannels. Pharmaceutical Research. 2005; 22(4):550-5.  
217. Levin G. Advances in radio-frequency transdermal drug 
delivery.(Transdermal Delivery). Pharmaceutical Technology. 2008; 32(4):s12.  
218. Lee W-R. Erbium:YAG laser enhances transdermal peptide delivery and skin 
vaccination. Journal of Controlled Release. 2008; 128(3):200-208.  
193 
 
219. Lee W-R. Skin pretreatment with an Er:YAG laser promotes the transdermal 
delivery of three narcotic analgesics. Lasers in Medical Science. 2007; 22(4):271.  
220. Fang J-Y. Transdermal delivery of macromolecules by erbium:YAG laser. 
Journal of Controlled Release. 2004; 100(1):75-85.  
221. Noel H, James D. Minimally Invasive Systems for Transdermal Drug 
Delivery. In: Transdermal Drug Delivery Systems: Informa Healthcare; 2002. 
222. Westerling D. Transdermal administration of morphine to healthy subjects. 
British Journal of Clinical Pharmacology. 1994; 37(6):571-6.  
223. Svedman PS, Svedman. Administration of antidiuretic peptide (DDAVP) by 
way of suction de-epithelialised skin. Lancet. 1991; 337(8756):1506-1509.  
224. Eppstein J, inventor; Altea Therapeutics Corporation, assignee. Apparatus for 
microporation of biological membranes using thin film tissue interface devices. US. 
2010. 
225. Bramson J, Dayball K, Evelegh C, Wan YH, Page D, Smith A. Enabling 
topical immunization via microporation: a novel method for pain-free and needle-
free delivery of adenovirus-based vaccines. Gene Therapy. 2003; 10(3):251-260.  
226. Gebhart S. Glucose sensing in transdermal body fluid collected under 
continuous vacuum pressure via micropores in the stratum corneum. Diabetes 
Technology & Therapeutics. 2003; 5(2):159-66.  
227. Badkar AV, Smith AM, Eppstein JA, Banga AK. Transdermal delivery of 
interferon alpha-2B using microporation and iontophoresis in hairless rats. 
Pharmaceutical Research. 2007; 24(7):1389–1395.  
228. Heidl M. Peptides for prolonging youth. Advances in experimental medicine 
and biology. 2009; 611:263-264.  
229. Zhang L, Falla TJ. Cosmeceuticals and peptides. Clinics in Dermatology [doi: 
10.1016/j.clindermatol.2009.05.013]. 2009; 27(5):485-494.  
230. Donald L B. Common cosmeceuticals. Clinics in Dermatology [doi: 
10.1016/j.clindermatol.2009.05.006]. 2009; 27(5):435-445.  
231. Choi CM, Berson DS. Cosmeceuticals. Seminars in Cutaneous Medicine and 
Surgery. 2006; 25:163-168.  
194 
 
232. Brandt FS, Cazzaniga A, Hann M. Cosmeceuticals: Current Trends and 
Market Analysis. Seminars in Cutaneous Medicine and Surgery [doi: 
10.1016/j.sder.2011.05.006]. 2011; 30(3):141-143.  
233. Lupo MP, Cole AL. Cosmeceutical peptides. Dermatologic Surgery. 2007; 
20(5):343-349.  
234. Robinson LR, Fitzgerald NC, Doughty DG. Topical palmitoyl pentapeptide 
provides improvement in photoaged human facial skin. International Journal of 
Cosmetic Science. 2005; 27:155–160.  
235. Vleugels RA. Cosmeceuticals: From topical antioxidants to peptides. The 
Dermatology Report. 2008; 2(1).  
236. Katyama K, Armendariz-Borunda J, Rachow R. A pentapeptide from Type I 
procollgen promotes extracellular matrix production. Journal of Biological 
Chemistry. 1993; 268:9941-9944.  
237. Dipeptide - 2. [05/08/09]. Available from: 
http://www.truthinaging.com/ingredients/dipeptide-2/. 
238. Bascom CC, inventor; The Procter and Gamble Company, assignee. 
Compositions for treating wrinkles comprising a peptide. United States patent 
5492894. 1993 June 25. 
239. Farra CD, Domloge N, Botto J-M, inventors; Novel sirtuin 6 activating 
peptides and cosmetic or pharmaceutical composition containing them. USA patent 
20110318284. 2011. 
240. Quinn PJ, Boldyrev AA, Formazuyk VE. Carnosine: Its properties, functions 
and potential therapeutic applications. Molecular aspects of Medicine. 1992; 13:379-
444.  
241. Kansci G, Genot C, Meynier A, Gandemer G. The antioxidant activity of 
carnosine and its consequences on the volatile profiles of liposomes during 
iron/ascorbate induced phospholipid oxidation. Food Chemistry. 1997; 60(2):165-
175.  
242. Hipkiss AR. Carnosine, a protective, anti-ageing peptide? The International 
Journal of Biochemistry and Cell Biology. 1998; 30:863-868.  
195 
 
243. Alan R H. On the enigma of carnosine’s anti-ageing actions. Experimental 
Gerontology. 2009; 44(4):237-242.  
244. Linter K, inventor; Sederma, assignee. Cosmetic or dermopharmaceutical use 
of peptides for healing, hydrating and improving skin appearance during natural or 
induced ageing (Heliodermia, Pollution). France. 2003. 
245. Martin DC, inventor; L'Oreal Paris, assignee. Cosmetic compositions 
containing a lipid ceramide compund and a peptide having a fatty chain and their 
uses. France. 1998. 
246. Niyonsaba F, Ogawa H. Protective roles of the skin against infection: 
Implication of naturally occurring human antimicrobial agents [beta]-defensins, 
cathelicidin LL-37 and lysozyme. Journal of Dermatological Science. 2005; 40:157-
168.  
247. Harder J, Schroder JM. Psoriatic scales: A promising source for the isolation 
of human skin derived antimicrobial proteins. Journal of Leukocyte Biology. 2005; 
77:476–486.  
248. Marks R. The stratum corneum barrier - the final frontier. Journal of 
Nutrition. 2004.  
249. Katayama K, Armendariz-Borunda J, Raghow R, Kang AH, Seyer JM. A 
pentapeptide from type I procollagen promotes extracellular matrix production. 
Journal of Biological Chemistry. 1993; 268(14):9941-9944.  
250. Schultz G. EGF and TGF-alpha in wound healing and repair. Journal of 
Cellular Biochemistry. 1991; 45(4):346-52.  
251. Meyer-Ingold W. Wound therapy: Growth factors as agents to promote 
healing. Trends in Biotechnology. 1993; 11(9):387–392.  
252. Braff MH. Structure-function relationships among human cathelicidin 
peptides: Dissociation of antimicrobial properties from host immunostimulatory 
activities. The Journal of Immunology. 2005; 174(7):4271-4278.  
253. Lee PHA. HB-107, a nonbacteriostatic fragment of the antimicrobial peptide 
cecropin B, accelerates murine wound repair. Wound Repair and Regeneration. 
2004; 12(3):351-358.  
196 
 
254. Carraway JH. Using Aldara, copper peptide, and niacinamide for skin care 
Aesthetic Surgery Journal. 2004; 24(1):83-84  
255. Leung DYM, Boguniewicz M, Howell MD, Nomura I, Hamid Q. New 
insights into atopic dermatitis. Journal of Clinical Investigation. 2004; 113(5):651-
657.  
256. Madsen P, Rasmussen HH, Leffers H, Honore B, Dejgaard K, Olsen E, et al. 
Molecular cloning, occurrence, and expression of a novel partially secreted protein 
"psoriasin" that is highly up-regulated in psoriatic skin. Journal of Investigative 
Dermatology. 1991; 97(4):701-712.  
257. Ruzicka T, Simmet T, Peskar B, Ring J. Skin levels of arachidonic acid—
Derived inflammatory mediators and histamine in atopic dermatitis and psoriasis. 
Journal of Investigative Dermatology. 1986; 86(2):105–108.  
258. Nonomura K, Yamanish K, Yasuno H. Upregulation of elafin/SKALP gene 
expression in psoriatic epidermis. Journal of Investigative Dermatology. 1994; 
103(1):88–91.  
259. Harder J, Schröder J-M. RNase 7, a novel innate immune defense 
antimicrobial protein of healthy human skin. Journal of Biological Chemistry. 2002; 
277(48):46779-46784.  
260. Taleisnik S. Regulation of Formation and Proposed Structure of the Factor 
Inhibiting the Release of Melanocyte-Stimulating Hormone. Proceedings of the 
National Academy of Sciences of the United States of America. 1971; 68(7):1428-
1433.  
261. Pignatiello. MIF-1 is active in a chronic stress animal model of depression. 
Pharmacology, Biochemistry and Behavior. 1989; 32(3):737-742.  
262. Stratton L. Increased acquisition of a complex appetitive task after MSH and 
MIF. Pharmacology, Biochemistry and Behavior. 1975; 3(5):901-904.  
263. Ishihara Y. Melanostatin, a new melanin synthesis inhibitor. Production, 
isolation, chemical properties, structure and biological activity. The Journal of 
Antibiotics. 1991; 44(1):25-32.  
264. Skinner KK, inventor; Methods and compositions for improved uptake of 
biological molecules US. 2010. 
197 
 
265. Abdel Malek Z. Melanoma prevention strategy based on using tetrapeptide 
alpha-MSH analogs that protect human melanocytes from UV-induced DNA damage 
and cytotoxicity. The FASEB Journal. 2006; 20(9):1561-3.  
266. Dhatt S. Rebuilding the dermal matrix with this new in-demand ingredient in 
skin care products. Aesthetic Trends and Technologies. 2006:17-20.  
267. Kumar N, Kishore R. Determination of an unusual secondary structural 
element in the immunostimulating tetrapeptide rigin in aqueous environments: 
insights via MD simulations, 1H NMR and CD spectroscopic studies. Journal of 
Peptide Science. 2010; 16(9):456-464.  
268. Veretennikova NI, Chipens GI, Nikiforovich GV, Betinsh YR. Rigin, another 
phagocytosis-stimulating tertrapeptide isolated from human IgG: confirmations of a 
hypothesis. International Journal of Peptide and Protein Research. 1981; 17(4):430-
435.  
269. Rocchi R, Biondi L, Cavaggion F, Filira F, Gobbo M, Dagan S, et al. 
Synthesis and biological activity of tuftsin and rigin derivatives containing 
monosaccharides or monosaccharide derivatives. International Journal of Peptide and 
Protein Research. 1987; 29(2):262-275.  
270. Navolotskaya EV, Zargarova TA, Lepikhova TN, Turobov VI, Nurieva RI, 
Malkova NV, et al. Study of immunosuppressive activity of a synthetic decapeptide 
corresponding to an ACTH-Like sequence of human immunoglobulin G1. 
Biochemistry. 1999; 64(7):906-913.  
271.  In: Syn
R
-Coll : Pentapharm Ltd Engelgasse : Basel 
272. Prausnitz MR. A peptide chaperone for transdermal drug delivery. Nature 
Biotechnology. 2006; 24(4):416-417.  
273. van der Maaden K, Jiskoot W, Bouwstra J. Microneedle technologies for 
(trans)dermal drug and vaccine delivery. Journal of Controlled Release. (0).  
274. Morris MC, Deshayes S, Heitz F, Divita G. Cell-penetrating peptides: from 
molecular mechanisms to therapeutics. Biology of the Cell. 2008; 100(4):201-217.  
275. Lopes LB. Comparative study of the skin penetration of protein transduction 
domains and a conjugated peptide. Pharmaceutical Research. 2005; 22(5):750-757.  
198 
 
276. Sebbage V. Cell-penetrating peptides and their therapeutic applications. 
Bioscience Horizons. 2009; 2(1):64-72.  
277. Christophers E, Kligman AM. Visualisation of the cell layers of the stratum 
corneum. Journal of Investigative Dermatology. 1964; 42:407-409.  
278. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression 
of a mitogen-responsive gene encoding prostaglandin synthase is regulated by 
mRNA splicing. Proceedings of the National Academy of Sciences. 1991; 
88(7):2692-2696.  
279. Blobaum AL, Marnett LJ. Structural and functional basis of cyclooxygenase 
inhibition. Journal of Medicinal Chemistry. 2007; 50(7):1425-1441.  
280. Nugteren DH, Hazelhof E. Isolation and properties of intermediates in 
prostaglandin biosynthesis. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid 
Metabolism. 1973; 326(3):448-461.  
281. Hamberg M, Samuelsson B. Detection and Isolation of an Endoperoxide 
Intermediate in Prostaglandin Biosynthesis. Proceedings of the National Academy of 
Sciences. 1973; 70(3):899-903.  
282. Lu MF, Lee D, Carlson R, Rao GS, Hui HW, Adjei L, et al. The effects of 
formulation variables on iontophoretic transdermal delivery of leuprolide to humans. 
Drug Development and Industrial Pharmacy. 1993; 19(13):1557-1571.  
283. Badkar AV, Banga AK. Electrically enhanced transdermal delivery of a 
macromolecule. Journal of Pharmacy and Pharmacology. 2002; 54(7):907-912.  
284. Christensen JM, Chuong MC, Le H, Pham L, Bendas E. Hydrocortisone 
diffusion through synthetic membrane, mouse skin, and Epiderm™ cultured skin. 
Archives of Drug Information. 2011; 4(1):10-21.  
285. Aguzzi C, Rossi S, Bagnasco M, Lanata L, Sandri G, Bona F, et al. 
Penetration and distribution of thiocolchicoside through human skin: comparison 
between a commercial foam and a drug solution. AAPS PharmSciTech. 2008; 
9(4):1185-1190.  
286. Mueller B, Anissimov YG, Roberts MS. Unexpected clobetasol propionate 
profile in human stratum corneum after topical application in vitro. Pharmaceutical 
Research. 2003; 20(11):1835-1837.  
199 
 
287. Dragicevic-Curic N, Scheglmann D, Albrecht V, Fahr A. Temoporfin-loaded 
invasomes: Development, characterization and in vitro skin penetration studies. 
Journal of Controlled Release. 2008; 127(1):59-69.  
288. Lee VHL. Penetration and enzymatic barriers to peptide and protein 
absorption. Advanced Drug Delivery Reviews. 1989; 4(2):171-207.  
289. Goolcharran C, Jones AJS, Borchardt RT. Comparison of the rates of 
deamidation, diketopiperazine formation, and oxidation in recombinant human 
vascular endothelial growth factor and model peptides. AAPS Pharmsci. 2000; 
2(1):1-6.  
290. Carpenter KA, Weltrowska G, Wilkes BC, Schmidt R, Schiller PW. 
Spontaneous Diketopiperazine formation via end-to-end cyclization of a 
nonactivated linear tripeptide: An unusual chemical reaction. Journal of the 
American Chemical Society. 1994; 116(19):8450-8458.  
291. Kubo A, Takahashi K, Arai T. Diketopiperazines containing L-proline from 
Streptomyces lavendulae and their stereochemistry in solution. Cellular and 
Molecular Life Sciences. 1977; 33(1):12-13.  
292. Teixidó M, Mohammed Y, Benson H, Giralt E. European Peptide 
Symposium [In: Across the skin barrier, a comparative transport study of a 
diketopiperazine-based shuttle. 2010. Copenhagen] 
293. Jones SW, Christison R, Bundell K, Voyce CJ, Brockbank SMV, Newham P, 
et al. Characterisation of cell-penetrating peptide-mediated peptide delivery. British 
Journal of Pharmacology. 2005; 145(8):1093-1102.  
294. Morris MC, Depollier J, Mery J, Heitz F, Divita G. A peptide carrier for the 
delivery of biologically active proteins into mammalian cells. Nature Biotechnology. 
2001; 19(12):1173-1176.  
295. Boisseau S, Mabrouk K, Ram N, Garmy N, Collin V, Tadmouri A, et al. Cell 
penetration properties of maurocalcine, a natural venom peptide active on the 
intracellular ryanodine receptor. Biochimica et Biophysica Acta (BBA) - 
Biomembranes. 2006; 1758(3):308-319.  
296. Huang R, Zhou X, Xu T, Yang X, Liu Y. Diketopiperazines from marine 
organisms. Chemistry & Biodiversity. 2010; 7(12):2809-2829.  
200 
 
297. Watts KR, Ratnam J, Ang K-H, Tenney K, Compton JE, McKerrow J, et al. 
Assessing the trypanocidal potential of natural and semi-synthetic diketopiperazines 
from two deep water marine-derived fungi. Bioorganic &amp; Medicinal Chemistry. 
2010; 18(7):2566-2574.  
298. Bos J. The 500 dalton rule for the skin penetration of chemical compounds 
and drugs. Experimental Dermatology. 2000; 9(3):165-169.  
299. Altenbach M, Schnyder N, Zimmermann C, Imanidis G. Cutaneous 
metabolism of a dipeptide influences the iontophoretic flux of a concomitant 
uncharged permeant. International Journal of Pharmaceutics. 2006; 307(2):308-317.  
300. Lin R-Y, Hsu C-W, Chen W-Y. A method to predict the transdermal 
permeability of amino acids and dipeptides through porcine skin. Journal of 
Controlled Release. 1996; 38(2-3):229-234.  
301. Sakuma S, Suita M, Yamamoto T, Masaoka Y, Kataoka M, Yamashita S, et 
al. Performance of cell-penetrating peptide-linked polymers physically mixed with 
poorly membrane-permeable molecules on cell membranes. European Journal of 
Pharmaceutics and Biopharmaceutics. 2012; 81(1):64-73.  
302. Nokhodchi A, Sharabiani K, Rashidi MR, Ghafourian T. The effect of 
terpene concentrations on the skin penetration of diclofenac sodium. International 
Journal of Pharmaceutics. 2007; 335(1–2):97-105.  
303. Galer BS, Rowbotham M, Perander J, Devers A, Friedman E. Topical 
diclofenac patch relieves minor sports injury pain: results of a multicenter controlled 
clinical trial. Journal of Pain and Symptom Management. 2000; 19(4):287-294.  
304. Rainsford KD, Kean WF, Ehrlich GE. Review of the pharmaceutical 
properties and clinical effects of the topical NSAID formulation, diclofenac 
epolamine. Current Medical Research and Opinion. 2008; 24(10):2967-2992.  
305. Donnelly RF, Pascuet E, Ma C, Vaillancourt R. Stability of diclofenac 
sodium oral suspensions packaged in amber polyvinyl chloride bottles. The Canadian 
Journal of Hospital Pharmacy. 2010; 63(1).  
306. Dehghanyar P, Mayer BX, Namiranian K, Mascher H, Mller M, Brunner M. 
Topical skin penetration of diclofenac after single- and multiple-dose application. 
201 
 
International Journal of Clinical Pharmacology and Therapeutics. 2004; 42(7):353-
359.  
307. Rojo-Vergara C, López-Alarcón C, Alvarez-Figueroa MJ. Transdermal 
penetration of diclofenac in the presence of AAPH-derived peroxyl radicals. Drug 
Development and Industrial Pharmacy. 2009; 35(8):976-980.  
308. Magnette JL, Kienzler JL, Sallin D, Ménart C, Nollevaux F, Knops A. 
Diclofenac systemic exposure is not increased when topical diclofenac is applied to 
ultraviolet-induced erythema. European Journal of Clinical Pharmacology. 2004; 
60(8):591-594.  
309. Abdulmajed K, McGuigan C, Heard CM. Topical delivery of retinyl 
ascorbate co-drug. 5. In vitro degradation studies. Skin Pharmacology and 
Physiology. 2006; 19(5):248-258.  
310. Cohen-Avrahami M, Libster D, Aserin A, Garti N. Sodium diclofenac and 
cell-penetrating peptides embedded in HII mesophases: Physical characterization and 
delivery. The Journal of Physical Chemistry B. 2011; 115(34):10189-10197.  
311. Cohen-Avrahami M, Libster D, Aserin A, Garti N. Penetratin-induced 
transdermal delivery from HII mesophases of sodium diclofenac. Journal of 
Controlled Release. 2012; (0).  
312. Lohcharoenkal W, Manosaroi A, Götz F, Werner RG, Manosroi W, 
Manosaroi J. Potent enhancement of GFP uptake into HT-29 cells and rat skin 
permeation by coincubation with tat peptide. Journal of Pharmaceutical Sciences. 
2011; 100(11):4766-4773.  
313. Drugs & Medications - diclofenac sodium oral. 2012 [updated 25th Feb]. 
Available from: http://www.webmd.com/drugs/mono-4049-
DICLOFENAC+SODIUM+ENTERIC-COATED+TABLET+-
+ORAL.aspx?drugid=4284&drugname=diclofenac+sodium+oral. 
314. Panje WR. Regression of head and neck carcinoma with a prostaglandin-
synthesis inhibitor. Archives of Otolaryngology. 1981; 107(11):658-663.  
315. Braun DP, Taylor SG, Harris JE. Modulation of immunity in cancer patients 
by prostaglandin antagonists. Progress in Clinical and Biological Research. 1989; 
288:439-48.  
202 
 
316. Brown MB, Jones SA. Hyaluronic acid: a unique topical vehicle for the 
localized delivery of drugs to the skin. Journal of the European Academy of 
Dermatology and Venereology. 2005; 19(3):308-318.  
317. Garsha K. Quantitative Fluorescence Microscopy: Considerations and 
Controls Standardization and Quality Assurance in Fluorescence Measurements II. 
In: Resch-Genger U, editor.: Springer Berlin Heidelberg; 2008. p. 55-88. 
318. Pirard GE. In vivo confocal microscopy: a new paradigm in dermatology. 
Dermatology. 1993; 186(1):4-5.  
319. Branzan A, Landthaler M, Szeimies R-M. In vivo confocal scanning laser 
microscopy in dermatology. Lasers in Medical Science. 2007; 22(2):73-82.  
320. Skvara H, Kittler H, Schmid JA, Plut U, Jonak C. In vivo fluorescence 
confocal microscopy: indocyanine green enhances the contrast of epidermal and 
dermal structures. Journal of Biomedical Optics. 2011; 16(9):096010.  
321. Rajadhyaksha M, Gonzalez S, Zavislan JM, Anderson RR, Webb RH. In vivo 
confocal scanning laser microscopy of human skin II: Advances in instrumentation 
and comparison with histology. Journal of Investigative Dermatology. 1999; 
113(3):293-303.  
322. Jonak C, Skvara H, Kunstfeld R, Trautinger F, Schmid JA. Intradermal 
indocyanine green for In Vivo fluorescence laser scanning microscopy of human 
skin: A pilot study. PLoS ONE. 2011; 6(8):23972.  
323. Rajadhyaksha M, Grossman M, Esterowitz D, Webb RH, Anderson RR. In 
vivo confocal scanning laser microscopy of human skin: Melanin provides strong 
contrast. Journal of Investigative Dermatology. 1995; 104(6):946-952.  
324. Elkeeb R, Hui X, Chan H, Tian L, Maibach HI. Correlation of transepidermal 
water loss with skin barrier properties in vitro: comparison of three evaporimeters. 
Skin Research and Technology. 2010; 16(1):9-15.  
325. Gill H, Denson D, Burris B, Prausnitz M. Effect of microneedle design on 
pain in human volunteers. The Clinical Journal of Pain. 2008; 24(7):585-594.  
326. Sauermann K, Clemann S, Jaspers S, Gambichler T, Altmeyer P, Hoffmann 
K, et al. Age related changes of human skin investigated with histometric 
203 
 
measurements by confocal laser scanning microscopy in vivo. Skin Research and 
Technology. 2002; 8(1):52-56.  
327. Wurm EMT, Soyer HP. The Confocal Story Reflectance Confocal 
Microscopy for Skin Diseases. In: Hofmann-Wellenhof R, Pellacani G, Malvehy J, 
Soyer HP, editors.: Springer Berlin Heidelberg; 2012. p. 3-5. 
328. Mortensen LJ, Glazowski CE, Zavislan JM, DeLouise LA. Near-IR 
fluorescence and reflectance confocal microscopy for imaging of quantum dots in 
mammalian skin. Biomedical Optics Express. 2011; 2(6):1610-1625.  
329. Yan G, Warner KS, Zhang J, Sharma S, Gale BK. Evaluation needle length 
and density of microneedle arrays in the pretreatment of skin for transdermal drug 
delivery. International Journal of Pharmaceutics. 2010; 391(1–2):7-12.  
330. Carey JB, Pearson FE, Vrdoljak A, McGrath MG, Crean AM, Walsh PT, et 
al. Microneedle array design determines the induction of protective memory CD8 T 
Cell responses induced by a recombinant live malaria vaccine in mice. PLoS ONE. 
2011; 6(7):22442.  
331. Verbaan FJ, Bal SM, van den Berg DJ, Dijksman JA, van Hecke M, 
Verpoorten H, et al. Improved piercing of microneedle arrays in dermatomed human 
skin by an impact insertion method. Journal of Controlled Release. 2008; 128(1):80-
88.  
332. Cullander C, Guy RH. (D) Routes of delivery: Case studies: (6) Transdermal 
delivery of peptides and proteins. Advanced Drug Delivery Reviews. 1992; 8(2–
3):291-329.  
333. Priya B, Rashmi T, Bozena M. Transdermal iontophoresis. Expert Opinion on 
Drug Delivery. 2006; 3(1):127-138.  
334. Langer R. New methods of drug delivery. Science. 1990; 249(4976):1527-
1533.  
335. Montes LF, Day JL, Wand CJ, Kennedy L. Ultrastructural changes in the 
horny layer following local application of dimethyl sulfoxide. The Journal of 
Investigative Dermatology. 1967; 48(2):184-196.  
336. Benson HA, Prankerd RJ. Optimisation of drug delivery: transdermal drug 
delivery. Australian Journal of Hospital Pharmacy. 1997; 27:441 - 448.  
204 
 
337. Rezze G, Scramim A, Neves R, Landman G. Structural correlations between 
dermoscopic features of cutaneous melanomas and histopathology using transverse 
sections. The American Journal of Dermatopathology. 2006; 28(1):13-20.  
338. Rajadhyaksha M, Menaker G, Flotte T, Dwyer PJ, Gonzalez S. Confocal 
examination of nonmelanoma cancers in thick skin excisions to potentially guide 
Mohs micrographic surgery without frozen histopathology. 2001; 117(5):1137-1143.  
339. Meuwissen MEMJ, Janssen J, Cullander C, Junginger HE, Bouwstra JA. A 
cross-section device to improve visualization of fluorescent probe penetration into 
the skin by confocal laser scanning microscopy. Pharmaceutical Research. 1998; 
15(2):352-356.  
340. Zellmer S, Pfeil W, Lasch J. Interaction of phosphatidylcholine liposomes 
with the human stratum corneum. Biochimica et Biophysica Acta (BBA) - 
Biomembranes. 1995; 1237(2):176-182.  
341. Hibbs AR, MacDonald G, Garsha K. Practical Confocal Microscopy 
Handbook Of Biological Confocal Microscopy. In: Pawley JB, editor.: Springer US; 
2006. p. 650-671. 
342. Boi S, Fascio U. A method of quantitative measurement of fluorescence 
intensity by confocal laser scanning microscopy. Journal of Computer-Assisted 
Microscopy. 1998; 10(4):163-166.  
343. Zucker RM, Price OT. Statistical evaluation of confocal microscopy images. 
Cytometry. 2001; 44(4):295-308.  
344. Patzelt A, Richter H, Buettemeyer R, Huber HJR, Blume-Peytavi U, Sterry 
W, et al. Differential stripping demonstrates a significant reduction of the hair 
follicle reservoir in vitro compared to in vivo. European Journal of Pharmaceutics 
and Biopharmaceutics. 2008; 70(1):234-238.  
345. Teichmann A. Differential stripping: Determination of the amount of 
topically applied substances penetrated into the hair follicles. Journal of Investigative 
Dermatology. 2005; 125(2):264-269.  
346. Voegeli R, Heiland J, Doppler S, Rawlings AV, Schreier T. Efficient and 
simple quantification of stratum corneum proteins on tape strippings by infrared 
densitometry. Skin Research and Technology. 2007; 13(3):242-251.  
205 
 
347. Uchida T, Kanazawa T, Takashima Y, Okada H. Development of an efficient 
transdermal delivery system of small interfering RNA using functional peptides, Tat 
and AT-1002. Chemical & Pharmaceutical Bulletin. 2011; 59(2):196-201.  
348. Chen Y, Shen Y, Guo X, Zhang C, Yang W, Ma M, et al. Transdermal 
protein delivery by a coadministered peptide identified via phage display. Nature 
Biotechnology. 2006; 24(4):455-460.  
349. Desai P, Patlolla RR, Singh M. Interaction of nanoparticles and cell-
penetrating peptides with skin for transdermal drug delivery. Molecular Membrane 
Biology. 2010; 27(7):247-259.  
350. Martanto W, Davis SP, Holiday NR, Wang J, Gill HS, Prausnitz MR. 
Transdermal delivery of insulin using microneedles in vivo. Pharmaceutical 
Research. 2004; 21(6):947-952.  
351. Sivamani RK, Stoeber B, Wu GC, Zhai H, Liepmann D, Maibach H. Clinical 
microneedle injection of methyl nicotinate:stratum corneum penetration. Skin 
Research and Technology. 2005; 11:152 - 156.  
352. Ralston E, De Coen JL, Walter R. Tertiary structure of H-Pro-Leu-Gly-NH2, 
the factor that inhibits release of melanocyte stimulating hormone, derived by 
conformational energy calculations. Proceedings of the National Academy of 
Sciences of the United States of America. 1974; 71(4):1142-1144.  
353. Lee JH, Lim SK, Huh SH, Lee D, Lee W. Solution structures of the 
melanocyte-stimulating hormones by two-dimensional NMR spectroscopy and 
dynamical simulated-annealing calculations. European Journal of Biochemistry. 
1998; 257(1):31-40.  
354. Sasidhar YU, Dhingra MM, Saran A. Conformational preference of Leu side 
chain in melanostatin in DMSO. Indian Journal of Biochemistry and Biophysics. 
1990; 27(2):69-75.  
355. Shapiro I, Gorbatiuk VI, Kabanov VM, Mazurov AA, Andronati SA, 
Lobasiuk BA, et al. [Conformational properties of biologically active melanostatin 
analogs . Bioorganicheskai a  khimii a . 1990; 16(12):1607-1617.  
206 
 
356. Voronina TA, Markina NV, Kalinina TS, Kabanov VM, Mazurov AA, 
Andronati SA. Anti-amnestic and antidepressant activity of melanostatin analogs. 
Pharmaceutical Chemistry Journal. 1992; 26(9):753-756.  
357. Val'dman AV, Kozlovskaya MM, Klusha VE, Svirskis SV. The 
psychopharmacological spectrum of melanostatin. Bulletin of Experimental Biology 
and Medicine. 1980; 89(6):780-783.  
358. Valle G, Crisma M, Toniolo C, Yu KL, Johnson RL. Crystal-state structural 
analysis of two gamma-lactam-restricted analogs of Pro-Leu-Gly-NH2. International 
Journal of Peptide & Protein Research. 1989; 33(3):181-190.  
359. Bjrkman S, Castensson S, Sievertsson H. Tripeptide analogues of 
melanocyte-stimulating hormone release-inhibiting hormone (Pro-Leu-Gly-NH2) as 
inhibitors of oxotremorine-induced tremor. Journal of Medicinal Chemistry. 1979; 
22(8):931-935.  
360. Hennemann J, Schatton W, Lyssy RH. Parkinsonism Treatment. In: 
Ullmann's Encyclopedia of Industrial Chemistry: Wiley-VCH Verlag GmbH & Co. 
KGaA; 2000. 
361. Ripka JFJ, FL), inventor; Bio-Logic Research and Development Corporation 
(Jacksonville, FL), assignee. Compositions for enhancing immune function. United 
States. 1999. 
362. Fields K, Falla TJ, Rodan K, Bush L. Bioactive peptides: signaling the future. 
Journal of Cosmetic Dermatology. 2009; 8:8-13.  
363. Ortonne J-P, Bissett DL. Latest insights into skin hyperpigmentation. Journal 
of Investigative Dermatology Symposium. 2007; 13(1):10-14.  
364. Dutta RC, Puri A, Anand N. Immunomodulatory potential of hydrophobic 
analogs of Rigin and their role in providing protection against Plasmodium berghei 
infection in mice. International Immunopharmacology. 2001; 1(5):843-855.  
365. Najjar VA. Preface. Molecular and Cellular Biochemistry. 1983; 53-54(1):7-
7.  
366. Siemion IZ, Kluczyk A. Tuftsin: On the 30-year anniversary of Victor 
Najjar’s discovery. Peptides. 1999; 20(5):645-674.  
207 
 
367. Nishioka K, Babcock GF, Phillips JH, Banks RA, Amoscato AA. In Vivo and 
in Vitro antitumor activities of tuftsin. Annals of the New York Academy of 
Sciences. 1983; 419(1):234-241.  
368. Corazza GR, Ginaldi L, Profeta V, Quaglino D, Zoli G, Gasbarrini G, et al. 
Tuftsin deficiency in AIDS. The Lancet. 1991; 337(8732):12-13.  
369. Ashish, Grover A, Kishore R. Characterization of a novel type VII β-turn 
conformation for a bio-active tetrapeptide rigin. European Journal of Biochemistry. 
2000; 267(5):1455-1463.  
370. Martinez J, Winternitz F. New synthetic and natural tuftsin-related 
compounds and evaluation of their phagocytosis-stimulating activity. Annals of the 
New York Academy of Sciences. 1983; 419(1):23-34.  
371. MTS Clinical Resolution Laboratory I.  In: MTS Anti-Aging Complex™. 
2011 
372. Osborne R, inventor; Personal care compositions. US patent 20070020220. 
2006. 
373. Fu JJJ, Hillebrand GG, Raleigh P, Li J, Marmor MJ, Bertucci V, et al. A 
randomized, controlled comparative study of the wrinkle reduction benefits of a 
cosmetic niacinamide/peptide/retinyl propionate product regimen vs. a prescription 
0.02% tretinoin product regimen. British Journal of Dermatology. 2010; 162(3):647-
654.  
374. Kaczvinsky J, Griffiths CEM, Schnicker M, Li J. Efficacy of anti-aging 
products for periorbital wrinkles as measured by 3-D imaging. Journal of Cosmetic 
Dermatology. 2009; 8(3):228-233.  
375. Abu Samah NH, Heard CM. Topically applied KTTKS: a review. 
International Journal of Cosmetic Science. 2011; 33(6):483-490.  
376. Bergstrom K. Beyond tretinoin: cosmeceuticals for aging skin. Journal of 
Drugs in Dermatology. 2009; 8(7):674-677.  
377. Reszko A, Berson D, Lupo M. Cosmeceuticals: practical applications. 
Dermatologic clinics. 2009; 27(4):401-416.  
208 
 
378. Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating 
aged skin. International Journal of Cosmetic Science. 2009; 31(5):327-345.  
379. Bariya SH, Gohel MC, Mehta TA, Sharma OP. Microneedles: an emerging 
transdermal drug delivery system. Journal of Pharmacy and Pharmacology. 2012; 
64(1):11-29.  
380. Alvarez-Román R, Naik A, Kalia YN, Fessi H, Guy RH. Visualization of 
skin penetration using confocal laser scanning microscopy. European Journal of 
Pharmaceutics and Biopharmaceutics. 2004; 58(2):301-316.  
381. Krishnan G, Edwards J, Chen Y, Benson HAE. Magnetic enhanced delivery 
creates transient epidermal pores. Perth: OBJ Ltd; 2010. Available from: 
http://www.obj.com.au/wp-content/uploads/Epidermal-Pore-Formation-by-
Magnetic-Fields.pdf. 
382. Mitragotri S. Synergistic effect of enhancers for transdermal drug delivery. 
Pharmaceutical Research. 2000; 17(11):1354-1359.  
383. Vemulapalli V, Yang Y, Friden PM, Banga AK. Synergistic effect of 
iontophoresis and soluble microneedles for transdermal delivery of methotrexate. 
Journal of Pharmacy and Pharmacology. 2008; 60(1):27-33.  
384. Garland MJ, Caffarel–Salvador E, Migalska K, Woolfson AD, Donnelly RF. 
Dissolving polymeric microneedle arrays for electrically assisted transdermal drug 
delivery. Journal of Controlled Release. 2012; (1).  
385. Wermeling DP, Banks SL, Hudson DA, Gill HS, Gupta J, Prausnitz MR, et 
al. Microneedles permit transdermal delivery of a skin-impermeant medication to 
humans. Proceedings of the National Academy of Sciences. 2008; 105(6):2058-2063.  
386. Priyadarsini KI. Photophysics, photochemistry and photobiology of 
curcumin: Studies from organic solutions, bio-mimetics and living cells. Journal of 
Photochemistry and Photobiology C: Photochemistry Reviews. 2009; 10(2):81-95.  
387. Schantz EJ, Lauffer MA. Diffusion measurements in agar gel. Biochemistry. 
1962; 1(4):658-663.  
388. Lauffer MA. Theory of diffusion in gels. Biophysical Journal. 1961; 
1(3):205-213.  
209 
 
389. Labouta H, Liu D, Lin L, Butler M, Grice J, Raphael A, et al. Gold 
nanoparticle penetration and reduced metabolism in human skin by toluene. 
Pharmaceutical Research. 2011; 28(11):2931-2944.  
390. Lin L, Grice J, Butler M, Zvyagin A, Becker W, Robertson T, et al. Time-
correlated single photon counting for simultaneous monitoring of zinc oxide 
nanoparticles and NAD(P)H in intact and barrier-disrupted volunteer skin. 
Pharmaceutical Research. 2011; 28(11):2920-2930.  
391. Yow HN, Wu X, Routh AF, Guy RH. Dye diffusion from microcapsules with 
different shell thickness into mammalian skin. European Journal of Pharmaceutics 
and Biopharmaceutics. 2009; 72(1):62-68.  
392. Moser K, Kriwet K, Naik A, Kalia YN, Guy RH. Passive skin penetration 
enhancement and its quantification in vitro. European Journal of Pharmaceutics and 
Biopharmaceutics. 2001; 52(2):103 - 112.  
393. Chen L, Han L, Lian G. Recent advances in predicting skin permeability of 
hydrophilic solutes. Advanced Drug Delivery Reviews. 2012.  
394. Smartplanet ACPw. Business / Smart Takes [In: 3M’s new drug delivery 
system: disposable microneedles. 2011] 
395. Kim Y-C, Park J-H, Prausnitz MR. Microneedles for drug and vaccine 
delivery. Advanced Drug Delivery Reviews. 2012.  
396. van der Maaden K, Jiskoot W, Bouwstra J. Microneedle technologies for 
(trans)dermal drug and vaccine delivery. Journal of Controlled Release. 2012; 
161(2):645-655.  
 
"Every reasonable effort has been made to acknowledge the owners of copyright 
material. I would be pleased to hear from any copyright owner who has been 
omitted or incorrectly acknowledged." 
